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Abstract
Damage to the central nervous system (CNS) of higher vertebrates, including humans, often results in
devastating and persistent functional deficits. The limited capacity of the adult mammalian CNS to
repair lesions by axonal regeneration is mainly caused by the inhibitory molecules in myelin: Myelin-
associated glycoprotein (MAG), Nogo, and Oligodendrocyte-myelin glycoprotein (OMgp).
Gangiosides, such as GD1a, GT1b and GQ1bα, are specific functional ligands responsible for MAG-
mediated inhibition of neurite outgrowth. Based on the previous SAR studies, partial structure of
natural ligands and derivatives thereof (1, 2 0 , 45 , 54α  and 54β) were chemically and chemo-
enzymatically synthesized.
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Their biological affinities were tested in a fluorescent hapten inhibition assay; the binding epitopes
were identified by STD NMR; and the bioactive conformations were deduced by trNOEs NMR. This
led to the design of two families of novel mimics with either modifications at the C-9 position of the
α(2,3)-linked terminal sialic acid (87, 97), or substitutions of the disaccharide core by non-
carbohydrate moieties (104-107, 120-122).
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Abbreviations
τc motional correlation or tumbling time
Ac acetyl
BHT butylated hydroxytoluene
Bn benzyl
BSA bovine serum albumin
Bz benzoyl
CAM cell adhesion molecules
CAN cerium ammonium nitrate
CHO cell Chinese hamster ovary cell
CIAP calf intestine alkaline phosphatase
CMP cytidine monophosphate
CNS central nervous system
CSA camphor sulfonic acid
DCE dichloroethane
DCM dichloromethane
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone
DEAD diethyl azodicarboxylate
DEAE anion diethylaminoethyl anion
DMAP 4-dimethylaminopyridine
DMF N, N'-dimethylformamide
DMTST dimethyl(methylthio)sulfonium triflate
dppf 1,1'-Bis(diphenylphosphino)ferrocene
DRG dorsal root ganglion
ESI-MS electrospray ionization mass spectrometry
FDP fluorescein diphosphate
Fuc fucose
Gal galactose
GalNAc N-acetyl galactosamine
Glc glucose
GPI glycosylphosphatidylinositol
HRMS (FAB) high resolution mass spectrometry (fast-atom bombardment)
IC50 concentration required for 50% inhibition
i-PrOH 2-propanol
KD dissociation constance
kDa kiloDalton
KDN 5-deaminated neuraminic acid
Ki inhibitory constance
logD7.4 n-octanol/water partition coefficient at pH 7.4
VLRR leucine rich repeat
MAG Myelin-associated glycoprotein
MAG-/- MAG-deficient
MAG+/+ MAG-wild type
MPM 4-methoxy phenylmethyl
Neu5Ac N-acetylneuraminic acid
NeuGc N-glycolyl neuraminic acid
NgR Nogo receptor
NIS N-iodosuccinimide
NMR nuclear magnetic resonance
OMgp Oligodendrocyte-myelin glycoprotein
OSE 2-(trimethylsilyl)ethyl
P4 1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol
PE petrolether
PND post-natal day
PNS peripheral nervous system
py pyridine
R118A mutation of Arg118 to Ala
R118D mutation of Arg118 to Asp
RG retinal ganglion
rIP relative inhibitory potency
RP reversed phase
SAR structure-activity relationship
Sia sialic acid
siglec sialic acid binding immunoglobulin-like lectin
sLeX sialyl lewisX
SMP Schwann cell myelin protein
Sn sialoadhesion
ST sialyltransferase
STD saturation transfer difference
TBAB tetrabutylammonium bromide
TBAHS tetrabutylammonium hydrosulfate
TBAI tetrabutylammonium iodide
TFA trifluoroacetic acid
TfOH trifluoromethanesulfonic acid, triflic acid
THF tetrahydrofuran
TMS trimethylsilyl
trNOE transfer nuclear overhauser effect
TsOH p-toluenesulfonic acid
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1Introduction
1. Myelin-associated inhibitors of axonal regeneration in adult mammalian CNS
1.1. Failure of axonal regeneration in adult mammalian CNS
Damage to the central nervous system (CNS) of higher vertebrates, including humans,
often results in devastating and persistent functional deficits. Hence, victims of stroke,
trauma or neurodegenerative diseases suffer permanently from the losses in, e.g.
movement, body functions, sensation, and thinking.
In contrast to the peripheral nervous system (PNS) and the embryonic CNS, the
capacity of the adult brain and spinal cord to repair lesions by axonal regeneration is
extremely limited. Although injured axons can sprout spontaneously, this regeneration
attempt is transitory and no significant regrowth occurs over long distances.1
However, this failure is not due to an intrinsic or irreversible lack of the ability of
CNS neurons to regenerate, but rather to the non-permissive nature of the CNS
environment. This was demonstrated by studies showing that many types of CNS
neurons can extend long axons either by grafting pieces of peripheral nerves onto a
lesion site,2,3 or by isolating neurons and growing them in culture.4,5
Several factors may account for the regenerative failure observed in the adult
mammalian CNS, including a post-natal decline in available neurotrophic factors and
intracellular cyclic nucleotides, the formation of a glial scar, the presence of myelin-
associated inhibitors of axonal extension, and possibly the presence of developmental
repulsive guidance cues.6 Among them, inhibitors in myelin and glial scar are the two
major obstacles to axonal regeneration after injury.7
The scar is formed by astrocytes, which change their morphology to act as a physical
barrier to axonal outgrowth and also upregulate several extracellular-matrix-
associated inhibitors after injury.8 However, since the glial scar takes a considerable
2time to become fully mature, immediately after injury the main impediments to
regeneration are inhibitors in myelin.
In the CNS and PNS, many axons are wrapped concentrically and tightly by a fatty
sheath of myelin, which is produced by oligodendrocytes in the CNS and Schwann
cell in the PNS.9 Behaving as an insulator, this multilamellar membrane is essential
for rapid nerve conduction, as evidenced by debilitating demyelinating diseases in the
CNS and PNS such as multiple sclerosis and Guillain Barré syndrome.10 The myelin
sheath is interrupted at regular intervals by the nodes of Ranvier that are relatively
small, regularly spaced, unmyelinated regions of axons. In the axonal membrane at
these nodes, voltage-gated sodium channels are highly concentrated, thus allowing for
the saltatory propagation of the action potential down the length of myelinated
axons.11 The rapid impulse conduction that results from the focal position of sodium
channels along the axon has facilitated the evolution of complex, yet compact,
nervous system.
Except its insulating function, myelin in the adult mammalian CNS is also recognized
as a major inhibitor for axonal regeneration from a variety of neurons both in vivo and
in vitro.1,12-15 This inhibitory role was strongly confirmed by a study in which mice
were immunized with myelin before a spinal cord injury was inflicted. A considerable
axonal regeneration across the lesion was detected compared with the control mice
that were immunized with liver tissue.16 Consistent with this view is the observation
that lesioned embryonic spinal cord neurons can regenerate for a period that ends at
about the same time as the onset of myelination in the spinal cord.14
Why does regeneration capacity differ so dramatically between the PNS and CNS,
while axons from both systems are wrapped by myelin sheaths? Actually, myelin in
the PNS does inhibit neurite outgrowth. Shen’s study showed that myelin prepared
from the CNS inhibits neurite outgrowth by 70% while PNS myelin inhibits by about
60%, relative to the control membranes.17 Nearly all the inhibitory molecules
identified so far in the CNS myelin are present in the PNS myelin as well. The
permissive environment in the PNS for axonal regeneration is at least partly due to the
different behavior of Schwann cells and oligodendrocytes. In the PNS, Schwann cells
3and macrophages rapidly clear myelin after injury, a process known as Wallerian
degeneration.8 Regeneration takes place only after myelin debris has been cleared,
Schwann cells have reverted into a non-myelinating phenotype and the expression of
myelin proteins is downregulated.7 Unlike Schwann cells, oligodendrocytes continue
to express myelin proteins—including inhibitors—after injury and they do not engulf
myelin debris. In addition, the immune response triggered by the injury in the CNS is
much weaker than that in the PNS, i.e. fewer macrophages are recruited to the injury
site. As a consequence, the removal of myelin in the CNS is much slower after injury,
and takes several weeks or month to complete.18,19 Therefore, myelin–associated
inhibitors exposed from the damaged myelin sheath in the CNS are regarded to be the
major obstacles for injured axonal regeneration followed by glial scar formation.
1.2. Myelin-associated inhibitors
Following the discovery that myelin is adverse to axonal outgrowth, at least three
myelin specific inhibitors—MAG, Nogo, OMgp—have been identified and
characterized to date. Substantial progress towards the elucidation of the precise
nature of these inhibitory molecules enhanced the understanding of the signaling
mechanism involved in the inhibition of axonal regeneration in the adult mammalian
CNS at molecular level.
1.2.1. Myelin-associated glycoprotein
Myelin-associated glycoprotein (MAG, figure 1), initially described in 1973,20 was
the first protein in myelin to be characterized as an inhibitor of axonal
outgrowth.21,22 MAG is a 100  kDa glycoprotein which has 8 to 9 potential N-linked
glycosylation sites and consists of typically 30% carbohydrate by weight.23 As a
member of siglec (sialic acid binding immunoglobulin-like lectin) family24, MAG
contains five Ig-like domains in its extracellular sequence and the first Ig-domain
adopts an unusual conformation by folding over the second Ig-domain. This
transmembrane protein exists in two alternatively spliced isoforms, a large (L) and a
small (S) form that differ only in their cytoplasmic sequences.25,26,27 In the CNS, MAG
4located in the periaxonal myelin membrane, while in the PNS, it is found in the
outermost membrane of the myelin sheath.28,29
Figure 1: L-MAG and S-MAG.
Because of its localization immediately next to the axon, MAG was suspected to
maintain the interface of myelin and axon, and therefore, to influence the integrity of
the axon. This idea is greatly strengthened by observations of extensive PNS
demyelination and axonal degeneration in MAG-deficient (MAG-/-) mice older than
8 months,30 while the similar experiment in the CNS has not been reported.
MAG’s inhibitory character of axonal regeneration was initially observed by
Mckerracher et al.21 They employed octyl glucoside to extract the CNS myelin,
followed by chromatography on a diethylaminoethyl (DEAE) anion exchange
column, and consistently found MAG as a major component of the multiple neurite
growth inhibitory proteins present in the CNS myelin. In addition, immunodepletion
of MAG from total extracts of CNS myelin resorted neurite outgrowth up to 63% of
control levels, indicating that in vitro MAG may contribute significantly to the failure
of injured axon to regeneration in the adult mammalian CNS.21
Interestingly, depending on age and type, a number of neurons respond to MAG by
switching from promotion to inhibition during development.22,31 For retinal ganglion
(RG) neurons and spinal neurons, the switch has already occurred by birth, while for
dorsal root ganglion (DRG) neurons, the transition takes place sharply at post-natal
day 3 (PND 3). MAG inhibits CNS neurite outgrowth from all post-natal neurons
L-MAG S-MAG
5tested to date, including retinal, superior cervical ganglion, spinal and hippocampal
neurons.31
To further elucidate the inhibitory role of MAG, MAG-/- mice were created by
deletion of the MAG gene by homologus recombination.32,33 Surprisingly, tests both in
vitro and in vivo showed no significant difference of axonal regeneration between
MAG-/- and MAG+/+ mice.34 The most likely explanation might be that in response
to the absence of MAG, other proteins may be upregulated to compensated for MAG,
since MAG is just one of the inhibitory factors presented in myelin. Additionally, it is
possible that the effect of inhibitory molecules on regeneration is not addictive,
therefore the presence of any one inhibitor may be sufficient to prevent most
regeneration.
As a member of siglec family, MAG binds to neurons in a sialic-acid dependent
manner regardless of whether neurite outgrowth is promoted or inhibited.
Importantly, both functions are reduced or even completely abolished, either by
desialylation of the neurons by sialidase or by including small sialic-acid-bearing
sugars in the cultures.31
Arg118 of the first Ig-domain of MAG was recently identified to be crucial for its
sialic acid binding capability, because mutation of this amino acid to either Ala
(R118A) or Asp (R118D) abolished binding completely. Likewise, inhibition of
axonal growth by soluble MAG was lost with this mutation.35 Surprisingly, when
mutated MAG (R118A or R118D) was expressed from either Schwann cell or CHO
cells, inhibition was as effective as with native MAG. Therefore, sialic acid binding
by itself is not sufficient to effect inhibition of axonal regeneration: there must be a
second, yet unknown site on MAG, distinct from the sialic acid binding site at Arg118
for inhibition. However, for soluble MAG, interaction of the inhibition site with the
neuron is completely dependent on MAG’s inherent sialic acid binding capacity. In
contrast, other proteins (CAM, cell adhesion molecules) in live cells can compensate
for the MAG’s sialic acid binding to the neuron, allowing the inhibition site to interact
and to elicit the effort.35
61.2.2. Nogo
A first indication that specific molecules in myelin were involved in neurite
outgrowth was the IN-1 monoclonal antibody, which was raised against an inhibitory
fraction of myelin. In its presence, axons are growing on myelin both in vitro36 and in
vivo.1 It was not until a decade later that the antigen for the IN-1 antibody was cloned
independently by three groups, which was named Nogo for its inhibitory action on
axonal growth (figure 2).37-39 Nogo belongs to the reticulon family, and is expressed as
the distinct isoforms A, B, and C in CNS, but not in PNS.38 Among all three isoforms,
Nogo-A is the only one that is expressed in oligodendrocytes, and therefore has been
studied extensively. The amino terminus includes at least two inhibitory domains: a
specific amino-Nogo that is not shared by Nogo-B and C, and a 66 amino acid loop
termed Nogo-66 that is common to all three isoforms. The C-terminal region of all
three isoforms exhibits a considerable degree of homology (70%) to the reticulon
family.38 Although the topology of Nogo-A has not been clearly established, the
model that is best supported by current evidence places Nogo-66 on the extracellular
surface, and amino-Nogo on the intracellular surface. As both segments are potent
inhibitors of axonal outgrowth, the inhibitory amino terminus may only be exposed
following damage to myelin and oligodendrocytes.7
Figure 2: Nogo-A, B, and C.
Recombinant Nogo-A is recognized by the monoclonal antibody IN-1, and it inhibits
neurite outgrowth from DRG and spreading of 3T3 fibroblasts in an IN-1 sensitive
manner,37 which showed that Nogo-A is a potent inhibitor of neurite outgrowth.
Amino-Nogo
71.2.3. Oligodendrocyte-myelin glycoprotein
Like MAG, Oligodendrocyte-myelin glycoprotein (OMgp, figure 3) was also known
long before it was shown to be an inhibitor of axonal regeneration.40 Except being
revealed as the inhibitory component of the fraction of bovine brain myelin by the
same strategy as MAG,41 OMgp was also independently identified as an important
myelin-associated inhibitor in a screen for glycosylphosphatidylinositol (GPI)-
anchored CNS myelin proteins that mediate axonal outgrowth inhibition.42 In contrast
to its name, OMgp is expressed not only by oligodendrocytes, but also at high levels
in various neurons. It is a minor component of myelin with a relative abundance much
lower than that of MAG, and is found largely in the paranodal loops, next to the node
of Ranvier.43 OMgp is localized on the outer leaflet of the plasma membrane by a GPI
linkage and contains a leucine rich repeat (LRR) domain, followed by a C-terminal
domain with serine/threonine repeats. In vitro, OMgp causes growth cone collapse
and potentially inhibits neurite outgrowth, while the function in vivo has not yet been
reported.42
Figure 3: Oligodendrocyte-myelin glycoprotein (OMgp).
1.2.4. Axonal receptors for Myelin-associated inhibitors
A key step in understanding how axons respond to inhibitory influences is to identify
the axonal receptors that bind and respond to myelin-associated inhibitory molecules.
In 2001, using a soluble form of Nogo-66 to screen a cDNA expression library,
Strittmatter cloned a binding partner for Nogo-66 which was termed Nogo receptor
(NgR).44 NgR is an 85 kDa GPI-linked protein that contains eight consecutive LRR
domains followed by the C-terminal LRR. Direct interaction of Nogo-66 with NgR is
required to induce growth cone collapse.44
OMgp
8Perhaps one of the most surprising recent findings was the discovery that NgR can
also bind and mediate the inhibitory activity of MAG and OMgp.42,45,46 It is
particularly striking since there is no obvious sequence or domain similarity between
Nogo-66, MAG and OMgp. A small peptide consisting of the first 40 aa residues of
the Nogo-66 sequence, which is essential for binding to NgR but does not contribute
to the inhibitory activity, has been found to enhance the majority of axons to
regenerate over long distance.47 In addition, this peptide could also be interfering with
the ability of MAG and OMgp to bind to NgR.7
NgR is a GPI-linked protein, and therefore has no transmembrane or cytoplasmic
domain. It needs a partner to transduce the signal across the membrane. The low-
affinity neurotrophin receptor p75NTR was identified as a co-receptor for NgR.48,49 It
can be co-precipitated by MAG, Nogo-66 or OMgp, and NgR is present in the
precipitate of each. It was also observed that after injury, upregulation of p75NTR has
been shown in many axonal tracts.50,51 Neurons from p75NTR-/- mice were not inhibited
by either of the three inhibitors, or by myelin in general.7 Furthermore, a truncated
p75NTR protein lacking the intracellular domain, when overexpressed in primary
neurons, attenuates the same set of inhibitory activities, suggesting that p75NTR is a
signal transducer of inhibitory signals into the interior of responding neurons.48
Figure 4: Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS.
9MAG, Nogo and OMgp, the three main myelin-associated inhibitors identified to
date, interact with the same receptor complex NgR-p75NTR to transduce the inhibitory
signal across the membrane, followed by signaling cascades leading to the inhibition
of axonal outgrowth after injury (figure 4).52 However, the postulated model implies
that there is functional redundancy between these inhibitors. This idea of redundancy
can explain many confusing results of in vivo experiments in which either MAG or
Nogo was blocked or absent. In the MAG-/- mouse, only a small amount of
spontaneous axonal regeneration was recorded in one study,53 and none at all in
another.34 Likewise, application of the antibody to Nogo (IN-1) after injury in wild-
type mice allowed improved regeneration to occur, but only 5-10% of axons
regrowth.1,54,55 Presumably, in all of these situations, other ligands for NgR are
presented or even upregulated to inhibit axonal regeneration, and the presence of any
one inhibitor is sufficient to prevent regeneration by activating an inhibitory signal
through a single receptor complex.8
The additional inhibitory activity of amino-Nogo which does not act through NgR-
p75NTR, and perhaps other as yet unidentified myelin inhibitors might be relatively
minor since the blocking of NgR or p75NTR can substantially block the inhibitory
effects of total myelin for the neurons tested so far.7
1.3. Role of gangliosides in MAG-mediated neurite outgrowth inhibition
Besides the common pathway of MAG, Nogo, and OMgp to transduce the inhibitory
signal through the NgR-p75NTR complex, it has long been assumed that MAG
mediates neurite outgrowth inhibition by the interaction with gangliosides (figure 4).
However, the role of gangliosides became debatable after NgR had been identified as
the receptor of MAG. In contrast to the opinion that gangliosides can only potentiate
and augment MAG-mediated inhibition of neurite outgrowth by facilitating the
clustering of signaling molecules,6 many lines of evidence supports the hypothesis
that the nerve cell surface gangliosides are specific functional ligands responsible for
MAG-mediated neurite outgrowth inhibition.10,56,57
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1.3.1. Gangliosides are functional ligands for MAG
Gangliosides, sialic acid-bearing glycosphingolipids, are the major glycans of nerve
cells and the major sialic acid-containing glycoconjugates in the brain.58 They are
common to all vertebrate tissues, but 10- to 1000-fold more concentrated in the
brain.59 Brain gangliosides are characterized by their structural diversity, which
derives primarily from the number and linkage position of N-acetylneuraminic acid
(Neu5Ac, sialic acid) residues on the neutral sugar core, whereas the core itself shows
only limited varieties. Indicated by a recent study, the major brain gangliosides have
the physiological functions to maintain myelin stability, and to control nerve
regeneration. Notably, both functions may be mediated, at least in part, via their
specific interactions with MAG.10
Table 1: Established members of the siglec family.60,61
Siglec Alternative
name
Tissue/Cell type distribution Minimal carbohydrate structure(s)
recognized
Siglec-1 Sialoadhesin Macrophages in spleen, lymph
nodes, and bone marrow
Neu5Ac-α(2-3)-Gal-β(1-3/4)-GlcNAc-
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-
Siglec-2 CD22 B cells Neu5Ac-α(2-6)-Gal-β(1-4)-GlcNAc-
Siglec-3 CD33 Myeloid cell lineage Neu5Ac-α(2-3)-Gal-β(1-3/4)-GlcNAc-
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-
Siglec-4a MAG Peripheral and central nerve system Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-
Siglec-4b SMP Schwann cells in quail Neu5Ac-α(2-3)-Gal-
Siglec-5 Granulocytes and monocytes Neu5Ac-α(2-3/6)-Gal-
As mentioned above (1.2.1.), MAG belongs to the siglecs, a structurally and
functionally related family of cell surface receptors that bind to sialic acid containing
glycoproteins and glycolipids.24 To date, as many as eleven members have been
identified, including sialoadhesin (Sn, siglec-1), CD22 (siglec-2), CD33 (siglec-3),
MAG (siglec-4a), Schwann cell myelin protein (SMP, siglec-4b), and siglec-
5~11(table 1).60,61 Each member contains two or more Ig-like domains: an amino-
terminal V-set domain followed by one or more C2-set domains, a single
transmembrane anchor, and a short cytoplasmic tail.62,63 The ligand recognition site
has been localized in the amino-terminal V-set domain or the V-set domain with
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contributions from the adjacent C2-set domain (CD22).64,65 The first two domains
share very high amino acid sequence similarity between MAG and SMP (>70%), and
significant similarity across all siglecs (>30% in pairwise comparisons).62,66,67 Each
siglec, by definition, recognizes a terminal sialic acid residue that is essential for
binding, whereas significant differences in sialic acid linkage specificity are
observed.68 For example, sialoadhesin binds terminal α2,3- or α2,8-linked sialic
acid,69 CD22 recognizes solely α2,6-linked sialic acid,70 and MAG requires α2,3-
linked sialic acid, preferentially, a Neu5Acα(2→3)Galβ(1→3)GalNAc terminus as
implicated by initial specificity study.56 As already reported 30 years ago,
gangliosides carry 75-80% of the sialic acids content in the brain.58 Representative
examples are the major brain gangliosides GD1a and GT1b (figure 5). In addition,
these gangliosides abound on the neuronal cell surface and also along the axons, are
placed directly apposed to MAG in vivo.10 The presence of the MAG binding glycan
sequence on gangliosides, and their location on the axon surface led to the hypothesis
that gangliosides may be endogenous ligands for MAG, and may, therefore, mediate
MAG’s physiological functions.
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Figure 5: major brain gangliosides GD1a, GT1b.
Substantial data are consistent with this hypothesis. Firstly, direct binding study
showed that MAG binds to GD1a, GT1b and related gangliosides with high
specificity and affinity in vitro.71 Secondly, the binding of MAG with gangliosides is
blocked by mAb 513, a conformationally specific anti-MAG antibody that also blocks
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MAG-neuron binding.71 Finally, mice genetically lacking the Neu5Acα(2→3)
Galβ(1→3)GalNAc terminus on gangliosides (but not on glycoproteins) suffer from
axon degeneration and demyelination similar to that in MAG knockout mice.72
Furthermore, evidence from extensive studies demonstrated that gangliosides are both
necessary and sufficient to support MAG-mediated neurite growth inhibition.57
• Treatment with V. cholerae neuraminidase, which converts the MAG-binding
gangliosides GD1a and GT1b to the nonbinding GM1 (table 2, entry 2), eliminates
MAG-mediated inhibition.57
• Gangliosides are synthesized by sequential addition of monosaccharides to
ceramide by specific glycosyltransferases (figure 6). By treating with
glucosylceramide synthase inhibitor 1-phenyl-2-palmitoylamino-3-pyrrolidino-1-
propanol (P4), which blocks synthesis of all glycosphingolipids without influencing
cell viability or neurite outgrowth,73 cell surface gangliosides were completely
depleted. As a consequence, a significant reversal of MAG-mediated inhibition was
observed with P4 treated neurons.57 Furthermore, genetically engineered mice lacking
the GalN Ac transferase, which is required for the biosynthesis of the
Neu5Acα(2→3)Galβ(1→3)GalNAc terminus, expressed compensatory amount of the
simpler gangliosides GD3 or GM3 (table 2, entries 1 and 4) instead of GD1a and
GT1b. Consequently, neurons from these mice showed attenuated response to MAG-
mediated inhibition.57
Figure 6: The biosynthetic pathway for major brain gangliosides. Pharmacological (P4) and genetic
(GalNAcT -/-) blocks in the pathway are indicated.
P4
GalNAcT-/-
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• Monoclonal antiganglioside Abs can block MAG-mediated inhibition of neurite
outgrowth. Anti-GD1a Ab sharply reduced the inhibition, anti-GT1b Ab had an
intermediate effect, whereas anti-GD1b or anti-GD3 Abs had no effects.57
• Multivalent Ab-induced clustering of gangliosides GD1a or GT1b mimics MAG-
mediated neurite outgrowth inhibition without MAG’s involvement, probably through
a direct interaction with P75NTR.74 In contrast, precomplexed anti-GM1 IgG had no
such effect.57
As a summary of the above, gangliosides containing the Neu5Acα (2→3)
Galβ(1→3)GalNAc terminus, are not only highly necessary to support MAG-
mediated neurite outgrowth inhibition, but also sufficient to induce the same
inhibition by multivalent clustering. In addition, GT1b was found to have specific
association with P75NTR,74 implicating that, besides MAG-NgR-P75NTR, gangliosides
and P75NTR may also form a receptor complex for MAG to transmit the inhibitory
signals into neurons.
1.3.2. Structural specificities of gangliosides for MAG binding
Mammalian ganglioside-binding proteins have distinct structural specificities for their
carbohydrate targets. One of the most highly specific ganglioside binding lectins is
MAG.56 To date, certain structure-function studies of MAG-mediated cell adhesion to
gangliosides and related glycosphingolipids were carried out to elucidate structural
specificities of MAG-recognized carbohydrate (table 2).56,75,71
Table 2: Adhesion of natural and modified gangliosides to MAG-transfected COS cell.
Entry Ganglioside
Conc. of ganglioside supporting
half-maximal cell adhesion
[pmol/well] [Ref.]
1
Neu5Ac-α(2-3)-Gal-β(1-4)-Glc-β-Cer
GM3
>100a 71
2
Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-3) GM1
n.d.b 56,75
3 Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-6)
GM1α
n.d. 56,75
14
4
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
GM1b
80 56,75
5
Neu5Ac-α(2-8)-Neu5Ac-α(2-3)-Gal-β(1-4)-Glc-β-Cer
GD3
n.d. 71
6 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-6)
GD1α
19 56,75
7
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-3) GD1a
50 56,75
8
Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3) GD1b
n.d. 71
9 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-3)
Neu5Ac-α(2-6)
GT1aα
17 56,75
10 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-6)
GT1β
50 56
11
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3) GT1b
50 56,75
12 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-6)
GQ1βNeu5Ac-α(2-8)
n.d. 56
13
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3) GQ1bNeu5Ac-α(2-8)
n.d. 56
14 Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
Neu5Ac-α(2-8)-Neu5Ac-α(2-3)
Neu5Ac-α(2-6)
GQ1bα
6.0 56,75
15 Neu5Ac-α(2-3)-Gal-β(1-3)-GlcNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer 240 56,75
16 Neu5Ac-α(2-3)-Gal-β(1-6)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer 87 56,75
17
Neu5Ac-α(2-3)-Gal-β(1-3)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
HO3S-(6)
22 56,75
18 Neu5Ac-α(2-3)-Gal-β(1-4)-GalNAc-β(1-4)-Gal-β(1-4)-Glc-β-Cer
HO3S-(6)
HO3S-(3)
1.5 56,75
a low but statistically significant adhesion over background.
b no detectable adhesion at >100 pmol/well.
Firstly, data in table 2 show, that MAG only binds to gangliosides containing a
terminal α2,3-linked sialic acid (compare GM1 to GD1a, GD1b to GT1b, entries 2, 7,
8 and 11), but the adhesion was abrogated when it is capped by a α2,8-linked sialic
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acid (compare GT1β to GQ1β, GT1b to GQ1b, entries 10, 12, 11 and 13).56 Secondly,
it is notable that an unique quantitatively minor family of gangliosides termed “Chol-
1” gangliosides, including GQ1bα (figure 7), GT1aα, GD1α, and GM1α (entries 14,
9, 6 and 3), displays enhanced potency for MAG-mediated adhesion except GM1α
(GQ1bα > GT1aα, GD1aα > GT1b, GD1a > GM1b).75 Chol-1 gangliosides are
related to the major brain gangliosides but have an additional α2,6-linked sialic acid
on the GalNAc of a gangliotetraose core, making them part of the “α -series”
ganglioside family.76-78 GQ1bα (0.5 mg/kg of brain) and GT1aα (0.9 mg/kg), defined
as the two major Chol-1 gangliosides, are very minor species compared with GD1a,
the major ganglioside of brain (1200 mg/kg).76-78 Nevertheless, their high binding
affinities for MAG demonstrated the contribution of the additional α2,6-linked sialic
acid, which by itself does not support MAG binding (GM1α has no affinity).56,75
GQ1bα, the most potent natural ganglioside identified so far, is about 10-fold more
active in supporting MAG-mediated adhesion than GT1b, the closely related
ganglioside lacking only the α2,6-linked sialic acid (entries 14 and 11).56,75
Furthermore, the different affinity between GD1α and GD1a suggests that as an
additional contributor, α2,6-linked sialic acid is more significant than α2,3-linked
internal sialic acid, although both of them can enhance MAG-mediated adhesion
(entries 6 and 7).56,75 Last, in contrast to the marked binding effect of sialic acids
attached on the neutral core, changes in the oligoaccharide core have only minor
effects. The replacement of the core GalNAc with GlcNAc (entry 15) reduced the
binding affinity about 3-fold as compared to GM1b (entry 4), suggesting a modest
impact on recognition.56 Surprisingly, altering the Gal-GalNAc linkage from β1,3 to
β1,6 (entry 16), which might be expected to have a large conformational effect, did
not influence MAG binding by comparing with GM1b.56 This is consistent with a
study by Kelm, where modifications on either monosaccharide residue of the neutral
core (e.g. 4/6-deoxy, 6-O-methyl, 6-NH2 of Gal; various N-substituted glucosamines,
Fuc instead of GalNAc) or the linkage between them did not cause significant
difference for MAG-binding.79 These data indicated that some tolerance for
modifications of the neutral saccharide backbone. The core behaves more like a
spacer to hold two sialic acids in the specific orientation needed for binding with
MAG.
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Figure 7: Ganglioside GQ1bα with tetrasaccharide “Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]
GalNAc” in box.
In summary, the α2,3-linked sialic acid on the terminal Gal is the primary
determinant for MAG binding, while the additional α2,6-linked sialic acid on GalNAc
can remarkably increase the binding affinity. Compared with the significant impacts
of these two sialic acids, the disaccharide core is not comparably specific, which
means that it may be not greatly involved in the protein-binding site. According to
these observations from the above structure-function studies, tetrasaccharide
Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]GalNAc, which is a partial structure of
GQ1bα, can be deduced as the minimal determinant structure for MAG binding with
high affinity (figure 7, in box).
1.3.3. Sialic acids substructural specificities for MAG-binding
Sialic acids occur on cell surfaces at exposed positions, mostly terminal components
with different linkages to the glycans of glycoconjugates. A unique feature of sialic
acids is their structural variability leading to more than 40 naturally occurring
modifications. Therefore, sialic acids are thought to play important roles in cellular
interactions.80,81 As discussed before, the sialic acids of gangliosides are highly
essential for MAG-binding. To further investigate the contributions of substructural
features of sialic acid for MAG-binding affinity, chemically synthesized and modified
gangliosides were employed for extensive structure-function study.
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Research in this field was carried out mostly by two groups: Schnaar et al.56,57,71,75,82
studied adhesion between natural and synthetic gangliosides adsorbed onto microwell
plastic plates and full-length MAG expressed on the transiently transfected COS cell
surface; Kelm et al.79,83 employed “heptan inhibition assay” which observed the
binding between Fc-chimera containing N-terminal 3 or 5 domains of MAG (Fc-
MAG1-3 or Fc-MAG1-5) and soluble natural and synthetic gangliosides in the presence
of human erythrocytes. Due to the different assays, some conflicting data were
reported by these two groups. However, most results are consistent, or supplementary
with each other, which made the picture of sialic acid substructural specificities for
MAG binding more and more clear.
α2,3-linked terminal sialic acid  Sia(I)
When GD1a is modified at the carboxylic acid by esterification, amidation, or
reduction, MAG-binding is abolished, strongly demonstrating that the anionic charge
is crucial for protein binding (data not shown).71 Additionally, this carboxylic acid
needs to be in axial position, since only α-anomer, the natural conformation in
sialylated glycans support MAG-binding.83 It is in good agreement with the X-ray
structure of the N-terminal immunoglobin-like domain of the sialoadhesin in complex
with 2,3-sialyllactose, which shows the axial carboxylic acid of the terminal sialic
acid directedly involved in binding by forming a salt bridge with Arg97.84 It should be
noted that this Arg is highly conserved in the first Ig-domain of other members of
siglec family, while Arg97 in sialoadhesin corresponds to Arg118 in MAG.35
The glycerol side chain of sialic acid was shown to be crucial for binding in Schnaar’s
studies with modified GD1a. The binding affinity to MAG was abolished with
truncated glycerol chain, 7/8-aldehydes, 7/8-alcohols, as did deoxy and/or methoxy
derivatives of the 7, 8 or 9- position of Sia(I) of GM3 (data not shown).71,82 These
results suggested that the intact glycerol chain is needed for binding and that
eliminating or derivating any of the OHs in this part reduced binding. The role of 9-
OH attracts the interest based on the X-ray of sialoadhesin cocrystallized with
sialyllactose, which implicates that an additional contact with the protein at that place
might be exist.84 From Kelm’s study of a series of methyl sialosides, additional
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structural information was obtained demonstrating the requirement of 9-OH for
binding (table 3).83 Replacement of 9-OH with hydrogen (entry 3) or halogens
(entries 4 to 6) did not support binding, while a 9-NH2-analogue (entry 8) showed a 3-
fold increase in binding, suggesting 9-OH functions as a hydrogen bond donor for one
or more amino acids in the binding pocket. The introduction of a thiol group resulted
in much lower affinity (entry 7), because SH forms weaker hydrogen bonds with the
protein, and the steric constraints by the large sulfur atom may also be the reason.
More recently, a systematic study based on C(9)-NH2 was carried out by differently
substituting the amine.85 Notably, acyl groups such as benzoyl, biphenylcarbonyl,
naphthylcarbonyl (entries 9 to 11) increased the binding dramatically. Among them,
methyl-α-9-N-benzamido-9-deoxy-Neu5Ac enhanced the binding as much as 700-
fold compared with the reference (entry 1). This indicates indeed an additional
hydrophobic contact with the Tyr 44, 46 residues of MAG.86
Table 3: Relative inhibitory potencies (rIPs) of modified methyl sialosides for MAG
Entry Compound rIP [Ref.]
1 Neu5Ac-α-Me 1.00 83
2 Neu5Ac-α-Bn 9.80 83
3 9-deoxy-Neu5Ac-α-Me n.a. 83
4 9-Cl-Neu5Ac-α-Me n.a. 83
5 9-Br-Neu5Ac-α-Me n.a. 83
6 9-I-Neu5Ac-α-Me n.a. 83
7 9-thio-Neu5Ac-α-Me n.a. 83
8 9-NH2-Neu5Ac-α-Me 2.98 83
9 9-benzoyl-NH-Neu5Ac-α-Me 704 85
10 9-bipheyl-4-carbonyl-NH-Neu5Ac-α-Me 218 85
11 9-naphthyl-2-carbonyl-NH-Neu5Ac-α-Me 236 85
12 Neu5Propyl-α-Me 1.56 83
13 Neu5aminoAc-α-Me n.a. 83
14 Neu5ThioAc-α-Me 3.85 83
15 Neu5FAc-α-Me 16.94 83
16 Neu5ClAc-α-Me 7.00 83
17 Neu5F3Ac-α-Me 4.04 83
n.a. not applicable since less than 50% inhibition at the highest concentration tested.
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Concerning the modifications of the N-acetyl group at C5, R.L. Schnaar reported that
GM3 bearing N-glycolyl neuraminic acid (NeuGc), which is rare in humans but
common in rodents, did not support adhesion.82 Furthermore, GM4 derivatives
bearing a 5-deaminated neuraminic acid (KDN-GM4) failed to support binding as
well (data not shown).71 Both results clearly demonstrated that modifications at 5-
position are not tolerated by the protein. Based on the X-ray structure of sialoadhesin
cocrystallized with sialyllactose showing that a Trp residue in the binding site
interacts specifically with the methyl group of the acetyl moiety, Kelm et al.
investigated this position in much detail.83 Except the contradictory finding about the
terminal KDN of a pentasaccharide, which bind to MAG 6.47 times stronger than its
NeuAc analogue (data not shown), Kelm’s investigation confirmed the crucial role of
N-acetyl group for recognition. In a study where propionyl (entry 12), amionacetyl
(entry 13), thioacetyl (entry 14) or halogenated acetyl groups (entries 15-17) were
compared with the acetyl residue, MAG showed significant enhancement of the
binding affinity with halogenated acetyl groups. It should be noted that N-fluoroacetyl
sialic acid derivative (entry 15) is bound about 17-fold better than the reference, while
N-chloroacetyl and N-trifluroacetyl analogues increased affinities with 7- and 4-fold,
respectively (entries 16 and 17).  The enhanced affinity can be rationalized by
halogen mediated additional contacts with the protein or by electronic effects on the
amide, which results in a weaker hydrogen bond acceptor quality of the carbonyl
oxygen and a significantly increased hydrogen bond donor quality of the amino
group.83
α2,6-linked internal sialic acid  Sia (II)
The increased potency of Chol-1 gangliosides, like GQ1bα , to support MAG-
mediated adhesion suggests a potential direct interaction between the α2,6-linked
internal sialic acid and the protein. Extended explorations of the substructural
specificity of Sia(II) to further define the determinant for MAG binding are reported
in the literature.75
To test the role of the anionic charge, the entire Sia(II) moiety of GD1a was replaced
with a sulfate group (table 2, entry 17) which had only a small influence on MAG
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binding, indicating negative charge to be the key pharmacophore in the Sia(II)
moiety.75 Notably, an analogue of GT1aα bearing two sulfate groups instead of two
sialic acid moieties showed a 10-fold increase in binding affinity for MAG, compared
with GT1aα (entries 9 and 18).75 Unlike for Sia(I), modifications of the exocyclic
glycerol chain (GD1α bearing a 7-, 8- or 9-deoxy) supported MAG-mediated
adhesion, suggesting that the OHs on this exocyclic glycerol chain are not strictly
required for enhanced recognition.75
In summarize, numerous evidence showed that gangliosides are MAG ligands.
Furthermore, they are both necessary and sufficient to support MAG-mediated neurite
outgrowth inhibition. Structure-activity relationship (SAR) studies with natural
gangliosides suggest to focus on the tetrasaccharide terminus Neu5Acα(2→3)
Galβ(1→3)[Neu5Acα(2→6)]GalNAc for high binding affinity with MAG, where
both sialic acids are essential for recognition, while the Galβ(1→3)GalNAc core
seems to act predominantly as a linker (figure 8). Extended investigation of
substructural specificity of Sia (I), Sia (II), mapped the epitopes important for
binding: the intact Sia (I) moiety is necessary for binding, while modification at 5-, 9-
positions can greatly enhanced the affinity; the anionic charge is the key point for the
interaction of the Sia (II) moiety.
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2. Drawbacks of carbohydrates to be drugs
Carbohydrates are a major focus of current biological research. By interactions with
proteins, carbohydrates play an important role in diverse cellular recognition and
signaling events, such as cellular growth, adhesion, bacterial and viral infections,
cancer metastasis, inflammation, and immune surveillance.87 As a result, the
development of carbohydrate-based therapeutics appears to have great potential for
the treatment of myriad human disease. However, there is a series of obstacles that
make carbohydrates a problematic class of lead structures for drug development, e.g.
complicate carbohydrates synthesis, poor bioavailability, and low binding affinity for
target proteins.88-90
2.1. Synthetic difficulties
Of the three major classes of biomolecules proteins, nucleic acids, and
carbohydratescarbohydrates are the least exploited, which is due to the structural
complexity resulting from the various regio- and stereo-specific linkages of
oligosaccharides.  The degree of molecular diversity generated from glycosidic
linkage assembly is enormous: more than 10 million tetrasaccharides can be
assembled from the 9 common monosaccharides, compared with 256 tetranucleotides
and 16,000 tetrapeptides from the corresponding 4 nucleotides and 20 amino acid
building blocks, respectively.89 Moreover, to synthesize peptides or oligonucleotides,
automated synthesizers are available for an iterative formation of a single bond type
(peptide or phosphodiester bond respectively). However, synthesis of specific
glycosidic linkage is much more difficult, as carbohydrates are densely functionalized
with hydroxyl groups of similar reactivity. Laborious protecting-deprotecting
manipulations make long overall synthetic routes. Despite recent advances in solid
phase synthesis,91-93 efficient regio- and stereoselective synthesis of oligosaccharides
remains a challenge.
2.1. Low bioavailability
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Many natural saccharides are rapidly degraded in vivo. In the stomach and in the
intestine most of the glycosides are hydrolyzed, either by the action of the acidic
environment (stomach) or by the action of glycosidases (small intestine).94 This is the
reason that oligosaccharides are generally not stable enough to allow oral
administration. In addition, glycosidases are presented also in other body fluids which
can reduce a carbohydrate-based drug’s half-life to just a few minutes, depending on
its structure.90
One of the best-investigated examples is sialyl Lewisx (sLex), a terminal
tetrasaccharide of cell surface glycoproteins and glycolipids. It is a ligand for E-
selectin, which mediates the early stage of inflammatory reactions or metastasis.95-97
Though sLex has been considered to be potentially useful as an anti-inflammatory
agent, this natural oligosaccharide can only be applied intravenously for acute
symptoms, as it is orally inactive.98 Even though, it can be hydrolyzed by glycosidase
in blood, moreover, the majority was observed to be rapidly excreted from renal due
to its high water solubility.
2.3. Low binding affinity
Carbohydrate-protein interactions show typically low affinities: the dissociate
constant is most often in the millimolar to micromolar range (KD≈10-3 to 10-6 M),
while the general perception of the one required for pharmaceutical applications is
much lower (KD≈10-9 M).99
X-ray crystallographic studies show that extracellular carbohydrate binding sites are
generally shallow and solvent exposed.99 In addition, the protein makes only few
direct contacts, which are distributed over a large contact area to the ligand. Hydrogen
bonding is expected to play an important role in carbohydrate-protein recognition
processes. Since the directionality of hydrogen bonds is critical, they contribute
predominantly to the specificity of carbohydrate recognition. Their energetic
contributions to carbohydrate-protein binding are rather small and have been
extensively debated.99,100,101
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Besides, the lack of hydrophobic groups, which are often dominant in high-affinity
receptor-ligand interactions in the carbohydrate moieties, might also be responsible
for the low affinity, although weak hydrophobic interactions between non-polar
surface of sugars (i.e. α-face of β-galactose) and proteins have been identified. In
addition, except certain anionic groups containing saccharides such as sLex, other
sialic acid derivatives, and heparin, Coulomb interactions which stabilize the complex
by ion pair or direct hydrogen bond contacts with the protein is missing in most
carbohydrate-protein interactions.99
By considering entropy, the binding of most carbohydrates to proteins is an
entropically unfavorable process due to the conformational flexibility of
oligosaccharides. It is difficult to dissect the entropy costs on ligand binding from
other thermodynamic parameters. However, the conformational restriction of inter-
saccharide rotational freedom upon binding has been estimated to be as large as 1-2
kcal/mol.99
It should be noted that as both a hydrogen bond donor and acceptor, water is greatly
involved in carbohydrate-protein binding, which is demonstrated by numerous X-ray
crystallographic studies.99,100 Its energetic impetus for complex formation has been
debated, and Lemieux has argued that the driving force for carbohydrate
complexation is the reorganization of water molecules upon binding.102 For example,
as revealed by the X-ray structure of Griffonia simplicifolin lectin complexed to the
lewis b tetrasaccharide α-L-Fuc(1→2)β-D-Gal(1→3)[α-L-Fuc(1→4)]β-D-GlcNAc, 8
of 11 water molecules present in the binding site of the uncomplexed lectin are
displaced by the ligand during binding.100 The release of the more ordered structural
water to bulk upon binding is enthalpically unfavorable but entropically favorable.
The thermodynamics of carbohydrate-protein interaction is determined by
calorimetrically measured changes in enthalpies, entropies, free energies and molar
heat capacity upon binding.99,103 Virtually all the examples show free binding energies
of 4-8 kcal/mol, corresponding to association constants of 103-105 M-1,103 which
confirms the low binding affinity of carbohydrate-protein interaction generally
observed.
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2.4. Carbohydrate mimics
A number of strategies were pursued to circumvent the carbohydrate-specific
problems for drug discovery. Besides research on multivalent carbohydrate ligands
that increase the affinity by multiple simultaneous binding events,104-107 numerous
studies have been focused on carbohydrate mimics.88,108 There are two main strategies
in the construction of carbohydrate mimics: Firstly, the substitution of the O-
glycosidic bond with non-natural linkages or replacement of ring oxygen by other
atoms and secondly, the replacement of the entire glycosidic scaffold with a small,
non-carbohydrate framework bearing the required functional groups in the same
spatial orientation as the parent sugar structure.109 The former type of mimics,110 such
as C-glycosides, S-glycosides, carba-sugars, would ideally have increased resistance
to endogenous enzymatic hydrolysis and chemical degradation, while conserving the
global geometry of the native oligosaccharide. The second type of mimics is generally
based on different core structures, and mimic the functions of lead sugars by keeping
the essential functional groups required for recognition. Additionally, by virtue of the
rational design based on structural details of the protein binding site, higher affinities
and selectivities can be achieved by additional interactions with hydrophobic or
charged groups of their cognate receptors.88
The second strategy described above is demonstrated with example from the selectin
research. CGP69669 is a mimic of the tetrasaccharide sLex, the natural ligand for E-
selectin (figure 9). Basing on the knowledge that anionic charge is the only
pharmacopher of the terminal sialic acid, and the GlcNAc behaves merely as a spacer
to hold Gal and Fuc in the appropriate position, CGP69669 was designed in such a
way that sialic acid was replaced by the much simpler cyclohexane L-lactic acid and
GlcNAc by cyclohexane 1,2-diol. The resulting IC50 was about 12-fold better than that
of sLex from in vitro biological assay.111
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Figure 9: sLeX and its mimic CGP 69669.
Another interesting example is the development of anti-influenza agents (figure 10).112
Zanamivir was designed to mimic the transition state of sialic acid (Neu5Ac2en) in
the hydrolysis reaction by neuraminidase. By keeping the carboxylic acid, the
glycerol chain and N-acetyl function that are essential for the binding, the basic
guanidinyl group was attached on 4-position, due to the strong interaction with Glu
119 and Glu 227 identified by X-ray crystal analysis.112 Notably, Ki of Zanamivir is
1,000 times better than the parent compound Neu5Ac2en.113 However, due to its poor
bioavailability of only 2% (logD7.4≈ -6), Zanamivir can not be applied orally. By
further modification based on a prodrug concept, Oseltamivir with 78%
bioavailability (logD7.4≈ 0.5) and similar activity (Ki ≈ 1 nM) was obtained, which is
now on the market as an orally administered drug to block influenza virus
infection.114-116
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Figure 10: Neu5Ac2en, Zanamivir and Oseltamivir at physiological pH.
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3. Aim of this work
3.1. General strategy
The aim of MAG project—a collaboration of the Institute of Molecular Pharmacy,
University of Basel (Prof. B. Ernst), University of Bremen (Prof. S. Kelm), University
of Hamburg (Prof. B. Meyer) and University of Lübeck (Prof. T. Peters)—is to
further define the structural requirements of the carbohydrate specificity for MAG,
and in turn design and synthesize novel mimics with simplified structures and
retained or even better binding affinities. The approach is based on the integration of
results from various approaches:
• Partial structures and derivatives of high affinity natural ganglioside GQ1bα were
chemically and chemo-enzymatically synthesized;
• The affinities of chemical entities to MAG were tested in a fluorescent hapten
inhibition assay;
• STD-NMR was employed to identify the binding epitopes of the chemical entities;
• The bound conformation was deduce by trNOE-NMR and;
• A 3-D homology model for MAG based on the X-ray structure of sialoadhesin and
cognate ligand illustrated the interaction between functional groups of ligand and
the amino acid residues in the protein-binding site.
Results from this multidisciplinary study are expected to give guidance for the
rational design of novel MAG antagonists.
The goal of this thesis is focused on the synthesis of MAG antagonists based on
partial structure and derivatives of natural ligands and mimics thereof. As discussed
above (1.3.), the tetrasaccharide Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]
GalNAc, which is a partial structure of GQ1bα, is the key determinant for MAG
binding. In this thesis, besides trisaccharide Neu5Acα(2→3)Galβ(1→3)GalNAc,
Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]Gal and derivatives with Gal instead of
GalNAc at the reducing end were chemically and chemo-enzymatically synthesized.
In turn, according to the biological and NMR analyses, together with the previous
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SAR studies, two groups of mimics focusing on the modifications on C-9 of Sia (I)
and the disaccharide core respectively were designed and synthesized.
3.2. Chemical and chemo-enzymatic synthesis
Despite considerable recent progress, efficient regio- and stereoselective chemical
synthesis of oligosaccharides remains a significant challenge. In vivo,
oligosaccharides are synthesized by glycosyltransferases that sequentially transfer a
single pyranosyl residue from a sugar nucleotide donor to a growing carbohydrate
chain.117 In contrast to the chemical synthesis, enzymatic synthesis using
glycosyltransferases offers a number of advantages: high regio- and stereoselectivity,
no requirement for chemical protection and deprotection and very mild reaction
conditions.118,119 The synthetic value of glycosyltransferases would be greatly
enhanced, if their substrates tolerance would allow the glycosylation of non-natural
substrates.120 The combined approach of chemical and enzymatic synthesis, named
chemo-enzymatic synthesis, would then greatly facilitate the preparation of complex
carbohydrates and their mimics, which would increasingly provide insight into the
biological roles of carbohydrates and initiate the rational design of new generations of
carbohydrate based therapeutic agents.
It should be noted that stereoselective sialylation remains a major problem in
carbohydrate chemistry, due to the sterically hindered tertiary anomeric center, the
presence of an electron withdrawing carboxylate and the lack of a participating
neighboring group in the 3-position of the sialic acid moiety.121 Enzymatic synthesis
employing sialyltransferases as biocatalysts offers an alternative approach with
excellent stereoselectivity and generally good to excellent yield.118,119 In this thesis,
α(2→3)-sialyltransferase ST3Gal III122-124was used to transfer the sialic acid moiety
from cytidine-5'-monophospho-N-acetylneuraminic acid (CMP-Neu5Ac) to the non-
natural substrates.
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3.3. Fluorescent hapten inhibition assay (in collaboration with Prof. S. Kelm,
University of Bremen)
To analyze the inhibitory potentials of the partial structures of GQ1bα and derivatives
and mimics thereof, a chimeric protein consisting of the Fc-portion of human IgG and
the N-terminal 3 or 5 domains from MAG (Fc-MAGd1-3 or Fc-MAGd1-5) was produced
in COS cell and purified.79,83
Figure 11: Fluorescent hapten inhibition assay. 1. Inhibitor was added to the sialic acid coated
microtitre plates; 2. Fc-MAG complexed with polyclonal goat anti human IgG(Fc) coupled with
alkaline phosphatase was subsequently added; 3. Incubation and removal of unbound complexes; 4. By
treating with fluorescein diphosphate (FDP), the resulting fluorescence intensity that is proportional to
the amount of bound complexes can be determined.
The fluorescent hapten inhibition assay (figure 11) employed in this project is a
successor of the previous one which was based on radio-labeled MAG and
erythrocytes as target cells.79,83 In order to simplify the analyses, microtitre plates with
covalently attached sialic acids instead of erythrocytes have been used as ligands for
MAG. For the quantification of bound MAG, Fc-MAG is complexed with alkaline
phosphatase-labeled anti-Fc antibody. During incubation, inhibitors occupy the
protein-binding site and competitively inhibit the binding with the sialic acids coated
plate. After washing for the removal of inhibitor-Fc-MAG complexes, the amount of
Fc-MAG bound to the sialylated plates is determined by the initial velocity of
fluorescein released from fluorescein phosphate. This method proved to be more
reliable and easier to handle than the former assay relying on radiolabels. The
inhibitory potencies obtained for several reference compounds were similar in both
systems.
The concentrations required for 50% inhibition  (IC50) are determined from inhibition
curves obtained from titration experiments. Since IC50s may vary depending on the
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condition from assay to assay, relative inhibitory potencies (rIPs) calculated by
dividing the IC50 of the reference compound by the one of the tested compound were
employed.79,83 It is notable that rIP values are consistent, thus allowed a reliable
comparison among different assays as long as the same reference is used.
All the compounds synthesized in the thesis have been analyzed in the fluorescent
hapten inhibition assays using the same reference throughout the entire period.
3.4. STD NMR (in collaboration with Prof. B. Meyer, University of Hamburg)
The difference between a saturation transfer spectrum and a normal NMR spectrum
provides a new and fast method, namely, saturation transfer difference (STD) NMR
spectroscopy, to screen compound libraries for binding activity to protein,
additionally, to map the epitopes of the protein binding ligand.125
By selective irradiating the protein with the pulse does not directly affect the
resonances of small ligands, the saturation is spread over the entire protein by
intramolecular saturation transfer. Ligand molecules interacting with the protein are
saturated in turn by intermolecular transfer. Through chemical exchange these
saturated ligands are transferred into solution where they are detected.125 In addition,
the ligand’s binding epitope can be easily identified because ligand residues in direct
contact of the protein show much stronger STD signals.
The intensity of STD NMR signal increases in accordance with the ligand excess and
it is also correlated to the KD of the ligand-protein binding, which should be between
10-3 and 10-8 M, in the range of the one from protein-carbohydrate interaction.
Furthermore, there is no limit to the size of the protein. In fact, there is an increase of
sensitivity with the size of protein due to a more efficient inter- and intramolecular
saturation transfer.126
3.5. trNOE NMR (in collaboration with Prof. T. Peters, University of Lübeck)
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It has been shown in many instances that oligosaccharides are flexible
biomolecules.127,128 Therefore, different conformational families normally coexist in
solution. Upon binding to a receptor protein, one out of these numerous conformation
is selected, which is called bioactive conformation. Knowledge of the bioactive
conformation of various natural and artificial ligands is essential for a directed
designing of the modified ligands that exploit the conformational control necessary
for high binding affinity. For the analysis of bioactive conformation of
oligosaccharides, NMR spectroscopy based on transfer nuclear overhauser (trNOE)
effect is of fundamental importance. trNOE were originally observed and their
principles described more than 20 years ago.129 The experiment is based on a chemical
exchange between ligand molecules in solution and ligand molecules bound to
protein. One important physical parameter that distinguishes free and bound
molecules is so called motional correlation or tumbling time τc.130 τc is defined as the
time that is required for a molecule to advance by one radian during translational and
rotational diffusion. It is apparent that low or medium molecular mass molecules (<1-
2 kDa) have a short τc and, as a consequence, exhibit positive NOEs, no NOEs, or
very small negative NOEs depending on their molecular mass, shape and the field
strength. When a small molecule is liganded with a large-molecular-mass protein, the
relaxation is governed by the long τc of the protein, resulting in strong negative
NOEs. Upon dissociation, the small ligand tumbles again with its own characteristic
τc. Therefore, during a normal NOESY experiment, the large negative NOEs of the
bound ligand will be transferred to the sharp signals of the free ligand. It is always the
signal of the free ligand that carries the information about the bound state. trNOE
allows an analysis of bioactive conformation without requiring any knowledge about
the complex protein NMR spectrum. Additionally, trNOE experiments usually work
at optimum with a 10-20 fold excess of ligands, making it very easy to observe
signals of free ligand molecules against the background of broad protein signals.130
It is important to realize that trNOE is only observable for complexes with
dissociation constant KD approximately in the range between 10-6 to 10-3 M, since it is
required that the dissociation of the complex is fast on the relaxation time scale.
Consequently, trNOE is ideally suited for the investigation of protein-carbohydrate
complexes that are usually characterized by low binding affinity.130
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Results and Discussion
1. Partial structure of natural ligands and derivatives thereof
1.1. Synthesis of Neu5Acα(2→3)Galβ(1→3)GalNAcβ-OSE (1)
For the synthesis of Neu5Acα(2→3)Galβ(1→3)GalNAc terminus of GQ1bα and
derivatives thereof, the 2-(trimethylsilyl)ethyl (OSE) group was chosen as the
protecting group at the reducing end based on its compatibility of various reaction
conditions used in carbohydrate chemistry.131 According to the retro-synthesis
depicted in s c h e m e  1, the target molecule 1  was first dissected into
Neu5Acα(2→3)Gal and GalNAc. The former was then divided into the two
corresponding monosaccharides. For this purpose, three partially protected building
blocks 2, 3, 4 were required.
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Scheme 1: Retro-synthesis of Neu5Acα(2→3)Galβ(1→3)GalNAcβ-OSE (1).
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1.1.1. O -Ethyl S-[methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosyl)onate]dithiocarbonate (2)
2-O-Ethyl dithiocarbonate derivative of N-acetylneuraminic acid (Neu5Ac), or sialyl
2-xanthate was selected as the sialyl donor because of the mild condition for its
activation and its shelf stability.132 Sialyl 2-xanthate derivative 2 was easily prepared
in four steps from the commercial available Neu5Ac (5) as shown in scheme 2.133
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Scheme 2: a) cat. Amberlyst 15, MeOH, rt, 16 h (93%); b) Ac2O, py, DMAP, rt, 48h (91%); c) AcCl,
conc. HCl, CH2Cl2, rt, 16 h (77%); d) potassium O-ethyl dithiocarbonate, TBAHS, 5% aq. NaHCO3,
AcOEt, rt, 3 h (51%).
Esterification of Neu5Ac (5) with cat. Amberlyst 15 in MeOH afforded methyl ester 6
in 93% yield. Following acetylation with acetic anhydride (Ac2O) in py and cat.
amounts of 4-dimethylaminopyridine (DMAP) gave fully protected sialyl derivative
7. The subsequent transformation to 2-β-chloro derivative 8 was achieved in 77%
yield using acetyl chloride (AcCl), conc. HCl in a “Bombenrohr”, a procedure
originally reported by R. Kuhn et al.134 The final displacement of 2-chloro substituent
by O-ethyl dithiocarbonate with tetrabutylammonium hydrogensulfate (TBAHS) in
aq. NaHCO3-AcOEt proceeded via a SN2 mechanism (→ 2, 51%).133
1.1.2. 2-(Trimethylsilyl)ethyl 6-O-benzoyl-β-D-galactopyranoside (3)
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Based on the order of reactivity of the hydroxyl groups in galactose (primary
hydroxyl is much more reactive than secondary hydroxyls; 3-OH is mostly more
reactive than 2-OH, while the 4-OH is the least reactive one), building block 3 was
designed as shown in scheme 3: benzoyl protection at 6-OH and OSE at the anomeric
center. OSE was chosen not only for its stability under various conditions, but also
because it is amenable to selective removal or transformation to other activated
functional groups for further glycosylation.131
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Scheme 3: a) Ac2O, py, 0°C, 8 h, rt, 16 h (92%); b) 30% HBr-AcOH, CH2Cl2, 0°C, 2 h (87%): c)
HOSE, HgO, HgBr2, CaSO4, toluene, rt, 48 h (91%); d) NaOMe, MeOH, rt, 2 h (98%); e) benzoyl
cyanide, CH3CN-Et3N, -30°C, 2 h (56%).
By treating D-galactose (9) with Ac2O in py, per-acetylated D-galactose 10 was
formed quantitatively. Bromination135,136 in 30% HBr in AcOH afforded 11 with
exclusive α-configuration as confirmed by 1H NMR (J1,2 = 4.0 Hz) as a consequence
of the “anomeric effect”. Subsequent glycosylation of 2-(trimethylsilyl)ethanol
(HOSE) was accomplished in the presence of HgO, HgBr2 and dry CaSO4 to yield the
β-galactoside 12 (J1,2 = 7.8 Hz) via SN2 process.131 After deprotection under Zemplén
conditions, selective 6-O-benzoylation was reported either by a three step procedure
involving 3,4-O-isopropylidenation of 13, selective 6-O-benzoylation and subsequent
de-O-isopropylidenation (54%),137 or by the selective 3-O-benzylation of the 3,4-O-
stannylene acetal followed by selective 6-O-benzoylation and finally hydrogenolysis
to remove the benzyl group (36%).138 With benzoyl cyanide in CH3CN-Et3N (4:1) at
–30°C the 6-O-benzoylated product 3 was obtained in 56% yield. Compared to the
common regents for benzoylation as benzoyl chloride or benzoic anhydride, benzoyl
cyanide reacts smoothly with alcoholic, phenolic and mercapto functions with or
without base catalysis, depending on the character of the respective function.139 In the
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presence of a catalytic amount of a base, benzoylated products are formed with high
regioselectivity. The procedure is therefore extremely useful for the selective
benzoylation of the multifunctional molecules, such as carbohydrates, nucleosides and
nucleotides.139,140
1.1.3. Neu5Acα(2→3)Galβ(1→3)GalNAcβ-OSE (1)
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Scheme 4: a) NIS, TfOH, CH3CN-CH2Cl2 (3:2), -70°C, 18 h (29%); b) Ac2O, py, rt, 16 h (64%); c) BF3-Et2O,
CH2Cl2, 0°C, 6 h (84%); d) CCl3CN, Cs2CO3, CH2Cl2, 0°C, 8 h (74%); e) TMSOTf, CH2Cl2, 0°C, 4 h (18, 13%;
19, 46%); f) i. 80% aq. AcOH, 45°C, 4 h, ii. NaOMe, MeOH, rt, 4 h, iii. aq. NaOH, rt, 16 h (50%).
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The coupling reaction of sialyl donor 2 and acceptor 3 was carried out at –70°C with
N-iodosuccinimide (NIS) and trifluoromethanesulfonic acid (TfOH) as promoters141,142
in CH3CN-CH2Cl2 (3:2), affording the corresponding α-sialoside 14 in only 29%
yield, while the amount of traces of β-anomer was not determined. After acetylation
of the remaining hydroxyls, the reducing end was selectively deprotected by BF3-Et2O
in CH2Cl2,143 generating the hemiacetal saccharide 16 as an α/β-mixture. Subsequent
introduction of the trichloroacetimido group at the anomeric center was achieved with
trichloroacetonitrile in the presence of Cs2CO3 at 0°C in 74% yield. 17 was obtained
mainly as β-anomer as indicated by 1H NMR, which was in accordance with the
literature data (α:β=1:8).137 The following coupling reaction with acceptor 4 was first
carried out by using BF3-Et2O as promoter in CH2Cl2 at 0°C. Instead of the expected
product 18, only ortho-ester 19 was detected. The similar result was observed when
the reaction was promoted by trimethylsilyl trifluoromethanesulfonate (TMSOTf) in
CH2Cl2 at -20°C, however, when the reaction took place at 0°C with the same
condition, except 19, trisaccharide 18 as a minor product was formed in 13% yield.
Subsequent cleavage of its benzylidene group in 80% aq. AcOH, followed by
transesterification with NaOMe in MeOH and hydrolysis in aq. NaOH afforded the
target trisaccharide 1 in 50% yield.
1.2. Chemo-enzymatic synthesis of Neu5Acα(2→3)Galβ(1→3)Galβ-OSE (20)
Based on the SAR studies of gangliosides for MAG binding, the internal GalNAc
residue is not crucial for the binding affinity as compared to the terminal
Neu5Acα(2→3)Gal disaccharide.75 With a variety of monosaccharide moieties
(GlcNAc, Fuc), and/or with the different linkage patterns (Galβ1→4GlcNAc,
Galβ1→6GlaNAc), no significant effect on MAG recognition was observed.75,79
Trisaccharide 20 was therefore designed where Gal replaces GalNAc, which was
supposed to have comparable affinity as 1 but would be much more readily accessible
from the synthesis point of view. α(2→3)-Sialyltransferase (ST3Gal III, EC 2.4.99.6),
which can regio- and stereoselectively transfer the sialic acid moiety to the 3-OH of
the termial D-galactose,118,144 offers an elegant approach for the synthesis of 20
(scheme 5).
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Scheme 5: Retro-synthesis of Neu5Acα(2→3)Galβ(1→3)Galβ-OSE (20).
1.2.1. Chemical synthesis of Galβ(1→3)Galβ-OSE (22)
Galβ(1→3)Galβ-OSE (22) was initially designed to be chemically synthesized by the
coupling of partially protected galactosyl acceptor 23 with galactosyl donor: ethyl
2,3,4-tri-O-benzoyl-6-O-benzyl-1-thio-β-D-galactopyranoside145 (24 ), as shown in
scheme 6. Galβ-OSE (13) was treated with α,α-dimethoxytoluene in CH3CN in the
presence of p-toluenesulfonic acid monohydrate (TsOH⋅H2O) as catalyst, affording
the 4,6-O-benzylidene derivative 23 in 88% yield. With the galactosyl donor 24, the
coupling reaction was carried out under standard condition: NIS-TfOH as the
promoter in CH2Cl2 at –30°C. Surprisingly, the glycosylation took place at both 2-
and 3-position of the acceptor (53%, 25:26 = 1:3), with the 2-coupled disaccharide 26
as the major product.
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Scheme 6: a) α,α-dimethoxytoluene, TsOH⋅H2O, CH3CN, 0°C, 1.5 h (88%); b) NIS, TfOH, CH2Cl2, -
30°C, 1.5 h (53%, 25:26=1:3).
Additional experiments were executed to study the influence of the reaction
temperature and the amount of promoters on the regioselectivity. It was observed that
by either lowing down the temperature to –80°C, or decreasing the promoter to half
amount (1, 0.1 equiv. of NIS, TfOH respectively to donor 24), byproduct 26 was
predominantly formed together with 25 as indicated by TLC after 5 min., which
implicated that 2-coupling product is both kinetically and thermodynamically favored.
In contrast, as a general principle, 3-OH in 4,6-O-benzylidene-β-D-galactopyranoside
is mostly found to be more reactive than 2-OH, because the former is less influenced
by the electron-withdrawing effect of the anomeric center, hence is more nucleophilic
than 2-OH. To confirm the reactivity difference between the two hydroxyls, simple
benzylation was carried out under phase transfer condition, with benzyl bromide,
tetrabutylammonium bromide (TBAB) in 5% aq. NaOH-toluene (scheme 7). In good
agreement with the literature,131 3-benzylated product 27 was obtained as the major
product in 63% yield, while 2-benzylated product 28 (13%) and 2,3-dibenzylated
product 29 (4%) were also identified.
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Scheme 7: a) benzyl bromide, TBAB, 5% aq. NaOH, toluene, 60°C, 22h (27, 63%; 28, 13%; 29, 4%).
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Besides the different reactivity of hydroxyls, it is well known that regioselectivity also
depends largely on the steric effect. The bulky substitution (4,6-O-benzylidene) might
result in steric hindrance around 3-OH, which accounts for the reversed
regioselectivity observed. To address this question, galactosyl donor ethyl 2,3,4,6-
tetra-O-benzoyl-1-thio-β-D-galactopyranoside146 (3 0 ) was coupled with 6-O -
benzoylated galactosyl derivative 3 under the identical conditions (scheme 8). Again,
the β(1,3)-linked product 31 was obtained as the minor component with a ratio of 1:3
in favor of the β(1,2)-linked product 32 . Since signals of H-2 and H-3 were
overlapped in the 1H NMR spectra of both products, the structures were confirmed
after acetylation, leading to products 33 and 34 which exhibited a significant low field
shift for the protons at the 2- or 3-position, respectively (H-2 of 31→33: 3.75→5.16
ppm; H-3 of 32→34: 3.71→4.99 ppm). Therefore, the influence of steric hindrance
from 4,6-O-benzylidene substituent to the regioselectivity of glycosylation can be
excluded.
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Scheme 8: a) NIS, TfOH, CH2Cl2, -30°C, 3 h (36%, 31:32=1:3); b) Ac2O, py, rt, 16 h (33, 90%; 34,
90%).
Taken together, although 3-OH is more reactive than 2-OH in β-D-galactose moiety,
coupling reactions took place primarily at the 2-position of the acceptors 23 and 3,
independent of a bulky substituent at the 4-position. A possible reason might be the
bulky donors 24 and 30, both of which were fully protected by benzoyl and/or benzyl
groups. Since the β-face of the Gal ring for both acceptors (23 and 3) is partially
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occupied by 4,6-O-benzylidene or 6-O-benzoyl, respectively, it should be much easier
for the bulky donor to attack from the α-face (2-substitution). However, for small
electrophiles like benzyl, the influence from the steric effect of the donor is not so
pronounced, and consequently the substitution takes place predominantly at the more
reactive 3-OH.
To solve this problem of regioselectivity, one can either decrease the size of the donor
by changing the protecting groups, such as acetyls, or protecting the acceptor at both
the 2- and 6-position to prevent the side reaction. Here, we took the second option and
prepared the 2,6-O-disubstituted galactosyl acceptor.
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Scheme 9: a) aceton, TsOH⋅H2O, reflux, 1 h (82%); b) benzyl bromide, NaH, DMF, rt, 16 h.
As shown in scheme 9, the 6-O-benzoylated Gal derivative 3 was treated with acetone
in the presence of TsOH⋅H2O, generating the 3,4-O-isopropylidene derivative 35 in
82% yield. Subsequent benzylation at the 2-position was carried out with benzyl
bromide and NaH in DMF at rt. It took 16h for the starting material to be completely
consumed as observed by TLC. The product, although appears as one single spot on
TLC, is a mixture of expected product 36 and byproduct 37 with a ratio of 1:2.4 in
favor of 37. A trace of water included in the reagent and/or the solvent might convert
NaH to NaOH, which in turn hydrolyzed the 6-O-benzoyl, followed by benzylation at
the free 6-OH.
Instead of repeating the former procedure, we adopted another strategy to prepare the
acceptor 38 within fewer steps as shown in scheme 10. Starting from the known
building block 13, 3,4-O-isopropylidene derivative 39 was obtained in 85% yield by
treatment with 2,2-dimethoxypropane and cat. TsOH⋅H2O in DMF. After protecting
the 2- and the 6-OH as benzyl ethers, the isopropylidene was cleaved under acidic
condition to afford the 2,6-diprotected galactosyl acceptor 38 in 65% overall yield
(13→38).
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Scheme 10: a) 2,2-dimethoxypropane, TsOH⋅H2O, DMF, 80°C, 3 h (85%); b) benzyl bromide, NaH,
DMF, 0°C, 1.5 h (88%); c) 80% aq. AcOH, 90°C, 1 h (92%).
With the properly protected acceptor in hand, the coupling reaction with donor 30 was
carr ied out  under  two react ion condit ions:  NIS-TfOH or
dimethyl(methylthio)sulfonium triflate (DMTST, 40)147 (scheme 11), affording
Galβ(1→3)Gal derivative 41 in 60% and 87% yields, respectively.
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Scheme 11: a) NIS, TfOH, CH2Cl2, -30°C, 1 h (60%); b) DMTST, CH2Cl2, 7°C, 14 h (87%); c)
NaOMe, MeOH, rt, 2 h (85%); d) H2, 10% Pd-C, MeOH, rt, 3 h (83%).
Both promoters play a similar role in glycosylation reactions with thioglycoside
donors as shown in scheme 12. The soft electrophile E+ (e.g. I+ from NIS, and MeS+
from DMTST) attaches to the sulfur functionality of the glycosyl donor, whereafter
the anomeric carbo-sulfur bond is broken to generate an oxycarbenium ion (with
counterion X-, e.g. TfO- in both cases), which then reacts with the acceptor
nucleophile to yield the O-glycoside.148
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Scheme 12: General mechanism of glycosylation with thioglycoside donors.
In the case of this glycosylation reaction, although donor 30 is deactivated by the 4
electron-withdrawing benzoyl groups, 3-OH of the acceptor 38 is highly nucleophilic
41
due to the electron-donating effect from 2,6-O-dibenzyl substitution. Therefore, it is
reasonable that higher yield was achieved with DMTST, a promoter with modest
reactivity that can match perfectly with the reactivity of the donor/acceptor couple, as
compared with the one with more reactive NIS-TfOH promoter. It is notable that
DMTST, which was prepared from methyl disulfide (4 3 ) and methyl
trifluoromethanesulfonate (MeOTf, 44) in CH2Cl2 (scheme 13) is extremely sensitive
to H2O, O2, light, and heat. Therefore, great cautions should be taken during its
preparation, utilization, and storage.
SMe S Me F3C S
O
O
OMe S
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S Me OTf+
a)
43 44 40
Scheme 13: a) CH2Cl2, rt, 16 h (87%).
After smooth removal of the benzoate and benzyl protecting groups by
transesterification and hydrogenation successively, Galβ(1→3)Galβ-OSE (22) was
obtained in 72% yield (41→42→22).
1.2.2. Enzymatic sialylation
As discussed in Introduction part (3.2.), the enzymatic oligosaccharide synthesis
employing sialyltransferases as biocatalysts offers an alternative approach with
excellent stereoselectivity and generally good to excellent yield.118,119,149,150
Furthermore, the synthetic value of these enzymes would be greatly enhanced if they
would tolerate a broad spectrum of acceptor molecules in addition to their specificity
in vivo.120 Previous studies indicated that the natural substrates for ST3Gal III are type
I [Galβ(1→ 3)GlcNAc] and type II [Galβ(1→4)GlcNAc] disaccharides.122-124 In
addition, it was shown that ST3Gal III accepts a wide variety of substituents at the
glucosamine nitrogen,120,151 as well as lactal, lactose and 2-O-pivaloyllactose.119 Here,
rST3Gal III (EC 2.4.99.6) was used to transfer the sialic acid moiety from CMP-
Neu5Ac (21) to the 3-OH of the terminal galactose of non-natural substrates as shown
in scheme 14.
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Scheme 14: Enzymatic sialylation with rST3Gal III, a) pH 6.5, BSA, CIAP, sodium cacodylate buffer,
MnCl2.
In addition to the chemically synthesized disaccharide Galβ(1→3)Galβ-OSE (22),
trisaccharide Galβ(1→3)[Neu5Acα(2→ 6)]Galβ -OSE (45 ) (synthesis will be
discussed in 1.4.), Galβ(1→3)GalNAcβ-OSE (46) and Galβ(1→3)GalNTCAβ-OSE
(47),152 together with natural substrates type I 48153,154 and type II 49154,155 were
incubated with CMP-Neu5Ac and rST3Gal III  (9 U/L) following our standard
sialylation protocol.156 After 17-24 hours of incubation, one additional aliquot of
transferase was added (except for the natural substrates 48 and 49). However, the
addition of a further aliquot of rST3Gal III and CMP-Neu5Ac did not further increase
the yields anymore (table 4).
Table 4: Isolated yields and kinetic data of the enzymatic sialylations.a)
Entry Acceptorb) Product Isolated
product
[%]c)
Recovered
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[%]
Vmax
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 
 
 
 
 
 
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a). substrates and CMP-Neu5Ac were incubated with rST3Gal III for 3-5 days at 37 °C in a mixture of
50 mM sodium cacodylate buffer (pH 6.5), 60 mM MnCl2-solution and water containing BSA and
CIAP (EC 3.1.3.1); b). 48, 49: 3 mg, 21, 45, 46, 47: ∼10 mg; c). the course of the reactions was
monitored by TLC (silica gel, DCM/MeOH/H2O 10:4:0.8); d). prepared by Dr. Oliver Schwardt,
Institute of Molecular Pharmacy, University of Basel.
The natural substrates 48 and 49 were converted quantitatively into the corresponding
trisaccharides 50 and 51 (table 4, entries 1 and 2). In addition, the disaccharides 22,
4 6  and 47 were also sialylated by rST3Gal III affording the corresponding
trisaccharides 20, 52 and 53 in acceptable yields (entries 3, 5 and 6). In all three
cases, the unreacted substrates could be recovered almost quantitively. The kinetic
data for the sialylations indicate that the activity of rST3Gal III towards the substrates
22, 46 and 47 is reduced about 10-fold compared to the one for its natural substrates
48 and 59. As expected, the transfer efficiency Vmax/Km is much lower for the
unnatural substrates. This explains the incomplete, but still preparatively useful
conversion of the type III disaccharides. Probably, due to the bulkiness of the
substituent in the 6-position of galactose, the 6-O-sialylated trisaccharide 45 was not
tolerated as substrate by rST3Gal III (entry 4).152,157
The introduction of a sialic acid unit was indicated by signals in 13C NMR at
approximately 100 ppm and 40 ppm, which are characteristic for the C-2 and C-3 of
an α-linked sialic acid.120,151,155 In addition, down-field shift (~4 ppm) of the galactose
C-3 in 13C NMR and approximately 0.6 ppm of the galactose H-3 in 1H NMR
44
confirmed the regioselective introduction of sialic acid in the 3-position of the
galactose moiety.122-124
1.3. Synthesis of Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]Galβ-OSE (54)
“Chol-1” gangliosides, such as GQ1bα, GT1aα that contain an additional α2,6-linked
sialic acid on GalNAc display enhanced potency for MAG binding, indicating the
important role this moiety plays in the binding event.75 Based on this observation,
tetrasaccharide Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]Galβ-OSE (54 ) was
also planned to synthesize. Since the unavailability of α(2→6)-sialyltransferase,
different strategy was employed for chemical synthesis of 54. According to the retro-
synthesis (scheme 15), a properly protected disaccharide and one sialyl donor were
needed to carry out the whole synthesis.
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Scheme 15: Retro-synthesis of Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]Galβ-OSE (54).
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1.3.1. Preparation of the disaccharide core
As indicated in scheme 15, Galβ(1→3)Gal disaccharide core should be protected in
such a way that the first sialic acid moiety can be introduced to the 3-position of the
terminal Gal, and in turn, the second one goes to the 6-position of Gal at the reducing
end. Concerning the α2,3-sialylation, it is found that good yields and high α-anomeric
selectivities were achieved when glycosyl acceptors were partially protected
(glycosylation of diol and triols).121,137,138 When the acceptor is a galactose derivative,
the best results were obtained by the use of 2,3,4-trihydroxy derivatives rather than
the glycosylation of similar 3,4-diols. As shown in scheme 16, with the same sialyl
donor 55 and reaction system (DMTST, CH3CN, -40°C), 47% yield of pure α-anomer
56 was achieved with a lactoside derivative containing 2,3,4-trihydroxy in the
galactose moiety 57. However, yield and stereoselectivity were much lower  (58,
38%, α:β=4:1) when 2-OH was protected as a benzyl ether 59.121,158
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Scheme 16: Sialylations of diol and triol galactosyl acceptors.
The regioselectivity of sialylation is due to the greater reactivity of the equatorial OHs
(2-OH and 3-OH) compared to the axial one (4-OH). Furthermore, the 2-OH has a
lower nucleophilicity due to the electron-withdrawing effect of the adjacent anomeric
center. When a similar sialylation was performed with a galactosyl acceptor having
only a free 3-OH, both the yield and anomeric stereoselectivity were significantly
reduced.121 Additionally, it should also be considered that procedures for the
preparation of glycosyl acceptors having several free hydroxyls are often easier to
conduct and, hence, may offer shorter routes to oligosaccharides. Based on these
studies, compound 60 was selected as the disaccharide core for further α2,3- and
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α2,6-sialylation. As show in scheme 17, it can be reached in one step from the known
building block 42.
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Scheme 17: a) benzoyl cyanide (0.9 equiv.), CH3CN-Et3N (4 : 1), -40~-45°C, 1.5 h (80%).
Table 5: Studies of selective 6-O benzoylation conditions of 42
Entry Benzoyl cyanidea) CH3CN-Et3N Temp. Time 60b)
1c) 1.2 equiv. 4 : 1 -30°C 2 h 42%
2d) 1.1 equiv. 4 : 1 -40~-45°C 2 h 65%
3d) 1.1 equiv. 4 : 1e) -80°C 3 h f)
4d) 1.1 equiv. g) -40~-45°C 2 h f)
5d) 0.9 equiv. 4 : 1 -40~-45°C 1.5 h 80%h)
a). equivalent to 42; b). separated yields of 60; c). benzoyl cyanide was added in one portion to 42 in
solvents; d). benzoyl cyanide was dissolved in CH3CN (volumn depends on the reaction scale, see
experimental part) and added by drops; e). CH2Cl2 was used instead of CH3CN because of its low
melting point; f). no separated yields, reactions were followed by TLC, from which product and
unreacted starting material, together with multi-benzoylated byproducts were detected; g). 1.2
equivalent of Et3N to 42 was used; h). calculated according to the amount of benzoyl cyanide.
As summarized in table 5, we first tried the selective 6-O-benzoylation with the
standard procedure employed before (entry 1), affording the product 60 in 42% yield,
which was largely due to the side reactions of multiple benzoylation. Although the
multi-benzoylated byproducts can be separated from the expected product, and
recovered to be 42 after Zemplén deprotection, the low yield prompted us to modify
the reaction conditions for higher selectivity.
In contrast to the standard procedure, the way of adding benzoyl cyanide was
modified: it was dissolved in CH3CN and added dropwise in order to maintain its low
concentration in the reaction mixture, thus prevent side reactions to take place. In
addition, temperature effects were also studied. When the reaction took place at -40~-
47
45°C, combined with the effect of slow adding of benzoyl cyanide, the yield rose to
65% (entry 2). However, no improvement was observed by further decreasing the
temperature to –80°C (entry 3). The role of base in the reaction was studied by
minimizing the amount of Et3N to 1.2 equiv., which showed no better result (entry 4).
Furthermore, the amount of benzoyl cyanide was decreased to 0.9 equiv., which gave
the highest yield of 80% (entry 5). Therefore, the best reaction conditions were
generated: 0.9 equiv. of benzoyl cyanide dissolved in CH3CN was added dropwise to
the starting material 42 in CH3CN-Et3N (4:1) at -40~-45°C, followed by reacting for
1.5 h at the same temperature. Thus, properly protected disaccharide core 60 was
achieved in 80% yield.
1.3.2. Studies of α2,3-sialylations
Sialylation with high yield and stereoselectivity is one of the most challenging aspects
in oligosaccharide chemistry, which is mostly due to the following reasons:
1) The tertiary anomeric center is not only sterically hindered, but the reactivity is
also electronically disfavored by the carboxylic acid moiety;
2) No neighboring group is present at C-3 to guide the nucleophilic attack by the
glycosyl acceptor, additionally, the deoxy moiety in combination with the electron-
withdrawing carboxylic acid leads to β-elimination, the most serious side reaction
which forms sialic acid glycal;
3) The N-acetyl group may react with strong electrophiles to give byproducts;
4) The β-sialoside is the thermodynamically favored product, while virtually all sialic
acid containing saccharides in nature carry the sialic acid moiety in α-
configuration.132,159
To address these difficulties, various explorations were carried out concerning e.g.
functions of the activating group at the anomeric center, the participation of the C-3
auxiliary, the solvent effect of CH3CN, the substituent effect of carboxylic ester and
so on, which achieved considerable improvements during the past years.132,159
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In sialylation reactions, the character of the donor is a major determinant of the
anomeric selectivity. It depends on the leaving group at the anomeric center, the
protecting group of amine at C-5 and the ester of the carboxylic acid. It should be
noticed that the most successful sialyl donors use rather unusual anomeric leaving
groups.121 For example, fluorides and trichloroacetimidates are most widely applied
for common glycosyl donors, whereas sialyl donors rarely or never possess these
leaving groups. Among the common activating groups of sialyl donors, the family of
2-thio derivatives is one of the most attractive sialyl donors, such as 2-thioalkyl/aryl
and 2-xantho sialyl derivatives.148 Due to the excellent chemical stability, thio groups
offer efficient protection of the anomeric center and are compatible with many
reaction conditions often employed in carbohydrate chemistry.  However, in the
presence of soft electrophiles (NIS-TfOH, DMTST, etc.), thioglycosides can be
activated and used directly in glycosylations. Another attractive feature is that they
can be transformed into a range of other glycosyl donors. In view of the side reaction
caused by the N-acetyl group, modifications were carried out by employing more
electron-withdrawing groups, like N -acetylacetamido (N -Ac2),160 N-
trichloroacetamido (N-TFA),161 or masking it by N3,162 therefore decreased the
nucleophilicity, in turn avoided its reaction with electrophile and resulted in improved
yields and stereoselectivities. Recently, the auxiliary role of esters of the carboxylic
acid either by "long range participation", forming β-intermediate which facilitate α-
glycosidation,163,164 or by enhancing the solvent effect by stabilizing the β-oriented
nitrilium ion165 has been explored.
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Here, through the combination of 2-thiomethyl or 2-xanthate as the leaving groups, N-
Ac, N-Ac2, N-TFA at C-5 and methyl or benzyl carboxylate, the six sialyl donors 2,
55, 61-64 were readily prepared according to scheme 18. Starting from Neu5Ac (5),
methylation and acetylation gave fully protected 7, which can either be converted to
2-xantho sialoside methyl ester 2  (see also scheme 2), or coupled with
(methylthio)trimethylsilane (TMSSMe) and cat. TMSOTf giving 2-thiomethyl sialyl
donor 55 in a quantitative yield as a mixture of α/β-anomers.166 It should be noted that
in sialylations, the two anomers have very comparable glycosyl donor properties and
therefore do not need to be separated.121 Removal of O-acetyls and N-acetyl was
accomplished quantitatively by treating 55 with methylsulfonic acid (MsOH) in
MeOH at 60°C.167 Subsequent selective N-trifluoroacetylation of 65 with methyl
trifluoroacetate in the presence of Et3N in MeOH followed by O-acetylation with
Ac2O in py gave sialyl donor 61 in overall yield of 55% (55→61).161 By employing
iso-propenyl acetate (IPA) as an acetylating reagent in the presence of cat.
TsOH⋅H2O, sialyl derivative 66 with N-diacetyl functionality can be obtained in 80%
yield from Neu5Ac methyl ester.160 With the above-described procedure of
thiomethylation, 62 was readily obtained in 65% yield. Meanwhile, Neu5Ac benzyl
ester 67 was prepared by acetylation of 5 (→67 quant.), and following benzylation
with BnBr in the presence of KF in DMF (→68, 89%).168 The resulting 68 can either
be transformed to 2-thiomethyl sialyl donor 63 in 82% yield, or quantitatively
converted to 2-xantho sialoside benzyl ester 64 through 2-chloro sialyl derivative
69.169
With these six sialyl donors in hand, sialylations with disaccharide 60  or
monosaccharide 3 were carried out with NIS-TfOH or DMTST as promoters, in
CH3CN at low temperature. The proposed mechanism for α-predominant sialylation
with 2-thio sialyl donors in CH3CN is show in scheme 19.159
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Scheme 19: Proposed mechanism for α-predominant sialylations with 2-thio sialyl donors in CH3CN.
The soft electrophilic species (I+, MeS+) formed under the reaction conditions react
with the lone pair of sulfur resulting in the formation of a sulfonium intermediate
which is an excellent leaving group. Upon leaving, the generated oxycarbenium ion
can be attacked by nitrogen of CH3CN to give a nitrilium ion, which adopts a
preferred axial (β) configuration. Subsequent nucleophilic substitution of the nitrilium
ion with the acceptor gives predominantly the α-sialosides.
As shown in scheme 20, 2-thiomethyl sialyl donors 55, 61-63 were coupled with
disaccharide 60 using NIS-TfOH or DMTST as promoters in CH3CN at low
temperature. The sialylation with 55, the most commonly used sialyl donor, achieved
the highest yield of α-sialoside 70 (54%) by employing NIS-TfOH as the promoter in
CH3CN at –35°C overnight. However, only the sialic acid glycal 71 (39%) together
with quantitatively recovered starting material 60 were obtained when DMTST was
used in CH3CN at 0°C overnight, which is the general procedure with DMTST. The
significant difference between the two reactions is the reaction temperature. Due to
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the low reactivity of DMTST compared to NIS-TfOH, the reaction was carried out at
0°C (-35°C with NIS-TfOH), where the elimination to the corresponding glycal
become thermodynamically favored compared to the sialylation. A similar high yield
(72, 51%) was achieved with 2-thiomethyl sialoside benzyl ester 63 under the same
condition, indicating methyl and benzyl esters have similar influence on this
sialylation. Surprisingly, in contrast to the literatures,160,161 no major product was
observed by using 61 as sialyl donor, and only 34% of glycal 73 was obtained with
donor 62. Thus, 2-thiomethyl sialyl donors with both methyl and benzyl esters
showed comparable results, whereas N-acetyl at C-5 showed to be superior compared
to N-diacetyl and N-trifluoroacetyl functionalities.
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To further elucidate the function of the leaving groups at the reducing end, donor 2
and 64 were reacted with acceptor 3 as shown in scheme 21. By coupling of 2 and 3,
disaccharide 14 was obtained in 29% yield (see also scheme 4). The same reaction
conditions were employed with sialyl donor 64, resulting in product 74 with
comparable yield (26%).
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Scheme 21. Sialylations of 3 with 2-xantho sialyl donors: a) NIS, TfOH, CH2Cl2-CH3CN(2:3), -70°C,
16h (14 29%, 74 26%).
Based on these studies, sialyl donors 55, 63 with thiomethyl group at the anomeric
center, N-acetyl at C-5 and methyl or benzyl ester of the carboxylic acid showed the
best reactivity and α-stereoselectivity. They were therefore employed in α2,3- and
α2,6- sialylations in this work.
1.3.3. α2,6-sialylation
Trisaccharides 70 and 72 served as acceptors for subsequent α2,6-sialylation after
manipulations. In the case of 72, the carboxylic acid of sialic acid moiety and the 2,6-
positions in galactose at the reducing end are protected with benzyl groups. Before the
cleavage of 2,6-O-dibenzyl to generate free 6-OH for further glycosylation, benzyl
carboxylate had to be converted to the corresponding methyl ester by
transesterification with NaOMe in MeOH (scheme 22). The resulting 75 could be in
turn re-protected with acetyls followed by debenzylation. Unfortunately, no signal of
methyl ester was observed in 1H NMR spectrum after transesterification. The possible
reason might be that hydrolysis took place to generate the free carboxylic acid due to
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a trace of water included in the reagent or the solvent. However, due to the limited
amount of 72 available, we used trisaccharide 70 to continue the synthesis of target
tetrasaccharide 54.
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Scheme 22: a) NaOMe, MeOH, rt, 16h (no product).
By two simple steps, acetylation and debenzylation, the trisaccharide acceptor 76
could be obtained. As shown in scheme 23, 70 was acetylated with Ac2O in pyridine
giving 77 in 80% yield. Since the debenzylation step by hydrogenation was not
straightforward, various reaction conditions were examined as summarized in table 6.
O
O
OBn
OSE
HO
O
OBzHO
OH
OBn
OO
CO2Me
AcO
AcHN
AcO OAc
OAc
70
O
O
OBn
OSE
AcO
O
OBzAcO
OAc
OBn
OO
CO2Me
AcO
AcHN
AcO OAc
OAc
77
O
O
OH
OSE
AcO
O
OBzAcO
OAc
OH
OO
CO2Me
AcO
AcHN
AcO OAc
OAc
76
a)
b)
Scheme 23: a) Ac2O, py, rt, 16h (80%); b) 10% pd-C (150% w/w), EtOH-HOAc (5:1), 45°C, 5 h (76,
76%; 79, 15% see table 3, entry 4).
56
Table 6: Studies of debenzylation conditions of 77
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++
Entry
Catalyst
(w/w)
Solvents Temp. Timea) Pressure Yieldsb)
1 10% Pd-C
(200%)
dioxane-MeOH (1:4)
cat. AcOH
rt 68 h 4 bar
50%c)
76:78=3:2
2 10% Pd-C
(300%)
dioxane-MeOH-AcOH
(1:4:1)
rt 3 d 4 bar
70%c)
76:78=3:2
3 20% Pd(OH)2
(100%)
EtOH-AcOH (10:1) 45°C 4 d 1 bar
76:42%,
     79:30%
4 10% Pd-C
(150%)
EtOH-AcOH (5:1) 45°C 5 h 1 bar
76:76%,
     79:15%
5 10% Pd-C
(150%)
EtOH-AcOH (5:1) 45°C 18 h 1 bar d)
a). followed by TLC, till 77 was completely consumed; b). isolated yields; c). mixture of 76 and 78,
ratios were determined by 1H NMR; d). no isolated yield.
Hydrogenation of 77 under normal conditions (H2 with cat. 10% Pd-C at rt under
normal pressure) showed no reaction or to be impractically slow (result not shown in
table 6). Based on the experience gained from the hydrogenation of 41 (see 1.4.),
more vigorous reaction conditions, e.g. large amount of catalyst (10% Pd-C, 200%
w/w) and increased pressure (4 bar) were employed, allowing the complete
consumption of the starting material within 68 h (entry 1). According to the MS and
1H NMR, 76 and 78 were formed in a ratio of 3:2 (76:78). Under the extremely harsh
condition of hydrogenation, the phenyl ring of the benzoate at 6-position was partially
reduced to cyclohexane. Since these two substances 76 and 78 have exactly the same
Rf value with various systems of developing solvents, it was impossible to follow
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their formation by TLC. Under the similar conditions (entry 2), 70% of a 3:2 mixture
of 76 and 78 was obtained. It is known that 20% Pd(OH)2 is used frequently as the
catalyst at high temperature for the debenzylation of the similar molecules.170-172 By
treating 76 with 20% Pd(OH)2 (100% w/w) in EtOH-AcOH (10:1) at 45°C (entry 3),
the reaction took 4 d to complete, leading to the desired product 76 (42%) and 79
(30%). Gratifyingly, by using 10% Pd-C under similar condition, the reaction was
much faster. The starting material was completely consumed after 5 h as indicated by
TLC (entry 4). As a major product, 76 was obtained in 76% yield, while the side
product 79 was formed only to the extent of 15%. It should be noticed that the
byproduct appeared at the very early stage of the reaction. Instead of having two
impurities (79 and unreacted 77), it was practically preferred to let the starting
material to be fully consumed before stopping the reaction. By prolonging the
reaction time to 18 h, the amount of 79 was increased considerably as indicated by
TLC (entry 5). As a summary, 2,6-O-dibenzyl derivative of galactose at the reducing
end is difficult to be selectively removed, possibly due to the steric hindrance that is
very critical to heterogeneous hydrogenation. Difficulties of slow and incomplete
reaction were encountered under general conditions. By using the harsh conditions,
byproducts could not be avoided. Interestingly, different byproducts were obtained
according to different conditions employed. By catalytic hydrogenation under high
pressure (4 bar), the phenyl ring at the 6-position was reduced to the cyclohexane
(entries 1 and 2), while at high temperature, axial-O-acetyl group at 4-position was
cleaved possibly through the alcoholysis under acidic condition (entries 3-5).
Besides the traditional hydrogenation method, other debenzylation conditions were
also applied. Light-initiated debenzylation173,174 performed under UV irradiation
(375W lamp) by using N-bromosuccinimide (NBS) in the presence of aqueous
calcium carbonate is one alternative approach for de-O-benzylation of sterically
hindered benzyl ethers, which is supposed to involve radical bromination at the
benzylic position and subsequent hydrolysis of the resulting α-bromo ether. The
system of sodium bromate and sodium dithionite (NaBrO3-Na2S2O4) in AcOEt-H2O is
also reported to selectively cleave the benzyl ether with a similar mechanism.175
Unfortunately, both procedures didn’t result in the desired product in our case.
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By employing the modified catalytic hydrogenation, trisaccharide acceptor 76 was
available for the further α2,6-sialylation. The coupling reaction was carried out under
similar reaction condition with the same sialyl donor 55 as shown in scheme 24. The
desired tetrasaccharide with α-configuration 80α was achieved in 38% yield, along
with 12% of β-anomer 80β. After final deprotection by transesterification with
NaOMe in MeOH and following hydrolysis with LiOH in dioxane-H2O solution, 54α
and 54β were obtained in 49% and 68% respectively.
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Scheme 24: a) NIS, TfOH, CH3CN, -40°C, 16 h (80α, 38%; 80β, 12%); b) i. NaOMe, MeOH, rt, 7 h,
ii. LiOH (0.1M), dioxane-H2O (1:1), rt, 16 h, iii. Dowex 50×8 (Na+) (54α, 49%; 54β, 68%).
1.4. Synthesis of Galβ(1→3)[Neu5Acα(2→6)]Galβ-OSE (45)
It is known from the SAR studies of gangliosides that both sialic acid moieties, the
terminal α2,3-linked to Gal and the internal α2,6-linked to GalNAc are essential for
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binding affinity.56,57 The α2,6-linked sialic acid can enhance the adhesion as shown by
“Chol-1” gangaliosides, like GQ1bα, while no activity was found with gangliosides
without the terminal α2,3-linked sialic acid moiety, like GM1a.71 To further elucidate
the SAR, trisaccharide 45 was planned to be synthesized. According to the retro-
synthesis shown in scheme 25, the preparation of 45  was supposed to be
straightforward. The sialyl donor 55 was readily available, while the acceptor 81 can
be synthesized in one step from building block 41.
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Scheme 25: Retro-synthesis of Galβ(1→3)[Neu5Acα(2→6)]Galβ-OSE (45).
Debenzylation of 41 under standard catalytic hydrogenation conditions turned out to
be extremely difficult (table 7). No reaction was observed under normal conditions
(H2 with cat. 10% Pd-C, rt, normal pressure) (entry 1). The starting material was
completely resistant to the hydrogenation even at high pressure (entry 2). Trace of
product could be observed by increasing the amount of 10% Pd-C (100% of the
amount of 41), the structure of which was assigned to be 82 (5%), mono-debenzylated
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at 6-position (entry 3). The desired product 81 was obtained when the amount of Pd-C
was further increased to 150% (w/w), adding MeOH and increasing the reaction time
as long as 5 d (entry 4). Even though, the reaction was not complete as the byproduct
82 and unreacted 41 could be detected from TLC, and the separated yield of 81 was
only 28%. The best yield was achieved by raising the amounts of MeOH and AcOH
(dioxane-MeOH-AcOH = 1:4:1) and reacting for 9 d at high pressure (entry 5, 67%).
Table 7: Studies of debezylation conditions of 41.
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Entry 10% Pd-C (w/w) Solvents Temp. Time Pressure 81a)
1 20% dioxane, cat. AcOH rt 22 h - b)
2 20% dioxane, cat. AcOH rt 20 h 4 bar b)
3 100% dioxane, cat. AcOH rt 15 h 4 bar c)
4 150%
dioxane-MeOH (1:2),
cat. AcOH
rt 5 d 4 bar 28%
5 150% dioxane-MeOH-AcOH 1:4:1 rt 9 d 4 bar 67%
a). isolated yields; b). no trace of product could be detected from TLC, 41 was quantatively recovered;
c). 5% of 82 and 90% of 41 were obtained after chromatography.
The difficulties encountered in the catalytic hydrogenation of 41 were presumably due
to the steric hindrance caused by four benzoyls in the terminal Gal moiety. Although
81 could be obtained in 67%, the harsh condition and the impractically long reaction
time prompted further study of this reaction. As shown in scheme 26, when the
benzoyls were converted to much smaller acetyls in two steps (41→42→83), the
debenzylated product 84 could be formed quantitatively, which confirmed the
61
postulated steric influence. It should be noted that the reaction time might be far less
than 2 d, since no TLC-control was tried during that period of time.
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Scheme 26: a) NaOMe, MeOH, rt, 2 h (87%); b) Ac2O, py, DMAP, rt, 16 h (92%); c) 10% Pd-C
(150% w/w), dioxane-MeOH-AcOH (1:4:1), rt, 4 bar, 2 d (94%).
With the disaccharide 81 in hand, the coupling reaction was carried out under the
standard conditions with sialyl donor 55 as shown in scheme 27. The desired α-
anomer 85 was obtained in 45% yield after chromatography, while the amount of a
trace of β-anomer was not determined. The final deprotection by transesterification
with NaOMe in MeOH followed by hydrolysis in aq. NaOH afforded 45 in 90%
yield.
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Scheme 27: a) NIS, TfOH, CH3CN, -30°C, 16 h (45%); b) i. NaOMe, MeOH, rt, 7 h, ii. aq. NaOH, rt,
16 h (90%).
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1.5. Biological assay (in collaboration with Prof. Soerg Kelm, Bremen)
By employing the fluorescent hapten inhibition assay, partial structure of GQ1bα and
derivatives thereof were tested. Trisaccharide 20 served as a reference compound in
this work with its rIP equal to 1, while the rIPs of the others were calculated by
dividing the IC50 of 20 by that of tested compounds respectively. In case the test
compound is more active than the reference compound, rIP > 1 is obtained. For a
better comparison, besides all the oligosaccharides described above, tetrasaccharides
Neu5Acα(2→3)Galβ(1→3)[Neu5Acα/β(2→6)]GalNAcβ-OSE (86α, 86β) were also
included in table 8.
The inhibition studies with the synthetic compounds readily revealed several aspects
of the interaction between MAG and sialylated oligosaccharides. First, α2,3-linked
terminal sialic acid is the prerequisite for binding to MAG. Without it, as in
trisaccharide 45, only a weak inhibition is observed; Second, the additional α2,6-
linked sialic acid residue enhanced the binding affinities, as shown by 54α and 86α,
which were 3 to 4 times more active than 20  and 1 respectively; Third, the
incorporation of a β2,6-linked sialic acid at this position leads to reduced binding as
indicated by low rIPs of 54β and 86β; Last, there is no significant difference in the
affinities when GalNAc is replaced by Gal, by comparing 20 with 1 and 54α with
86α. To further characterize the MAG-ligand interaction at atomic resolution, a few
selected compounds were subjected to STD NMR and trNOE experiments.
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Table 8: Bioaffinities of partial structures of GQ1bα and derivatives thereof.
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1.6. STD NMR (in collaboration with Prof. Bernd Meyer)
Trisaccharides 1, 20 and tetrasaccharide 86α were investigated by STD NMR
experiments with Fc-MAGd1-3 (figure 12). STD effects were normalized to the N-
acetyl of the α2,3-linked terminal sialic acid, which showed the absolute effect of
1:7.6%, 20: 3.4% and 86α : 24.8%, respectively. Larger values indicate closer
proximity of the respective functional group to the protein and thus describe the
binding epitopes.
Figure 12: STD effects of 1, 20 and 86α.
The STD data yield information on the binding events and on the binding epitopes of
the ligands upon interacting with Fc-MAGd1-3. For trisaccharides 1 and 20, it is clear
that the terminal sialic acid is mostly involved in binding, while the core disaccharide
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Gal-GalNAc or Gal-Gal residues should be in less intimate contact with the binding
site. In the case of tetrasaccharide 86α, both sialic acid residues are involved in
binding. It should be noticed that the α2,3-linked terminal sialic acid interacts with
the protein mostly via its N-acetyl group, glycerol side chain and carboxylic acid,
while the last interaction is indirectly proved by the strong STD effect on 4-H of Gal,
which is assumed to be caused by the salt bridge between the carboxylic acid of the
sialic acid and a matching residue on the protein surface. It is especially interesting
that the glycerol side chain of α2,6-linked internal sialic acid was greatly involved in
binding as compared with the other functional groups within the moiety. Similar to
that of the trisaccharides, the neutral Gal-GalNAc core showed low STD effects,
however, the 6-H of Gal demonstrated the most pronounced effect, which indicates
that the hydoxymethyl group of Gal is directly involved in the binding process. In
conjunction with the results from trNOE experiments (see 1.7.), it is likely that the
trisaccharide 20 and the tetrasaccharide 86α have a similar binding pattern.176
1.7. trNOE NMR (in collaboration with Prof. Thomas Peters, Lübeck)
The bioactive conformations of trisaccharide 20 and tetrasacchairde 86α were
obtained from trNOE NMR experiments. The most striking observation is the
conformational change of the flexible α2,3-glycosidic linkage between terminal
Neu5Ac and Gal from solution to bound conformation. In the case of trisaccharide 20,
an interglycosidic contact between Gal-H3 and Sia(I)-H3ax can be observed in the
NOESY spectrum of the free state, which disappeared upon binding to MAG. In the
presence of MAG, a contact between Gal-H3 and Sia(I)-H8 appears, suggesting a
conformational change which brings these two protons near each other. The similar
phenomenon was observed with sialyl LewisX bound to E-selectin.177 According to the
trNOE data of tetrasaccharide 86α, a similar conformational change is observed.
From the two major conformations that have been described previously by several
authors to be present in aqueous solution for the α2,3-glycosidic linkage the
experimental trNOE data are only consistent with the so called anti-conformation.
This conformation of the sialic acid linkage has also been observed in crystal
structures of the Cholera Toxin complexed with the GM1 pentasaccharide, and in the
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case of hemagglutinin complexed with LSTA. The analysis of the bioactive
conformation of the α2,6-glycosidic linkage was not yet possible on the basis of the
present data because of a heavy signal overlap, and currently is the subject to a more
detailed NMR analysis.176
Additionally, trNOE experiments were also carried out on trisaccharide 45. Since no
build up curves were available within the mixing time, it was classified as a weaker
binder to the protein, which fits with the results of the bioassay. 176
1.8. Homology model of MAG (in collaboration with Prof. Thomas Peters, Lübeck)
In order to better understand and analyze the experimental results by NMR, it is
necessary to develop a 3D model of the complexes of MAG with the ligand. The X-
ray structure of sialoadhesin complexed with sialyllactose served as a starting point
for the modeling and docking studies.84 The homology model was constructed by
aligning the sialoadhesin and the MAG sequences, and subsequent minimization. By
docking the tetrasaccharide 86α into the known binding pocket, a carbohydrate-MAG
complexe is available as shown in figure 13.
Figure 13: Homology model of MAG docking with Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]GalNAcβ-
OSE (86α).
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For the terminal α2,3-linked sialic acid residue, the most notable features include:
stacking interactions of the N-acetyl group with Trp22, stacking interactions of its
glycerol side chain with Tyr127 and an salt bridge between carboxylic acid and
Arg118. In the case of internal α2,6-linked sialic acid residue, another salt bridge
between carboxylic acid and Lys67, and hydrophobic and hydrogen bond interactions
of the N -acetyl group and glycerol side chain with Tyr65 can be observed.
Additionally, the hydroxymethyl group of Gal is also involved in the hydrogen bond
network with Tyr65. Besides, the N-acetyl group of the GalNAc is oriented away
from the binding pocket and should not contribute to the binding energy. It should be
noted that most of the observations from this model are in good agreement with the
experimental data (biological assay, STD NMR and trNOE NMR).176
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2. Carbohydrate mimics with 9-position modified α2,3-linked terminal sialic acid
2.1. Synthesis of 9-BzNH-Siaα(2→3)-Galβ(1→3)Galβ-OSE (87)
The extremely important role of terminal α2,3-linked sialic acid for MAG recognition
was in agreement with the previous studies.56 Recognizing the dramatic increase of
binding affinity achieved by the modification at 9-position of the α2,3-linked sialic
acid moiety,85 we were prompted to synthesize mimic 87.
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Scheme 28: Retro-synthesis of mimic 87.
As shown in scheme 28, mimic 87 can be easily prepared by employing the similar
strategy. The available sialyl donor 88178 contains an azido- group for further
modifications. para-Methoxy phenylmethyl (MPM) was chosen to protect 2,6-
position of the Gal at the reducing end of acceptor 89 due to the severe problems
encountered in the debenzylations of 41 and 77. Besides catalytic hydrogenation,179
MPM can be cleaved selectively by various options like oxidation by 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ)180-182 or cerium ammonium nitrate (CAN),183
acidic hydrolysis with camphor sulfonic acid (CSA) or trifluoroacetic acid (TFA),184
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and electronchemical conditions,185 etc., which makes it an attractive alternative to the
benzyl group.
2.1.1. Preparation of disaccharide core (89)
The synthesis of disacchride 89 was started from the known building block 39
(scheme 29). After protecting the 2,6-OHs with MPM, using para-methoxy benzyl
chloride (MPMCl) and NaH in DMF (→90, 61%), 3,4-isopropylidene group was
cleaved under acidic condition to generate acceptor 91 for further glycosylation at 3-
position. The subsequent coupling reaction with 30 was carried out by using DMTST
as promoter in CH2Cl2 at 0°C, affording disaccharide product 92 with desired β-
configuration in 76% yield. After removal of the benzoyl protections under Zemplén
conditions (→93, 85%), the selective 6-O-benzoylation was accomplished by
employing the established procedure (see 1.3.1.), which resulted in 89 in 67% yield.
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Scheme 29: a) MPMCl, NaH, DMF, 0°C, 3 h (61%); b) 80% aq. AcOH, 90°C, 1.5 h (50%); c)
DMTST, CH2Cl2, 0°C, 16 h (76%); d) NaOMe, MeOH, rt, 2 h (85%); e) benzoyl cyanide, Et3N-
CH3CH (1:4), -40∼-45°C, 1 h (67%).
2.1.2. 9-BzNH-Siaα(2→3)-Galβ(1→3)Galβ-OSE (87)
The coupling reaction between the readily available donor 88 and 89 was carried out
under the same condition as used in previous sialylations: NIS-TfOH as promoter,
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CH3CN as solvent, at low temperature (∼-30°C). Unexpectedly and repeatedly, only
trace of product 94 could be obtained while the major one is the sialic acid glycal.
When DMTST in CH3CN at 0°C was tried as the promoter, an excellent yield (63%)
and a good stereoselectivity (α :β=3:1) was achieved (scheme 30). After per-
acetylation (→95), the azido group was converted to benzoylamide using the
modified Staudinger reaction.186 95 was treated with triphenylphosphine (Ph3P) in the
presence of benzoyl chloride, which acylated the iminophosphorane formed in
Staudinger reaction187 to afford benzoylamide in one step (57%). MPMs were then
cleaved by DDQ in CH2Cl2-H2O (18:1), while the reaction with CAN in CH3CN-H2O
(9:1) was not successful. However, the product seemed unstable in solution (CDCl3).
During the time of 13C NMR measurement, one impurity was generated presumably
due to the migration of acetyl group from 4- to 6-position in Gal moiety at the
reducing end. Thus, deprotection was carried out immediately by transesterification
with NaOMe in MeOH followed by hydrolysis in aq. NaOH to afford 87 in 74% yield
of three steps.
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Scheme 30: a) DMTST, CH3CN, 0°C, 16 h (94α, 47%; 94β, 16%); b) Ac2O, py, DMAP, rt, 16 h
(87%); c) benzoyl chloride, Ph3P, DCE, rt, 16 h (57%); d) DDQ, CH2Cl2-H2O, rt, 3 h; e) i. NaOMe,
MeOH, rt, 5 h, ii. aq. NaOH, rt, 3 h (96→87, 74%).
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2.2. Synthesis of 9-O-Bn-Sia (97)
After the successful synthesis of the C-9 modified trisaccharide 87, for further
investigations of the binding properities at this position, a benzyl ether functionality
was proposed. It is more flexible than amide while the phenyl is retained for the
possible hydrophobic interaction. Since Neu5AcαBn was found to be ten times more
potent than Neu5AcαMe,83 mimic 97 was designed to have O-benzyl at 9-position
and another benzyl as aglycon at 2-position. As shown in scheme 31, sialyl donor 55
coupled with benzyl alcohol under normal condition to form 98 in 35% yield. After
deacetylation with NaOMe in MeOH, regioselective protection of the 8,9-diol as a
benzylidene acetal was accomplished by treatment with α,α-dimethoxytoluene in the
presence of cat. TsOH⋅H2O in CH3CN to afford 100 as a mixture of diastereomers as
indicated by 1H NMR.161 The benzylidene acetal of 100 was then regioselectively
opened to 9-O-Bn with BH3⋅NMe3, AlCl3 in THF and trace of H2O (99→101, 70%).
Hydrolysis of the methyl ester took place by treating with LiOH in H2O-dioxane
solution. The subsequent conversion of the lithium salt to the sodium salt was
achieved by passing through a Dowex 50×8 (Na+) column (97, 87%).
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Scheme 31: a) benzyl alcohol, NIS, TfOH, CH3CN, -35°C, 24 h (35%); b) NaOMe, MeOH, rt, 1 h
(78%); c) α,α-dimethoxytoulene, TsOH⋅H2O, CH3CN, rt, 1.5 h; d) BH3⋅NMe3, AlCl3, H2O, THF, rt, 4 h
(99→101, 70%); e) i. LiOH, H2O-dioxane, rt, 1.5 h, ii. Dowex 50×8 (Na+) (87%).
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2.3. Biological assay
With the fluorescent hapten inhibition assay, mimics 87 and 97 were tested together
with reference 20. The resulting rIPs are listed in table 9, which also included
compounds 102 and 103 for comparison.
Table 9: Bioaffinities of mimics with C-9 modified α2,3-linked sialic acid.
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a). compounds prepared by Sachin Shelke, Institute of Molecular Pharmacy, University of Basel.
According to the r IPs, trisaccharide mimic 87 with the only modification at 9-position
of the sialic acid residue achieved 203 times of affinity over the reference 20.
However, it is about 3 times weaker than its monosaccharide analogue 102, which has
a benzyl group as aglycon instead of disaccharide core. It is surprising since the
previous studies79 demonstrated that the additional contacts of the neutral core with
the protein contribute to the binding potency as well, although to a lesser degree,
which is also confirmed in this work either by biological data (e.g. 1 and 103), or by
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STD NMR effects observed on the core structure. Possibly, the dramatically improved
affinity of 102 might be caused by "induced fit" of the protein upon binding. The
same reason may also explain the relative low binding affinity of compound 87, in
which the disaccharide core is hindered from binding by the change of the protein
conformation.
Although monosaccharide 97 has a 2.3 times higher affinity than 103, the effect of the
substitution by a benzyl ether is not comparable to the dramatic enhancement by
benzoylamide replacement of 9-OH 102 . It is likely that the hydrogen bond
interaction is very crucial for the binding since one difference between benzoylamide
and benzyl ether is that the former can serve as a hydrogen bond donor and acceptor
while the latter acts only as an acceptor.
3. Mimics with modifications of the disaccharide core
In contrast to the important contribution of the two sialic acids to binding, numerous
SAR studies56,79 indicate that the disaccharide core behaves predominantly as a linker
holding the two sialic acid moieties in the desired spatial orientation. Therefore, the
core is a good point to develop mimics.
It has long been recognized that aromatic moieties are major players in molecular
recognition.188 For example, the protein binding of drugs that contain aromatic
substituents is dominated by interactions with aromatic and hydrophobic residues.189
As a consequence, aromatic and hetero aromatic moieties such as benzene, pyridine,
pyrimidine, were found to be the most commonly used elements in a retrospective
statistical analysis of privileged scaffolds of drugs.190 In addition, aromatics and
hetero aromatics have been shown to form favorable interactions with polar
substituents, such as amides191 or hydroxyl groups,192 and even positively charged
moieties.193,194 Therefore, they can serve as good candidates for carbohydrate
scaffolds. Besides the simplified structure and possibly increased binding affinity,
benefits caused by the substitution of carbohydrates by aromatics also include easier
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synthetic access, increased thermal and chemical stability, as well as the enhanced
bioavailability, all of which are essential for pharmacologically active molecules to
become drugs.
3.1. Phenoxyphenyl(methyl) and biphenyl(methyl) derivatives of sialic acid
It was reported by Kelm et al.83 that Neu5AcαBn has a ten-fold higher affinity for
MAG than the corresponding methyl sialoside, suggesting an additional hydrophobic
interaction of the benzyl residue with the receptor site. To further investigate such
interaction, and to test the spacer function of the disaccharide core, phenoxyphenyl
and biphenyl scaffolds were chosen for the substitution of the Galβ(1→3)Gal moiety.
Both phenoxyphenyl and biphenyl are privileged moieties that can be commonly
found in drugs.190 It is interesting to note that biphenyl substructures are found in
4.3% of all known drugs, and various therapeutic areas (e.g. diflunisal and
valsartan).188 A statistical analysis of NMR-derived binding data on 11 protein targets
indicates that the biphenyl motif, over naphthyl, diphenylmethane, or bibenzyl, is a
preferred substructure for protein binding.188 This preference for biphenyls was
rationalized by the degree of flexibility around the aromatic linkage. The naphthyl
group is completely rigid, which severely limits the number and type of pockets on
the protein site it can occupy, while the greater flexibility of the bibenzyl and
diphenylmethane substructures may result in entropic penalties upon binding.188
Therefore, mimetics 104-107 (figure 14) were designed with phenoxyphenyl(methyl)
and biphenyl(methyl) as aglycons. 107 has an extra acetic acid attached on the
biphenyl moiety to mimic the α2,6-linked internal sialic acid, the carboxylic acid of
which was supposed to contribute to MAG-binding substantially.75
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Figure 14: Phenoxyphenyl(methyl) and biphenyl(methyl) derivatives of sialic acid.
As shown in scheme 32, the preparation of 104 was very straightforward by coupling
the common sialyl donor 55 with 3-phenoxybenzyl alcohol (108) by the activation
with NIS-TfOH in CH3CN at –30°C. Product 109 was obtained of 81% yield with a
ratio of 2.5:1 (α :β). Transesterification with NaOMe in MeOH followed by
hydrolysis in aq. NaOH afforded 104α  and 104β  in 60% and 63% yields,
respectively. Similarly, the coupling reaction of 55 with 4-biphenyl methanol (110)
was carried out with the exception that TfOH was replaced by TMSOTf. 111 was
obtained with the anomeric stereoselectivity 3:1 (α:β) in 89% yield. The final
deprotection was accomplished in two steps in about 60% yield for both anomers
(106α and 106β, scheme 33).
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Scheme 32: a) NIS, TfOH, CH3CN, -30°C, 16 h (81% 109α:109β=2.5:1); b) i. NaOMe, MeOH, rt, 4 h,
ii. aq. NaOH, rt, 16 h (104α, 60%; 104β, 63%).
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Scheme 33: a) NIS, TMSOTf, CH3CN, -30°C, 16 h (89% 111α:111β=3:1); b) i. NaOMe, MeOH, rt, 4
h, ii. aq. NaOH, rt, 16 h (106α, 60%; 106β, 57%).
It should be noted, that in contrast to the sialylations of the benzyl alcohols, the
coupling reaction between sialyl donor 55 and 4-phenoxyphenol (112) under identical
conditions failed. With the NIS-TfOH promoter system, no product was formed
according to TLC. Meanwhile, when DMTST was employed as promoter in CH3CN
at 0°C, trace of product (10%) with a reversed stereoselectivity (α :β=1:2) as
determined by 1H NMR (data was not shown) were obtained. The failure was mostly
due to the low nucleophilicity of phenol by comparing with benzyl or sugar alcohols,
which normally react well under the traditional coupling conditions. Surprisingly,
there are only few methods described in the literature for the formation of aryl
sialosides. One of the most frequently used procedures employs phase transfer
conditions starting from phenols with 2-chloro derivatives of sialic acid.195 As shown
in scheme 34, the 2-chloro sialyl donor 8 was refluxed with 4-phenoxyphenol (112) in
chloroform-aq.  NaOH in the presence of benzyltriethylammonium chloride, affording
desired α-anomer 113α in 60% yield. Subsequent deprotection gave 105α in 81%
yield.
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Scheme 34: a) BnEt3N+Cl-, NaOH, CH3Cl-H2O, reflux, 2 h (60%); b) i. NaOMe, MeOH, rt, 5 h, ii. aq.
NaOH, rt, 16 h (81%).
The Suzuki reaction was investigated for the synthesis of mimetic 107 (scheme 35),
which can then serve as a general method to prepare various substituted biphenyls for
SAR study.  Sialic acid derivative 114 was prepared by phase transfer reaction of 2-
chloro sialyl donor 8 with meta-bromo-phenol196. The arylboronic ester 115 was
achieved in two steps. Esterification of 116 in the presence of CAN in MeOH was
followed by palladium-catalysted cross coupling reaction namely Miyaura
boronation,197 which was carried out in the presence of PdCl2(dppf), dppf and KOAc
in dioxane. It should be noted that the reaction was greatly speeded up under
microwave (300W) radiation, which afforded the boronic ester 115 in 50% yield.
In a systematic exploration of the Suzuki reaction with the similar substances,196
factors as base, catalyst, ligand and reaction conditions (e.g. solvent, temperature,
microwave) were optimized. This optimal procedure was employed in scheme 35.
Since the reaction was extremely slow under normal condition, side reaction
happened during extensive heating. Microwave radiation substantially accelerated the
reaction rate at high temperature. Even though, only 8% of the desired product 117,
along with the deprotected substance 107 (3%) and recovered starting material 114
(25%)were obtained after cumbersome chromatographic separation.
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Scheme 35: a) i. CAN, MeOH, rt, 16 h (90%), ii. bis(pinacolato)diboron, PdCl2(dppf), dppf, KOAc,
dioxane, 120°C (mocrowave 300W), 1.5 h (50%); b) PdCl2(dppf), dppf, BHT, K3PO4, dioxane, 170°C
(microwave 300W), 2.25 h (117, 8%; 107, 3%).
3.2. Development of Mitsunobu procedure for the synthesis of aryl sialosides
In contrast to aldoglycosides, only few methods for the stereoselective synthesis of
ketoglycosides, such as aryl sialosides, exist.195 Besides the phase transfer reaction
employed for the synthesis of 105α, Williamson ether synthesis based on phenolates
and 2-halogeno derivatives of sialic acid is another choice, although the low solubility
of sodium phenolates drastically limits the scope of this method.198,199 Both
approaches result in inversion of the anomeric configuration of the sialyl donor and
give moderate to good yields. However, side reactions caused by the basic reaction
conditions, e.g. hydrolysis of protecting groups or glycal formation by 2,3-
elimination, are inevitable.
Meanwhile, the Mitsunobu reaction200 is widely used for the synthesis of aryl,201-210
acyl,209-212 alkyl,209,213,214 and amino glycosides209,215 by reacting hemiacetals of
aldosugars, predominantly glucose, galactose and mannose, with weakly acidic
acceptors in the presence of diethyl azodicarboxylate (DEAD) and triphenylphosphine
(Ph3P). A major advantage of this direct dehydrative coupling procedure is that
activated glycosyl donors do not need to be isolated and all reaction steps –
anomerization, activation and glycosidic bond formation – occur in a single series of
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events.216 The stereochemical outcome depends on the anomeric ratio present in the
hemiacetal and its mutarotation occurring under reaction conditions. Phenolic
nucleophiles are good acceptors for this glycosylation reaction with aldosugars,
leading to aryl glycosides.201,206,208
To our knowledge, Mitsunobu conditions have not been applied to glycosylations
with ketosugars such as sialic acid, probably because their anomeric centers were
regarded as being too sterically hindered.217 However, a limited number of successful
non-carbohydrate cases with comparable steric circumstance have been reported,
albeit with moderate yields and stereoselectivities.218-220 Therefore, Mitsunobu
conditions were applied to the glycosylation reaction with sialyl hemiacetal 118 and
4-phenoxyphenol (112). Gratifyingly, after the exploration of various reaction
conditions, such as solvent, temperature, order of addition and additives, the
optimized procedure as shown in scheme 36 was developed. Hemiacetal 118221
predominantly adopting β-configuration222,223 was reacted with 4-phenoxyphenol
(112) in the presence of Ph3P, DEAD in CH3CN at 0°C, affording product 113 in 75%
isolated yield (α:β=64:36) with traces of byproducts 71 and 119, which have been
formed from 2,3-elimination and addition of DEAD, respectively.
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Scheme 36: a) Ph3P, DEAD, CH3CN, 0°C, 3 h (113, 75%; 113:71:119=1:0.3:0.1).
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To avoid a cumbersome chromatographic separation from the sialic acid glycal,132,159
which is formed as a side-product, an oxidative work-up procedure was employed. By
treating the crude product with 2-3 equiv. of NaIO4 in the presence of a catalytic
amount of RuCl3 for only 2-5 min, the glycal was selectively oxidized and the
resulting polar products were then readily removed by extraction with water.
To evaluate the optimized reaction conditions and oxidative work-up procedure, 10
other phenols were tested. In most cases, high yields and α/β-selectivites in the range
of 2 : 1 were obtained. It is noteworthy that the yields correlate with the acidity of the
glycosyl acceptors. Phenols bearing electron-withdrawing substituents gave excellent
yields, while phenols substituted with electron-donating groups resulted in lower
yields and increased amounts of byproducts.224
3.3. Phenyltriazole derivatives of sialic acid
Recently, the copper-(I)-catalyzed 1,2,3-triazole formation from azides and acetylenes
which is a modification of Huisgen 1,3-dipolar cycloaddition attracted increasing
attention.225 Besides all the advantages of click chemistry226 it possesses, its triazole
products are interesting molecules for drug discovery. They are more than just passive
linkers; they are able to interact with biological targets through hydrogen bonding and
dipole interactions. In addition, triazoles do not undergo hydrolytic cleavage
reactions, and are nearly impossible to oxidize or reduce, which is a desired properity
of a pharmacophore.227
In our study, the extremely low yield of the Suzuki coupling reaction in the synthesis
of biphenyl derivative 117 made the development of diverse mimetics of this family
quite cubersome. The idea of employing phenyltriazole moiety as the spacer instead
of biphenyl was greatly supported by in silico considerations (figure 15). The
superimposition of the two molecules showed a remarkable identity, since the acid
moieties mimicking the α2,6-linked sialic acid have the same spatial orientation.
Therefore, three phenyltriazole sialic acid derivatives 120-122 were synthesized
(figure 16).
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Figure 15: Superimposition of biphenyl and phenyltriazole sialic acid derivatives (107 and 121).
Mimic 107 is in brown, while mimic 121 is shown in colors according to the atom type.
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Figure 16: phenyltriazole sialic acid derivatives 120-122.
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As shown in scheme 37, phenylacetylene derivative 124 was obtained by a phase
transfer reaction of 2-chloro sialyl donor 8 and 3-hydroxyphenylacetylene (123).
Refluxing in CHCl3-aq. NaOH in the presence of benzyltriethylammonium chloride
afforded desired α-anomer 124 in 60% yield. Subsequent copper-(I)-catalyzed 1,2,3-
triazole formation from azides 125, 126 and 127, and acetylene 124 were carried out
under standard conditions.225 Surprisingly, in all the reactions, the starting material
124 was never consumed completely under the standard condition. Sodium ascorbate
and CuSO4⋅5H2O, which generate Cu(I) in situ had to be repeatedly added till the
completion of the reaction. The possible reason might be, instead of being reduced to
Cu (I) and then taking part into the catalysis cycle, Cu2+ form the complex with the
acetyls, which hinder the reaction. To prove this, acetylene 124 was fully deprotected,
then coupled with the azides 125-127 (scheme 38). With catalytic amount of sodium
ascorbate (0.1 equiv.) and CuSO4⋅5H2O (0.01 equiv.), phenyltriazole sialyl derivatives
120, 132, 122 were achieved in around 90% yields.
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Scheme 38: a) i. NaOMe, MeOH, rt, 2.5 h, ii. aq. NaOH, rt, 2.5 h (84%); b) 125-127, sodium ascorbate
(0.1 equiv.), CuSO4⋅5H2O (0.01equiv.), tBuOH-H2O, 16 h (120, 87%; 132, 93%; 122, 89%).
3.4. Biological assay
With the trisaccharide 20 as reference, the two families of mimics were tested by
fluorescence hapten inhibition assay as shown in table 10. Firstly, comparable
bioaffinities were obtained with the modification of natural disaccharide core by
phenoxyphenyl(methyl) and biphenyl(methyl) moieties (104α-106α), while the β-
anomers showed no binding affinities. Especially, mimic 105α achieved rIP of 0.89,
84
suggesting the retained affinity by comparing with the reference. Secondly,
phenyltriazole behaves as a good substitute of the biphenyl linkage, which is proved
by the similar rIPs of 107 and 121 (1.0 and 1.1). Lastly, the unexpected high affinity
of mimic 122 (rIP 1.7) implies that instead of the anionic charge, which was supposed
to be the key to enhance the binding affinity of α2,6-linked sialic acid moiety,75 a
hydrophobic interaction might be the main contributor to the biniding with MAG.
85
Ta
bl
e 1
0:
 B
io
af
fin
iti
es
 o
f t
he
 m
im
ic
s w
ith
 m
od
ifi
ca
tio
ns
 o
f t
he
 d
isa
cc
ha
rid
e 
co
re
.
Co
m
po
un
d
St
ru
ct
ur
e
rIP
s
Co
m
po
un
d
St
ru
ct
ur
e
rIP
s
10
4α
O
H
O
A
cH
N
H
O
O
H
O
H
C
O
2N
a
O
O
0.
27
10
4β
O
H
O
A
cH
N
H
O
O
H
O
H
O
C
O
2N
a
O
n.
a.
10
5α
O
H
O
A
cH
N
H
O
O
H
O
H
O
O
C
O
2N
a
0.
89
10
5β
O
H
O
A
cH
N
H
O
O
H
O
H
C
O
2N
a
O
O
n.
a.
10
6α
O
H
O
A
cH
N
H
O
O
H
O
H
C
O
2N
a
O
0.
38
10
6β
O
H
O
A
cH
N
H
O
O
H
O
H
O
C
O
2N
a
n.
a.
10
7
O
H
O
A
cH
N
O
H
O
H
O
H
C
O
2N
a
O
C
O
2N
a
1.
0
12
1
O
H
O
A
cH
N
O
H
O
H
O
H
C
O
2
N
a
O
N
N
N
C
O
2
N
a
1.
1
12
0
O
H
O
A
cH
N
O
H
O
H
O
H
C
O
2N
a
O
N
N
N
C
O
2N
a
0.
9
12
2
O
H
O
A
cH
N
O
H
O
H
O
H
C
O
2N
a
O
N
N
N
1.
7

86
Conclusion and Outlook
1. Summary of the thesis
Gangliosides, such as GD1a, GT1b and GQ1bα, were identified as specific functional
ligands responsible for MAG-mediated inhibition of neurite outgrowth. MAG, the
only siglec of the mammalian CNS binds gangliosides with high specificity. Based on
the previous SAR studies, partial structure of natural ligands, derivatives and mimics
thereof were chemically and chemo-enzymatically synthesized in this thesis. The
resulting information from biological assay and NMR based conformational analysis
gives guidance for the rational design of novel MAG antagonists.
1.1. Synthesis of the partial structure of natural ligands and derivatives thereof
Trisaccharides 1, 20, 45 and tetrasaccharides 54α, 54β were chemically or chemo-
enzymatically prepared to investigate the respective contribution of α2,3-linked and
α2,6-linked sialic acid to the affinity for MAG (figure 17). Compounds 1, 45, 54α,
54β were chemically synthesized using a 2-methylthio sialyl donor, and NIS-TfOH as
a promoter. Trisaccharide 20 was synthesized chemo-enzymatically on a preparative
scale by using rST3Gal III, which transfers the sialic acid moiety from CMP-Neu5Ac
to the non-natural substrate Galβ(1→3)Galβ-OSE.
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Figure 17: Partial structure of natural ligands and derivatives thereof.
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Results from the biological assay and NMR studies show that the α2,3-linked
terminal sialic acid is the primary request for MAG-binding, which interacts via its N-
acetyl group, the glycerol side chain and the carboxylic acid with the protein. The
additional α2,6-linked internal sialic acid, but not its β-anomer, can further enhance
the binding affinity. Retained or even better affinities were achieved by replacing the
disaccharide core Galβ(1→3)GalNAc by Galβ(1→3)Gal, which suggests that it acts
predominantly as a spacer.
1.2. Synthesis of carbohydrate mimics with C-9 modified α2,3-linked sialic acid
Recognizing the important role of the terminal α2,3-linked sialic acid for MAG-
binding and the dramatic improvement of binding affinity achieved by C-9
modifications of this moiety, mimics 87 and 97 were synthesized (figure 18).
87, rIP: 203 102, rIP: 690
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OHOH
O
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CO2Na
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CO2Na
OH
OH
O
N
O
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97, rIP: 2.3
OAcHN
HO
CO2Na
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Figure 18: Carbohydrate mimics with C-9 modified sialic acid.
According to the biological evaluation, mimic 87 is 203 times more potent than the
reference compound 20, but about 3 times weaker than its monosaccharide analogue
102. Surprisingly, mimic 97 is only 2.3 times better than 20, suggesting that the
benzoylamide functionality at C-9 extremely increases the potency of the ligand for
MAG-binding. The dramatically improved affinity of 102 might be caused by
"induced fit" of the protein upon binding. The same reason may also explain the
relative low binding affinity of compound 87, in which the disaccharide core is
hindered from binding by the change of the protein conformation.
1.3. Synthesis of carbohydrate mimics with modifications of disaccharide core
To elucidate the hypothesis of the "spacer" role of the disaccharide core, it was
replaced by phenoxyphenyl(methyl) and biphenyl(methyl) (figure 19). Mimics 104
88
and 106 were synthesized using the standard sialylation procedure, while the aryl
sialoside 105 was prepared in an excellent yield and with good stereoselectivity by
Mitsunobu reaction, which to the best of our knowledge, was used for the first time
for the glycosylation of ketosugars. The Suzuki reaction was employed for the
synthesis of the substituted biphenyl derivative 107. Results from the bioassay
confirmed the "spacer" role of the disaccharide, showing the similar affinities of the
mimics to that of the reference compound 20. It should be noted that these mimics are
structurally extremely simplified. In addition, the aromatic linker is expected to
improve their pharmacokinetic properties compared to natural carbohydrate ligands.
O
HO
AcHN
HO
OH
OH CO2Na
O
R:
R
O
104, rIP: 0.27 105, rIP: 0.89 106, rIP: 0.38 107, rIP: 1.0
CO2Na
O
Figure 19: Phenoxyphenyl(methyl) and biphenyl(methyl) derivatives of sialic acid.
Due to the low yields of the Suzuki reaction, which made the development of various
substituted biphenyl sialyl derivatives for further SAR study quite cumbersome,
another linkage, namely phenyltriazole, was investigated based on its similar
conformation in silico. Mimics 120-122 (figure 20) were obtained by a modified
Huisgen 1,3-dipolar cycloaddition with high yields. Their binding affinities showed
that phenyltriazole is a good substitute of the biphenyl linkage.
R:
120, rIP: 0.9 121, rIP1.1 122, rIP: 1.7
O
HO
AcHN
OH
OH
OH CO2Na
O
N N
N
R
CO2Na
CO2Na
Figure 20: Phenyltriazole derivatives of sialic acid.
2.  Outlook
Compared with the rIP of 120, the unexpected high affinity of mimic 122 (rIP: 1.7)
implies that instead of the anionic charge, which was supposed to be the key to
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enhance the binding affinity of α2,6-linked sialic acid moiety, a hydrophobic
interaction might be the main contributor of Sia (II) to the binding with MAG. Similar
results were obtained in another study where Gal at the reducing end of 20 was
substituted by 1,2-dideoxy-Gal.228 By using the same reference 20, the rIP of mimic
133 with a benzyl ether instead of Sia (II) is 2.0, while mimic 134 containing a
biphenyl substitutuion achieves its rIP of 4.1, which is comparable with those of
tetrasaccharides 54α and 86α (4.2 and 3.3 respectively) (figure 21).  Additionally, the
homology model of MAG with Neu5Acα(2→3)Galβ(1→3)[Neu5Acα(2→6)]
GalNAcβ-OSE (86α) indicates a salt bridge between Lys67 and carboxylic acid of the
α2,6-linked internal sialic acid. To further elucidate the substructural specificity of
Sia (II) to MAG binding, Fc-MAGd1-3 with the mutation of Lys67 to Ala (Fc-MAGd1-3
K67A) was employed in the biological assay, which showed no significant difference
from the wild type.
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Figure 21: Mimics with hydrophobic substitutions of the α2,6-linked sialic acid moiety.
Based on these observations, mimics 135-137 were designed to explore the potential
hydrophobic binding site on MAG (figure 22). Modification at 9-position of the α2,3-
linked terminal sialic acid by benzoylamine moiety was kept in all these structures
due to the dramatic improvement which was achieved in MAG binding. Mimic 135
(n=1) with one more aromatic functionality can further confirm the hydrophobic
interaction, while 135 (n=2, 3) may explore the distance of the potential hydrophobic
binding site by different length of linkers.
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STD NMR study of tetrasaccharide ligand 86α indicated the strongest STD effect on
6-position of internal Gal moiety (figure 12). Additionally, the homology model
showed the hydroxymethyl group, together with the N-acetyl group and the glycerol
side chain, are involved in the hydrophobic interaction and hydrogen bond network
with Tyr65 of MAG (figure 13). Therefore, mimic 137 was designed to link the
hydrophobic group directly on the Gal or 1,2-dideoxy-Gal moiety, which yielding
even simplified structures.
135, n = 1, 2, 3 136, R1 = OH, H; R2 = OSE, H.
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Figure 22: Exploration of the potential hydrophobic binding site on MAG.
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Experimental
General Methods
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer.
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY,
HSQC, TOCSY). Chemical shifts are expressed in ppm using residual CHCl3,
CHD2OD and HDO as references. Optical rotations were measured using a Perkin-
Elmer Polarimeter 241. ESI-MS analyses were carried out on a Bruker
esquire3000plus_01096 with Bruker Daltonics DataAnalysis 3.0 program. LC/HRMS
analyses were carried out using a Agilent 1100 LC equipped with a photodiode array
detector and a Micromass QTOF I equipped with a 4 GHz digital-time converter. All
spectra were recorded in positive EI mode. The LC method consisted of a separation
column (YMC ODS AQ 12.5 cm length, 2 mm i.d.) held at rt. The mobile phase was
CH3CN/H2O with the addition of 0.5% formic acid using a flow rate of 0.2 mL/min.
The linear gradient run from 5% to 95% CH3CN in 10 min followed by 8 min at 95%
CH3CN before returning to initial conditions. Elemental analyses were carried out
with a Perkin-Elmer 240 analyzer. Reactions were monitored by TLC using glass
plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or
by charring with a molybdate solution (a 0.02 M solution of ammonium cerium
sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4).
Column chromatography was performed on silica gel (Uetikon, 40-60 mesh).
Methanol (MeOH) was dried by refluxing with sodium methoxide and distilled
immediately before use. Pyridine (py) was freshly distilled under argon over CaH2.
Tetrahedrofuran (THF) was dried by refluxing with sodium, benzophenone and
distilled immediately before use. Dichloromethane (DCM), dichloroethane (DCE),
acetonitrile (CH3CN), and toluene were dried by filtration over Al2O3 (Fluka, type
5016 A basic). Petrolether (PE) was distilled over CaCl2. Ethanol (EtOH), 2-propanol
(i-PrOH), ethyl acetate (AcOEt), N,N'-dimethylformamide (DMF), carbon
tetrachloride (CCl4) and dioxane from Fluka (puriss) or Merck (absolute grade for
analysis) were used without purification.  Molecular sieves (3 Å) were activated in
vacuum at 500°C for 2 h immediately before use.
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Methyl 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-galacto-2-
nonulopyranosynate (7), (GG-003, I-002, 003).
By treating Neu5Ac 5 (4.75 g, 15.0 mmol) with cat. Amberlyst 15 in MeOH (250
mL) overnight, methyl 5-acetamido-3,5-dideoxy-D-glycero-β-D-galacto-2-
nonulopyranosylonate (6) was achieved (4.50 g, 93%) as a white solid. Without
further purification, 6 (1.00 g, 3.00 mmol) was stirred with Ac2O (13.5 mL, 0.132
mol), py (12.0 mL, 0.152 mol) and cat. DMAP at rt for 48 h under argon. The mixture
was concentrated under reduced pressure, co-evaporated with toluene (3×20 mL) and
the residue was purified by silica gel chromatography (DCM/MeOH 40:1) to afford 7
(1.50 g, 91%) as white foam.134
Methyl (5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-β-D-galacto-2-
nonulopyranosyl chloride)onate (8), (GG-005, I-005).
In a sealed vessel (Bombenrohr), AcCl (3.40 mL, 47.6 mmol) and conc. HCl (0.426
mL, 4.23 mmol) were subsequently added to a stirred solution of 7 (1.50 g, 2.80
mmol) in DCM (10 mL) at –20°C. After stirring at rt for 16 h, the mixture was
concentrated and the residue was diluted with DCM (50 mL), and washed with H2O
(2×30 mL), 5% KHCO3 (2×30 mL), and brine (20 mL). The organic layer was dried
over Na2SO4, filtered and concentrated under reduced pressure to afford 8 (1.11 g,
77%) as white foam, which was used in the next step without further purification.
O-Ethyl S-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosynate)dithiocarbonate (2), (GG-007, I-007).
A solution of 8 (1.11 g, 2.20 mmol), potassium ethyl xanthogenate (0.423 g, 2.64
mmol), and TBAHS (0.740 g, 2.20 mmol) in AcOEt (12 mL) and 5% NaHCO3 (12
mL) was stirred at rt for 3 h. The mixture was diluted with AcOEt (30 mL), washed
with H2O (2×30 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated
under reduced pressure. The residue was purified by silica gel chromatography
(PE/AcOEt/EtOH 6:4:1) to afford 2 (0.670 g, 51%) as white foam, the NMR data of
which were in accordance with Lit.133
2,3,4,6-Tetra-O-acetyl-α-D-galactopyransyl bromide (11), (GG-004, I-004).
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Per-acetylated galactose 10 (10.0 g, 25.6 mmol) was dissolved in DCM (45.0 mL).
30% HBr in AcOH (90 mL, 0.512 mol) was added dropwise within 2 h at 0°C. The
reaction was stirred at 0°C for additional 2 h, and poured onto icewater (250 mL),
which was extracted with DCM (3×80 mL). The combined organic layers were
washed with 5% NaHCO3 (3×60 mL), brine (2×60 mL) and dried over Na2SO4. After
filtration and concentration under reduced pressure, 11 (9.17g, 87%) was obtained as
white foam, which was used in the next step without further purification.
 2-(Trimethylsilyl)ethyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (12), (GG-
006, I-006).
A suspension of 11 (9.17 g, 22.3 mmol), HgO (4.83 g, 22.3 mmol), HgBr2 (61.0 mg,
0.170 mmol), CaSO4 (6.30 g, 44.6 mmol) and 2-(trimethylsilyl)ethanol (4.80 mL,
33.5 mmol) in toluene (200 mL) was stirred with light exclusion at rt for 12 h. The
mixture was filtered through a pad of Celite, and the Celite was washed with toluene
(3×20 mL). The combined filtrates were concentrated under reduced pressure and the
residue was purified by silica gel chromatography (PE/AcOEt 2:1) to afford 12 (9.10
g, 91%) as white foam, the NMR data of which were in accordance with Lit.131
2-(Trimethylsilyl)ethyl β-D-galactopyranoside (13), (GG-008, I-008).
To a stirred solution of 12 (9.10 g, 20.3 mmol) in MeOH (50 mL) was added freshly
prepared 1M NaOMe/MeOH (5.0 mL). The mixture was stirred at rt under argon for 2
h, then neutralized with Amberlite IRC 50 ion-exchange resin and filtered through a
pad of Celite. The Celite was washed with MeOH (3×30 mL). The combined filtrates
were concentrated under reduced pressure to afford 13 (5.59 g, 98%) as white foam,
which was used in the next step without further purification.
2-(Trimethylsilyl)ethyl 6-O-benzoyl-β-D-galactopyranoside (3), (GG-009, I-009).
To a stirred solution of 13 (5.59 g, 20.0 mmol) in Et3N (30 mL) and CH3CN (120 mL)
at –40°C under argon, benzoyl cyanide (3.15 g, 24.0 mmol) was added. The reaction
was stirred at –30°C for 2 h and then quenched by adding MeOH (10 mL). The
solution was concentrated under reduced pressure, and the residue was then dissolved
in DCM (80 mL), and washed successively with 2M HCl (2×30 mL), 5% NaHCO3
(2×30 mL), H2O (2×30 mL) and brine (30 mL). The organic layer was dried over
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Na2SO4, filtered and concentrated under reduced pressure. The residue was purified
by silica gel chromatography (DCM/EtOH 8:1) to afford 3 (4.29 g, 56%) as white
foam, the NMR data of which were in accordance with Lit.137
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-6-O-benzoyl-β-D-
galactopyranoside (14), (GG-010, I-010).
To a stirred solution of 2 (300 mg, 0.500 mmol) and 3 (290 mg, 0.755 mmol) in
CH3CN/DCM (3:2, 20 mL) was added activated powdered molecular sieves 3 Å (850
mg). The suspension was stirred at rt under argon for 5 h and then cooled to –70°C.
After the addition of NIS (215 mg, 0.960 mmol) and TfOH (8.3 µL, 96.0 µmol),
stirring was continued for 16 h at –70°C. Then the mixture was diluted with DCM (20
mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×20
mL). The combined filtrates were successively washed with 20% Na2S2O3 (30 mL),
saturated KHCO3 (2×20 mL) and H2O (20 mL), and dried over Na2SO4. After
filtration and concentration under reduced pressure, the residue was purified by silica
gel chromatography (DCM/i-PrOH 20:1) to afford 14 (123 mg, 29%) as white foam,
the NMR data of which were in accordance with Lit.137
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-2,4-di-O-acetyl-6-O-benzoyl-
β-D-galactopyranoside (15), (GG-014, I-014).
To a stirred solution of 14 (200 mg, 0.233 mmol) at 0°C in py (5.0 mL) was added
Ac2O (3.0 mL). The mixture was stirred for 16 h at rt under argon, and then quenched
by adding MeOH (2 mL). The solution was concentrated under reduced pressure and
co-evaporated with toluene (3×10 mL). The resulting syrup was purified by silica gel
chromatography (DCM/MeOH 30:1) to afford 15 (140 mg, 64%) as white foam, the
NMR data of which were in accordance with Lit.137
O-(Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosynate)-(2→3)-2,4-di-O-acetyl-6-O-benzoyl-D-galactopyranoside
(16), (GG-018, I-018).
95
To a stirred solution of 15 (140 mg, 0.149 mmol) in DCM (4.0 mL) at –10°C was
added BF3·Et2O (0.1 mL). The mixture was stirred at 0°C for 6 h, then diluted with
DCM (10 mL), washed with 5% NaHCO3 (2×5 mL), brine (5 mL), and dried over
Na2SO4. After filtration and concentration under reduced pressure, the residue was
purified by silica gel chromatography (DCM/MeOH 30:1) to afford 16 (105 mg, 84%)
as white foam, the NMR data of which were in accordance with Lit.137
O-(Methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosynate)-(2→3)-2,4-di-O-acetyl-6-O-benzoyl-β-D-galactopyranosyl
trichloroacetimidate (17), (GG-2-018, II-018).
To a stirred solution of 16 (170 mg, 0.200 mmol) in DCM (5 mL) at -5°C were added
CCl3CN (607 µL, 6.06 mmol) and Cs2CO3 (7.24 mg, 0.022 mmol). The mixture was
stirred at 0°C for 4 h, and then concentrated. The residue was purified by silica gel
chromatography (PE/AcOEt, gradient 1:1 to 1:10) to afford 17 (145 mg, 74%) as
white foam.
[α]D –4.9°, (c = 1.35, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.74 (t, J3a,3b = J3a,4 =
12.4 Hz, 1H, Sia-H3a), 1.85 (s, 3H, CH3-NHAc), 2.01, 2.04, 2.07, 2.14, 2.15, 2.18
(6s, 18H, 6×CH3-OAc), 2.61 (dd, J3a,3b = 12.7, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.64 (dd,
J5,6 = 10.7, J6,7 = 2.7 Hz, 1H, Sia-H6), 3.78 (s, 3H, OCH3), 3.98 (dd, J8,9a = 5.9, J9a,9b =
12.5 Hz, 1H, Sia-H9a), 4.06 (q, J4,5 = J5,6 = J5,NH = 10.4 Hz, 1H, Sia-H5), 4.21-4.28 (m,
2H, Gal-H5, Gal-H6a), 4.40 (dd, J8,9b = 2.5, J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.45 (dd,
J5,6b = 5.6, J6a,6b = 10.3 Hz, 1H, Gal-H6b), 4.79 (dd, J2,3 = 10.2, J3,4 = 3.4 Hz, 1H, Gal-
H3), 4.89 (ddd, J3a,b = 12.1, J3b,4 = 4.7, J4,5 = 10.5 Hz, 1H, Sia-H4), 5.10 (d, J5,NH = 10.3
Hz, 1H, Sia-NH), 5.13 (d, J3,4 = 3.3 Hz, 1H, Gal-H4), 5.33 (dd, J1,2 = 8.3, J2,3 = 10.2
Hz, 1H, Gal-H2), 5.37 (dd, J6,7 = 2.7, J7,8 = 9.0 Hz, 1H, Sia-H7), 5.57 (ddd, J7,8 = 8.7,
J8,9a = 5.9, J8,9b = 2.5 Hz, 1H, Sia-H8), 5.99 (d, J1,2 = 8.3 Hz, 1H, Gal-H1), 7.39-7.46,
7.54-7.58, 8.01-8.03 (m, 5H, C6H5), 8.68 (s, 1H, NH);
13C NMR (125 MHz, CDCl3): δ 21.55, 21.61, 21.62, 22.00, 22.27 (6C, 6×CH3-OAc),
24.01 (CH3-NHAc), 38.31 (Sia-C3), 49.95 (Sia-C5), 53.95 (OCH3), 62.33 (Gal-C6),
63.37 (Sia-C9), 67.97 (Sia-C7), 68.18 (Gal-C4), 68.89 (Sia-C8), 69.63 (Gal-C2),
70.14 (Sia-C4), 72.10 (Gal-C3), 72.29 (Gal-C5), 73.01 (Sia-C6), 91.49 (Gal-C1),
97.03, 97.69 (CCl3, Sia-C2), 129.15, 130.59, 134.01 (4C, C6H5-CH), 161.95, 166.59,
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168.77, 170.52, 171.09, 171.22, 171.42, 171.48, 171.73 (11C, C=NH, C6H5-C,
9×CO);
ESI-MS: Calcd for C39H47Cl3N2O21 (M+Na)+: 1007.2, 1009.2; Found: m/z 1007.0,
1009.0.
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-di-O-acetyl-6-O-benzoyl-
β-D-galactopyranosyl)-(1→3)-2-acetamido-4,6-O-benzylidene-2-deoxy-β-D-
galactopyranoside (18), (GG-2-024-3, II-024).
To a solution of 17 (68.1 mg, 69.0 µmol) and 4 (28.3 mg, 69.0 µmol) in DCM (3 mL)
was added activated powdered molecular sieves 3Å (600 mg). The mixture was
stirred at rt under argon for 1 h, then cooled to 0°C. To the stirred mixture was added
TMSOTf (3.74 µL, 21.0 µmol), and the stirring was continued for 4 h at 0°C. The
reaction was quenched by adding a few drops of Et3N, then diluted with DCM (5 mL)
and filtered through a pad of Celite. The Celite was washed with DCM (3×5 mL) and
the combined filtrate was concentrated under reduced pressure. The residue was
purified by silica gel chromatography (0.5% gradient of MeOH in DCM) to afford 19
(38.7 mg, 46%) and 18 (11.0mg, 13%) as white foams.
19: [α]D +0.65°, (c = 0.77, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H,
SiMe3), 0.89 (m, 1H, SiCH2-Ha), 0.99 (m, 1H, SiCH2-Hb), 1.73 (s, 3H, CH3CO3),
1.87 (s, 3H, CH3-NHAc), 1.88 (m, 1H, Sia-H3a), 1.94 (s, 3H, CH3-NHAc), 1.97, 1.98,
2.01, 2.03, 2.08 (5s, 15H, 5×CH3-OAc), 2.63 (dd, J3a,3b = 12.7, J3b,4 = 4.7 Hz, 1H, Sia-
H3b), 3.17 (m, 1H, GalNAc-H2), 3.52 (s, 1H, GalNAc-H5), 3.56 (m, 1H, OCH2-Ha),
3.77 (s, 3H, OCH3), 3.83 (dd, J5,6 = 10.8, J6,7 = 2.0 Hz, 1H, Sia-H6), 3.98-4.05 (m, 2H,
Sia-H5, OCH2-Hb), 4.08-4.15 (m, 3H, GalNAc-H6a, Sia-H9a, Sia-H9b), 4.17 (dd, J5,6a
= 6.5, J6a,6b = 11.2 Hz, 1H, Gal-H6a), 4.32-4.34 (m, 3H, Gal-H2, Gal-H5, GalNAc-
H6b), 4.40-4.44 (m, 2H, Gal-H6b, GalNAc-H4), 4.57 (m, 1H, Gal-H3), 4.73 (dd, J2,3 =
10.8, J3,4 = 3.8 Hz, 1H, GalNAc-H3), 4.93 (ddd, J3a,4 = 12.0, J3b,4 = 4.7, J4,5 = 10.5 Hz,
1H, Sia-H4), 5.17 (d, J5,NH = 10.0 Hz, 1H, Sia-NH), 5.20 (dd. J3,4 = 4.0, J4,5 = 1.9 Hz,
1H, Gal-H4), 5.29-5.32 (m, 2H, GalNAc-H1, Sia-H7), 5.55 (m, 1H, Sia-H8), 5.59 (s,
1H, PhCH), 5.72 (d, J1,2 = 5.2 Hz, 1H, Gal-H1), 6.17 (d, J2,NH = 6.7 Hz, 1H, GalNAc-
NH), 7.33-7.38, 7.41-7.44, 7.51-7.57, 8.03-8.05 (m, 10H, 2×C6H5);
97
13C NMR (125 MHz, CDCl3): δ -1.41 (3C, SiMe3), 17.92 (SiCH2), 20.50, 20.63,
20.69, 20.70, 20.81 (5×CH3-OAc), 22.19 (CH3CO3), 23.20, 23.70 (2× CH3-NHAc),
38.06 (Sia-C3), 49.34 (Sia-C5), 53.12 (OCH3), 55.07 (GalNAc-C2), 62.09 (Gal-C6),
62.18 (Sia-C9), 65.94 (Gal-C4), 66.35 (GalNAc-C5), 66.80 (OCH2), 66.91 (Sia-C7),
68.06 (Sia-C8), 68.94 (Gal-C2), 68.99 (Sia-C4), 69.09 (GalNAc-C3), 69.38 (GalNAc-
C6), 70.86 (Gal-C3), 72.21 (Sia-C6), 75.41 (GalNAc-C4), 75.73 (Gal-C5), 97.35 (Sia-
C2), 97.80 (Gal-C1), 98.14 (GalNAc-C1), 100.75 (PhCH), 121.05 (CO3), 126.22,
126.42, 128.07, 128.31, 128.91, 129.70, 129.75, 133.16, 138.00 (12C, 2×C6H5),
165.912, 167.96, 169.83, 170.02, 170.13, 170.27, 170.83, 170.93, 171.12 (9×CO);
ESI-MS: Calcd for C57H76N2O26Si (M+Na) +: 1255.4; Found: m/z 1255.1;
18: [α]D +8.8°, (c = 0.73, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3),
0.84-1.00 (m, 2H, SiCH2), 1.71 (m, 1H, Sia-H3a), 1.86, 1.98 (2s, 6H, 2×CH3-NHAc),
2.01, 2.07, 2.09, 2.12, 2.14, 2.22 (6s, 18H, 6×CH3-OAc), 2.59 (dd, J3a,3b = 12.7, J3b,4 =
4.6 Hz, 1H, Sia-H3b), 3.32 (s, 1H, GalNAc-H5), 3.47-3.56 (m, 2H, GalNAc-H2,
OCH2-Ha), 3.63 (dd, J5,6 = 10.7, J6,7 = 2.5 Hz, 1H, Sia-H6), 3.79 (s, 3H, OCH3), 3.82
(m, 1H, GalNAc-H6a), 3.96-4.09 (m, 4H, Gal-H5, Sia-H5, Sia-H9a, OCH2-Hb), 4.16
(dd, J5,6a = 5.9, J6a,6b = 11.1 Hz, 1H, Gal-H6a), 4.21 (d, J6a,6b = 11.8 Hz, 1H, GalNAc-
H6b), 4.28 (d, J3,4 = 2.9 Hz, 1H, GalNAc-H4), 4.34 (dd, J8,9b = 2.7, J9a,9b = 12.5 Hz, Sia-
H9b), 4.45 (dd, J5,6b = 6.9, J6a,6b = 11.1 Hz, 1H, Gal-H6b), 4.58-4.63 (m, 2H, Gal-H3,
GalNAc-H3), 4.83 (d, J1,2 = 7.9 Hz, 1H, Gal-H1), 4.89 (td, J3a,4 = J4,5 = 11.9, J3b,4 = 4.6
Hz, 1H, Sia-H4), 5.04 (d. J3,4 = 3.1Hz, 1H, Gal-H4), 5.09-5.14 (m, 3H, Gal-H2,
GalNAc-H1, Sia-NH), 5.39 (dd, 1H, J6,7 = 2.5, J7,8 = 9.3 Hz, Sia-H7), 5.45 (s, 1H,
PhCH), 5.53 (m, 1H, Sia-H8), 5.74 (d, J2, NH = 7.1 Hz, 1H, GalNAc-NH), 7.15-7.18,
7.24-7.27, 7.28-7.38, 7.42-7.61, 8.01-8.07 (m, 10H, 2×C6H5);
13C NMR (125 MHz, CDCl3): δ -1.40 (3C, SiMe3), 17.95 (SiCH2), 20.76, 20.78,
20.86, 21.10, 21.40 (6C, 6×CH3-OAc), 23.16, 23.62 (2× CH3-NHAc), 37.38 (Sia-C3),
49.14 (Sia-C5), 53.14 (OCH3), 54.25 (GalNAc-C2), 62.23 (Sia-C9), 62.42 (Gal-C6),
66.40 (GalNAc-C5), 66.64 (OCH2), 66.99 (Sia-C7), 67.49 (Gal-C4), 67.66 (Sia-C8),
69.24 (GalNAc-C6), 69.26 (Sia-C4), 70.05 (Gal-C2), 70.56 (Gal-C5), 71.68 (Gal-C3),
72.09 (Sia-C6), 75.14 (GalNAc-C4), 75.99 (GalNAc-C3), 96.74 (Sia-C2), 98.59
(GalNAc-C1), 100.76 (PhCH), 101.17 (Gal-C1), 126.31, 127.98, 128.20, 128.42,
128.67, 129.01, 129.63, 133.33 (12C, 2×C6H5), 165.80, 167.96, 169.49, 170.45,
170.58, 170.70, 170.89 (10C, 10×CO);
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ESI-MS: Calcd for C57H76N2O26Si (M+Na) +: 1255.4; Found: m/z 1255.0.
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosynate)-(2→3)-(β-D-galactopyranosyl)-(1→3)-2-acetamido-2-
deoxy-β-D-galactopyranoside (1), (GG-2-026, II-026).
A solution of 18 (14.0 mg, 11.4 µmol) in 80% aq. AcOH (2.0 ml) was stirred for 4 h
at 45°C. The solvent was evaporated in vacua. The remaining solid was dissolved in
MeOH (1.8 mL) and treated with freshly prepared 1 M NaOMe/MeOH (0.2 mL). The
mixture was stirred at rt under argon for 4 h, then H2O (0.25 mL) was added and the
mixture was stirred for 16 h at rt. The solution was concentrated and the residue was
purified by RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 1 as
white solid (4.5 mg, 50%) after a final lyophilization from H2O.
[α]D –7.8°, (c = 0.25, H2O); 1H NMR (500 MHz, D2O): δ 0.00 (s, 9H, SiMe3), 0.86
(m, 1H, SiCH2-Ha), 0.96 (m, 1H, SiCH2-Hb), 1.78 (t, J3a,3b = J3a,4 = 11.6 Hz, 1H, Sia-
H3a), 2.00, 2.02 (2s, 6H, 2×CH3-NHAc), 2.74 (m, 1H, Sia-H3b), 3.54 (m, 1H, Gal-
H2), 3.57-3.62 (m, 3H, GalNAc-H5, Sia-H6, Sia-H7), 3.63-3.74 (m, 5H, GalNAc-H6,
Gal-H6a, Sia-H4, Sia-H9a, OCH2-Ha), 3.75-3.81 (m, 2H, Gal-H5, Gal-H6b), 3.82-
3.87 (m, 4H, GalNAc-H3, Sia-H5, Sia-H8, Sia-H9b), 3.92 (m, 1H, Gal-H4), 3.97-4.06
(m, 3H, GalNAc-H2, GalNAc-H3, OCH2-Hb), 4.16 (m, 1H, GalNAc-H4), 4.49 (d, J1,2
= 7.6 Hz, 1H, Gal-H1), 4.53 (d, J1,2 = 8.3 Hz, 1H, GalNAc-H1);
13C NMR (125 MHz, D2O): δ  -1.8 (3C, SiMe3), 17.6 (SiCH2), 22.4, 22.6 (2×CH3-
NHAc), 40.1 (Sia-C3), 51.6 (GalNAc-C2), 52.2 (Sia-C5), 61.3, 61.4 (GalNAc-C6,
Gal-C6), 62.7 (Sia-C9), 67.7 (Gal-C4), 68.2 (GalNAc-C4), 68.3 (Sia-C7), 68.5 (Sia-
C4), 68.6 (OCH2), 69.2 (Gal-C2), 72.2 (Sia-C8), 72.7 (Sia-C6), 75.0, 75.1 (GalNAc-
C5, Gal-C-5), 76.1 (Gal-C3), 80.8 (GalNAc-C3), 100.2 (Sia-C2), 100.8 (GalNAc-C1),
104.9 (Gal-C1);
HRMS (FAB) Calcd for C30H54N2O19Si (M+H)+: 775.3168; Found: m/z 775.3110.
2-(Trimethylsilyl)ethyl 4,6-O-benzylidene-β-D-galactopyranoside ( 23), (GG-037,
I-037).
To a stirred solution of 13 (170 mg, 0.606 mmol) and α,α-dimethoxytoluene (0.167
mL, 1.21 mmol) in CH3CN (3 mL) at 0°C, TsOH·H2O (8.80 mg, 46.0 µmol) was
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added. The mixture was stirred at rt for 2.5 h, and then quenched by adding a few
drops of Et3N. After concentration under reduced pressure, the residue was purified
by silica gel chromatography (PE/AcOEt 3:2) to afford 23 (200 mg, 90%) as white
foam, the NMR data of which were in accordance with Lit.131
2-(Trimethylsilyl)ethyl (2,3,4-tri-O-benzoyl-6-O-benzyl-β-D-galactopyranosyl)-
(1→3)-4,6-O-benzylidene-β-D-galactopyranoside (25) and 2-(Trimethylsilyl)ethyl
(2,3,4-tri-O-benzoyl-6-O-benzyl-β-D-galactopyranosyl)-(1→2)-4,6-O-benzylidene-
β-D-galactopyranoside (26), (GG-040-2 and GG-040-3, I-040).
To a stirred solution of 23 (50.0 mg, 0.136 mmol) and ethyl 2,3,4-tri-O-benzoyl-6-O-
benzyl-1-thio-β-D-galactopyranoside145 24 (102 g, 0.163 mmol) in DCM (3.5 mL) was
added activated powdered molecular sieves 3 Å (200 mg). The reaction mixture was
stirred at rt under argon for 2 h and then cooled to –30°C. After the addition of NIS
(73.0 mg, 0.326 mmol) and TfOH (3.0 µL, 32.6 µmol), stirring was continued for 1.5
h at –30°C. Then the reaction was quenched by adding a few drops of Et3N, diluted
with DCM (10 mL) and filtered through a pad of Celite. The Celite was washed with
DCM (3×5 mL), the combined filtrates were successively washed with 20% Na2S2O3
(15 mL), saturated aq. KHCO3 (2×10 mL) and H2O (10 mL), and dried over Na2SO4.
After filtration and concentration under reduced pressure, the residue was purified by
silica gel chromatography (PE/AcOEt gradient 5:1 to 3:1) to afford 25 (17.0 mg,
13%) and 26 (50.0 mg, 40%) as white foams.
25: 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3), 0.95-1.06 (m, 2H, SiCH2),
3.37 (bs, 1H, Gal-H5), 3.55 (m, 1H, OCH2-Ha), 3.66 (dd, J5,6a = 6.0, J6a,6b = 9.7 Hz,
1H, Gal'-H6a), 3.71 (dd, J5,6b = 6.7, J6a,6b = 9.7 Hz, 1H, Gal'-H6b), 3.81 (dd, J2,3 = 10.0,
J3,4 = 3.5 Hz, 1H, Gal-H3), 3.92 (dd, J5,6a = 1.6, J6a,6b = 12.4 Hz, 1H, Gal-H6a), 3.93 (m,
1H, Gal-H2), 4.00 (m, 1H, OCH2-Hb), 4.18 (t, J5,6a = J5,6b = 6.5 Hz, 1H, Gal'-H5) 4.26
(d, J3,4 = 3.8 Hz, 1H, Gal-H4), 4.28 (m, 1H, Gal-H6b), 4.32 (d, J1,2 = 7.5 Hz, 1H, Gal-
H1), 4.44, 4.50 (A, B of AB, J = 11.8 Hz, 1H, PhCH2), 5.34(d, J1,2 = 8.0 Hz, 1H, Gal'-
H1), 5.41 (s, 1H, PhCH), 5.56 (dd, J2,3 = 10.4, J3,4 = 3.5 Hz, 1H, Gal'-H3), 5.80 (dd, J1,2
= 8.0, J2,3 = 10.4 Hz, 1H, Gal'-H2), 5.92 (d, J3,4 = 3.4 Hz, 1H, Gal'-H4), 7.18-7.26,
7.30-7.35, 7.39-7.51, 7.59-7.62, 7.78-7.80, 7.91-7.93, 8.04-8.05 (m, 25H, 5×C6H5);
26: 1H NMR (500 MHz, CDCl3): δ 0.04 (s, 9H, SiMe3), 1.03-1.08 (m, 2H, SiCH2),
2.30 (d, J3,OH = 7.4 Hz, 1H, Gal-3-OH), 3.39 (bs, 1H, Gal-H5), 3.59-3.72 (m, 4H, Gal-
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H3, Gal'-H6a, Gal'-H6b, OCH2-Ha), 3.81 (dd, J1,2 = 7.7, J2,3 = 9.4 Hz, 1H, Gal-H2),
4.00 (dd, J5,6a = 1.7, J6a,6b = 12.3 Hz, 1H, Gal-H6a), 4.04 (m, 1H, OCH2-Hb), 4.07 (d,
J3,4 = 3.6 Hz, 1H, Gal-H4), 4.17 (m, 1H, Gal'-H5), 4.30 (m, 1H, Gal-H6b), 4.37, 4.51
(A, B of AB, J = 11.8 Hz, 2H, PhCH2), 4.44 (d, J1,2 = 7.7 Hz, 1H, Gal-H1), 5.28(d, J1,2
= 8.1 Hz, 1H, Gal'-H1), 5.43 (s, 1H, PhCH), 5.53 (dd, J2,3 = 10.5, J3,4 = 3.4 Hz, 1H,
Gal'-H3), 5.76 (dd, J1,2 = 8.1, J2,3 = 10.4 Hz, 1H, Gal'-H2), 5.97 (d, J3,4 = 3.3 Hz, 1H,
Gal'-H4), 7.13-7.31, 7.32-7.45, 7.58-7.61, 7.78-7.79, 7.91-7.93, 8.02-8.04 (m, 25H,
5×C6H5).
2-(Trimethylsilyl)ethyl 3-O-benzyl- 4,6-O-benzylidene-β-D-galactopyranoside
(27),  2-(trimethylsilyl)ethyl 2-O -benzyl- 4,6-O -benzylidene-β -D-
galactopyranoside (2 8 ) and 2-(trimethylsilyl)ethyl 2,3-di-O-benzyl- 4,6-O-
benzylidene-β-D-galactopyranoside (29), (GG-042-2, GG-042-3, and GG-042-1, I-
042).
To a stirred solution of 23 (150 mg, 0.410 mmol), TBAB (27.0 mg, 82.0 µmol), and
benzyl bromide (85.0 µL, 0.700 mmol) in toluene (7.5 mL) was added aq. 5% NaOH
(0.75 mL). The mixture was stirred vigorously at 60°C for 22 h. The solution was
diluted with toluene (10 mL), the organic layer was washed with H2O (2×20 mL) and
dried over Na2SO4. After filtration and concentration under reduced pressure, the
residue was purified by silica gel chromatography (PE/AcOEt 2:1) to afford 27 (118
mg, 63%), 28 (25.2 mg, 13%) and 29 (10.0 mg, 4%) as white foams.
27: 1H NMR (500 MHz, CDCl3): δ 0.02 (s, 9H, SiMe3), 0.91-1.09 (m, 2H, SiCH2),
2.43 (bs, 1H, 2-OH), 3.36 (bs, 1H, Gal-H5), 3.50 (dd, J2,3 = 9.7, J3,4 = 3.6 Hz, 1H, Gal-
H3), 3.57 (m, 1H, OCH2-Ha), 3.97-4.08 (m, 3H, Gal-H2, Gal-H6a, OCH2-Hb), 4.13
(d, J3,4 = 3.5 Hz, 1H, Gal-H4), 4.31 (d, J1,2 = 7.7 Hz, 1H, Gal-H1), 4.32 (m, 1H, Gal-
H6b), 4.75, 4.78 (A, B of AB, J = 12.4 Hz, 2H, PhCH2), 5.46 (s, 1H, PhCH), 7.28-
7.41, 7.51-7.54 (m, 10H, 2×C6H5);
28: 1H NMR (500 MHz, CDCl3): δ 0.03 (s, 9H, SiMe3), 0.99-1.12 (m, 2H, SiCH2),
2.49 (d, J3,OH = 7.4 Hz, 1H, 3-OH), 3.45 (bs, 1H, Gal-H5), 3.58 (m, 1H, OCH2-Ha),
3.62 (dd, J1,2 = 7.7, J2,3 = 9.4 Hz, 1H, Gal-H2), 3.74 (m, 1H, Gal-H3), 4.04-4.10 (m,
2H, Gal-H6a, OCH2-Hb), 4.22 (d, J3,4 = 3.8 Hz, 1H, Gal-H4), 4.34 (dd, J5,6a = 1.3, J6a,6b
= 12.4 Hz, 1H, Gal-H6b), 4.41 (d, J1,2 = 7.7 Hz, 1H, Gal-H1), 4.73, 5.00 (A, B of AB,
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J = 11.3 Hz, 2H, PhCH2), 5.56 (s, 1H, PhCH), 7.26-7.29, 7.32-7.40, 7.51-7.53 (m,
10H, 2×C6H5);
29: 1H NMR (500 MHz, CDCl3): δ 0.02 (s, 9H, SiMe3), 0.98-1.08 (m, 2H, SiCH2),
3.31 (bs, 1H, Gal-H5), 3.55 (dd, J2,3 = 9.7, J3,4 = 3.7 Hz, 1H, Gal-H3), 3.58 (m, 1H,
OCH2-Ha), 3.84 (dd, J1,2 = 7.8, J2,3 = 9.7 Hz, 1H, Gal-H2), 4.02 (dd, J5,6a = 1.7, J6a,6b =
12.3 Hz, 1H, Gal-H6a), 4.06 (m, 1H, OCH2-Hb), 4.11 (d, J3,4 = 3.4 Hz, 1H, Gal-H4),
4.31 (dd, J5,6a = 1.4, J6a,6b = 12.3 Hz, 1H, Gal-H6b), 4.39 (d, J1,2 = 7.8 Hz, 1H, Gal-H1),
4.73-4.80 (m, 3H, PhCH2, PhCH2-HA), 4.95 (B of AB, J = 10.9 Hz, PhCH2-HB), 5.49
(s, 1H, PhCH), 7.26-7.40, 7.55-7.56 (m, 15H, 3×C6H5).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-6-
O-benzoyl-β-D-galactopyranoside (31) and 2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-
O-benzoyl-β-D-galactopyranosyl)-(1→2)-6-O-benzoyl-β-D-galactopyranoside
(32), (GG-048-1 and GG-048-2, I-048).
To a stirred solution of 3 (30.0 mg, 78.0 µmol) and ethyl 2,3,4,6-tetra-O-benzoyl-1-
thio-β-D-galactopyranoside146 30 (55.0 g, 86.0 µmol) in DCM (2.0 mL) was added
activated powdered molecular sieves 3 Å (150 mg). The suspension was stirred at rt
under argon for 2 h and then cooled to –30°C. After the addition of NIS (38.7 mg,
0.172 mmol) and TfOH (1.5 µL, 17.2 µmol), stirring was continued for 3 h at –30°C.
Then the reaction was quenched by adding few drops of Et3N, diluted with DCM (10
mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×5
mL), and the combined filtrates were successively washed with 20% Na2S2O3 (15
mL), saturated KHCO3 (2×10 mL), H2O (10 mL), and dried over Na2SO4. After
filtration and concentration under reduced pressure, the residue was purified by silica
gel chromatography (PE/AcOEt 4:1 to 2:1) to afford 31 (7.00 mg, 9%) and 32 (20.0
mg, 27%) as white foams.
31: 1H NMR (500 MHz, CDCl3): δ -0.05 (s, 9H, SiMe3), 0.91-0.99 (m, 2H, SiCH2),
3.53 (m, 1H, OCH2-Ha), 3.69-3.76 (m, 3H, Gal-H2, Gal-H3, Gal-H5), 3.95 (m, 1H,
OCH2-Hb), 4.11 (d, J3,4 = 3.0 Hz, 1H, Gal-H4), 4.20 (d, J1,2 = 7.3 Hz, 1H, Gal-H1),
4.37 (m, 1H, Gal'-H5), 4.42-4.48 (m, 2H, Gal-H6a, Gal'-H6a), 4.55 (dd, J5,6b = 7.6,
J6a,6b = 11.5 Hz, 1H, Gal-H6b), 4.65 (dd, J5,6b = 7.1, J6a,6b = 11.4 Hz, 1H, Gal'-H6b),
5.19 (d, J1,2 = 7.9 Hz, 1H, Gal'-H1), 5.66 (dd, J2,3 = 10.5, J3,4 = 3.5 Hz, 1H, Gal'-H3),
5.79 (dd, J1,2 = 7.9, J2,3 = 10.4 Hz, 1H, Gal'-H2), 5.99 (d, J3,4 = 3.5 Hz, 1H, Gal'-H4),
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7.24-7.27, 7.36-7.59, 7.63-7.66, 7.78-7.79, 7.94-7.96, 8.01-8.03, 8.10-8.11 (m, 25H,
5×C6H5);
32: 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3), 1.03-1.07 (m, 2H, SiCH2),
3.64 (m, 1H, OCH2-Ha), 3.71-3.72 (m, 2H, Gal-H2, Gal-H3), 3.78 (m, 1H, Gal-H5),
3.91 (d, J3,4 = 1.4 Hz, 1H, Gal-H4), 4.00 (m, 1H, OCH2-Hb), 4.33-4.40 (m, 2H, Gal'-
H5, Gal'-H6a), 4.48 (d, J1,2 = 7.4 Hz, 1H, Gal-H1), 4.52 (dd, J5,6a = 7.0, J6a,6b = 11.3 Hz,
1H, Gal-H6a), 4.57 (dd, J5,6b = 6.1, J6a,6b = 11.4 Hz, 1H, Gal-H6b), 4.71 (dd, J5,6b = 9.2,
J6a,6b = 14.6 Hz, 1H, Gal'-H6b), 5.30 (d, J1,2 = 7.9 Hz, 1H, Gal'-H1), 5.67 (dd, J2,3 =
10.4, J3,4 = 3.4 Hz, 1H, Gal'-H3), 5.77 (dd, J1,2 = 7.9, J2,3 = 10.5 Hz, 1H, Gal'-H2), 6.01
(d, J3,4 = 3.3 Hz, 1H, Gal'-H4), 7.22-7.26, 7.37-7.64, 7.76-7.79, 7.95-8.03, 8.09-8.11
(m, 25H, 5×C6H5).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-
2,4-di-O-acetyl-6-O-benzoyl-β-D-galactopyranoside (33), (GG-048-1', I-050).
To a stirred solution of 31 (7.00 mg, 7.27 µmol) in py (0.5 mL) was added Ac2O (0.25
mL). The mixture was stirred for 16 h at rt under argon, and then quenched by adding
MeOH (0.5 mL). The solution was concentrated under reduced pressure and co-
evaporated with toluene (3×5 mL). The residue was diluted with DCM (10 mL),
washed with 1M HCl (2×10 mL), 5% NaHCO3 (2×10 mL) H2O (10 mL), and dried
over Na2SO4. Filtration and concentration under reduced pressure afforded 33 as
white foam (7.00 mg, 94%).
1H NMR (500 MHz, CDCl3): δ -0.07 (s, 9H, SiMe3), 0.95-0.97 (m, 2H, SiCH2), 2.18,
2.23 (2s, 6H, 2×CH3-OAc), 3.47 (m, 1H, OCH2-Ha), 3.87-3.92 (m, 3H, Gal-H3, Gal-
H5, OCH2-Hb), 4.27-4.38 (m, 4H, Gal-H1, Gal-H6a, Gal'-H5, Gal'-H6a), 4.45 (dd,
J5,6b = 7.5, J6a,6b = 11.5 Hz, 1H, Gal-H6b), 4.68 (dd, J5,6b = 6.3, J6a,6b = 11.2 Hz, 1H,
Gal'-H6b), 4.11 (d, J3,4 = 3.0 Hz, 1H, Gal-H4), 4.93 (d, J1,2 = 7.7 Hz, 1H, Gal'-H1),
5.16 (dd, J1,2 = 8.1, J2,3 = 10.0 Hz, 1H, Gal-H2), 5.56 (dd, J2,3 = 10.4, J3,4 = 3.3 Hz, 1H,
Gal'-H3), 5.70 (dd, J1,2 = 7.7, J2,3 = 10.4 Hz, 1H, Gal'-H2), 5.72 (d, J3,4 = 2.8 Hz, 1H,
Gal-H4), 5.93 (d, J3,4 = 3.2 Hz, 1H, Gal'-H4), 7.22-7.26, 7.35-7.43, 7.48-7.55, 7.62-
7.65, 7.75-7.77, 7.91-7.92, 8.00-8.02, 8.05-8.06, 8.13-8.14 (m, 25H, 5×C6H5).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→2)-
3,4-di-O-acetyl-6-O-benzoyl-β-D-galactopyranoside (34), (GG-048-2', I-051).
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To a stirred solution of 32 (20.0 mg, 20.8 µmol) in py (1.0 mL) was added Ac2O (0.5
mL). The mixture was stirred for 16 h at rt under argon, and then quenched by adding
MeOH (1 mL). The solution was concentrated under reduced pressure and co-
evaporated with toluene (3×5 mL). The residue was diluted with DCM (10 mL),
washed with 1N HCl (2×10 mL), 5% NaHCO3 (2×10 mL), H2O (10 mL), and dried
over Na2SO4. Filtration and concentration under reduced pressure afforded 34 as
white foam (21.0 mg, 98%).
1H NMR (500 MHz, CDCl3): δ 0.07 (s, 9H, SiMe3), 0.95-0.97 (m, 2H, SiCH2), 2.18,
2.25 (2s, 6H, 2×CH3-OAc), 3.72 (m, 1H, OCH2-Ha), 3.95 (dd, 1H, J1,2 = 7.8, J2,3 =
10.2 Hz, 1H, Gal-H2), 4.00 (m, 1H, Gal-H5), 4.07 (m, 1H, OCH2-Hb), 4.23 (dd, 1H,
J5,6a = 6.9, J6a,6b = 11.2 Hz, 1H, Gal-H6a), 4.29-4.38 (m, 2H, Gal'-H5, Gal'-H6a), 4.50
(dd, J5,6b = 6.8, J6a,6b = 11.2 Hz, 1H, Gal-H6b), 4.62 (d, J1,2 = 7.7 Hz, 1H, Gal-H1), 4.75
(dd, J5,6b = 2.8, J6a,6b = 8.6 Hz, 1H, Gal'-H6b), 4.99 (dd, J2,3 = 10.2, J3,4 = 3.4 Hz, 1H,
Gal-H3), 5.34 (d, J1,2 = 8.0 Hz, 1H, Gal'-H1), 5.39 (d, J3,4 = 3.7 Hz, 1H, Gal-H4), 5.53
(dd, J2,3 = 10.3, J3,4 = 3.4 Hz, 1H, Gal'-H3), 5.74 (dd, J1,2 = 8.1, J2,3 = 10.3 Hz, 1H, Gal'-
H2), 5.99 (d, J3,4 = 3.4 Hz, 1H, Gal'-H4), 7.23-7.26, 7.37-7.44, 7.47-7.63, 7.76-7.78,
7.93-8.00, 8.08-8.10 (m, 25H, 5×C6H5).
2-(Trimethylsilyl)ethyl 6-O-benzoyl-3,4-O-isopropylidene-β-D-galactopyranoside
(35), (GG-049, I-049).
To a refluxing solution of 3 (100 mg, 0.260 mmol) in acetone (3.0 mL) was added
TsOH⋅H2O (16.5 mg, 87.0 µmol). The mixture was refluxed for 1 h, quenched by
adding 5% aq. NaHCO3 till neutral, and then concentrated under reduced pressure.
The residue was diluted with DCM (20 mL), washed with H2O (2×10 mL), and dried
over NaSO4. After filtration and concentration under reduced pressure, the residue
was purified by silica gel chromatography (PE/AcOEt 3:1) to afford 35 (90.0 mg,
82%) as white foam.
1H NMR (500 MHz, CDCl3): δ -0.01 (s, 9H, SiMe3), 0.94-1.07 (m, 2H, SiCH2), 1.37,
1.54 (2s, 6H, 2×CH3), 2.40 (bs, 1H, 2-OH), 3.55-3.61 (m, 2H, Gal-H2, OCH2-Ha),
4.00 (m, 1H, OCH2-Hb), 4.10-4.15 (m, 2H, Gal-H3, Gal-H5), 4.21 (d, J1,2 = 8.3 Hz,
1H, Gal-H1), 4.23 (d, J3,4 = 5.5, J4,5 = 2.2 Hz, 1H, Gal-H4), 4.60 (dd, J5,6a = 7.9, J6a,6b =
11.6 Hz, 1H, Gal-H6a), 4.67 (dd, J5,6b = 4.7, J6a,6b = 11.6 Hz, 1H, Gal-H6b), 7.43-7.46,
7.56-7.60, 8.04-8.06 (m, 5H, C6H5).
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2-(Trimethylsilyl)ethyl 3,4-O-isopropylidene-β-D-galactopyranoside (39), (GG-
065, I-070).
To a stirred solution of 13 (1.50 g, 5.35 mmol) in DMF (20 mL) were added 2,2-
dimethoxypropane (0.98 mL, 8.02 mmol) and TsOH⋅H2O (20.0 mg, 0.107 mmol).
The mixture was stirred at 80°C for 3 h, and quenched by adding a few drops of Et3N.
The solution was concentrated under reduced pressure to a syrup, and then purified by
silica gel chromatography (PE/AcOEt 1:1) to afford 39 (1.45 mg, 85%) as white
foam, the NMR data of which were in accordance with Lit.{Murase, 1989 #20}
2-(Trimethylsilyl)ethyl 2,6-di-O -benzyl -3 ,4-O - i sopropy l idene-β-D-
galacopyranoside (37), (GG-067, I-071).
To a solution of 39 (1.45 g, 4.52 mmol) in DMF (25 mL) at 0°C were added NaH in
(50% suspension in oil, 0.650 g, 13.6 mmol) and benzyl bromide (1.60 mL, 13.6
mmol). The mixture was stirred at 0°C for 1.5 h, then quenched by adding MeOH (2
mL), and evaporated under reduced pressure. The resulting syrup was diluted with
DCM (30 mL), washed with H2O (3×20 mL), and dried over Na2SO4. After filtration
and concentration under reduced pressure, the residue was purified by silica gel
chromatography (PE/AcOEt 15:1) to afford 37 (2.00 g, 88%) as white foam, the NMR
data of which were in accordance with Lit.229
2-(Trimethylsilyl)ethyl 2,6-di-O-benzyl-β-D-galactopyranoside (38), (GG-068, I-
068).
A solution of 37 (70.0 mg, 0.139 mmol) in aq. 80% AcOH (2.0 mL) was heated at
60°C for 1 h. The reaction mixture was concentrated under reduced pressure and co-
evaporated with toluene (3×5 mL). The residue was purified by silica gel
chromatography (PE/AcOEt 1:1) to afford 38 (59.0 mg, 92%) as white foam, the
NMR data of which were in accordance with Lit.229
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-
2,6-di-O-benzyl-β-D-galactopyranoside (41), (GG-074, I-074).
To a solution of 38 (300 mg, 0.648 mmol) and 30 (500 mg, 0.778 mmol) in DCM (10
mL) was added activated powdered molecular sieves 3Å (2.00 g). The reaction
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mixture was stirred at rt for 6 h under argon before DMTST (504 mg, 1.95 mmol) was
added at 0°C. The reaction mixture was stirred at 7°C for 16 h, diluted with DCM (10
mL), and filtered through a pad of Celite. The Celite was washed with DCM (3×10
mL), and the combined filtrates were washed with 5% KHCO3 (2×20 mL) and H2O
(20 mL). The organic layer was dried over Na2SO4, filtered and concentrated under
reduced pressure. The residue was purified by flash silica gel chromatography
(PE/AcOEt 5:1) to afford the corresponding disaccharide 41 (588 mg, 87%) as white
foam.
[α]D +56.4° (c = 0.96, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3),
0.90-1.02 (m, 2H, SiCH2), 3.54 (ddd, J = 5.8, 9.6, 11.5 Hz, 1H, OCH2-Ha), 3.58-3.62
(m, 2H, Gal-H2, Gal-H5), 3.71 (dd, J5,6a = 5.1, J6a,6b = 10.1 Hz, 1H, Gal-H6a), 3.75 (dd,
J5,6b = 6.6, J6a,6b = 10.1 Hz, 1H, Gal-H6b), 3.84 (dd, J2,3 = 9.4, J3,4 = 3.3 Hz, 1H, Gal-
H3), 4.00 (ddd, J = 6.1, 9.6, 11.4 Hz, 1H, OCH2-Hb), 4.13 (d, J3,4 =2.8 Hz, 1H, Gal-
H4), 4.28 (m, 1H, Gal'-H5), 4.34 (d, J1,2 = 7.8 Hz, 1H, Gal-H1), 4.36, 4.72 (A, B of
AB, J = 11.1 Hz, 2H, PhCH2), 4.45 (dd, J5,6a = 6.1, J6a,6b = 11.4 Hz, 1H, Gal'-H6a),
4.55, 4.59 (A, B of AB, J = 11.9 Hz, 2H, PhCH2), 4.65 (dd, J5,6b = 7.0, J6a,6b = 11.4 Hz,
1H, Gal'-H6b), 5.27(d, J1,2 = 8.0 Hz, 1H, Gal'-H1), 5.62 (dd, J2,3 = 10.5, J3,4 = 3.5 Hz,
1H, Gal'-H3), 5.89 (dd, J1,2 = 8.0, J2,3 = 10.5 Hz, 1H, Gal'-H2), 6.00 (dd, J3,4 = 3.5, J4,5
= 0.8 Hz, 1H, Gal'-H4), 7.16-7.18, 7.25-7.32, 7.35-7.37, 7.43-7.47, 7.53-7.57, 7.58-
7.68, 7.78-7.80, 7.87-7.89, 8.03-8.05, 8.12-8.14 (m, 30H, 6×C6H5);
13C NMR (125 MHz, CDCl3): δ -1.51 (3C, SiMe3), 18.41 (SiCH2), 61.98 (Gal'-C6),
67.25 (OCH2), 68.09 (Gal'-C4), 68.90 (Gal-C4), 69.49 (Gal-C6), 69.86 (Gal'-C2),
71.42, 71.50 (Gal'-C3, Gal'-C5), 73.16 (Gal-C5), 73.60 (PhCH2), 74.72 (PhCH2),
78.87 (Gal-C2), 80.82 (Gal-C3), 101.62 (Gal'-C1), 102.91 (Gal-C1), 127.46-138.50
(36C, 6×C6H5), 165.48, 165.54, 165.60, 165.94 (4×CO);
HRMS (FAB) Calcd for C59H62O15Si (M+NH4)+: 1056.4202; Found: m/z 1056.4186.
2-(Trimethylsilyl)ethyl (β-D-galactopyranosyl)-(1→3)-2,6-O-dibenzyl-β-D-
galactopyranoside (42), (GG-076, I-080).
To a solution of 41 (550 mg, 0.529 mmol) in MeOH (20 mL) was added freshly
prepared 1 M NaOMe/MeOH (2.0 mL). The mixture was stirred at rt for 2 h under
argon, then neutralized with Amberlite IRC 50 ion-exchange resin and filtered
through a pad of Celite. The Celite was washed with MeOH (3×10 mL), and the
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combined filtrates were evaporated under reduced pressure. The residue was purified
by silica gel chromatography (DCM/MeOH 15:1) to afford 42 (280 mg, 85%) as
white foam.
[α]D -7.7° (c = 0.75, CH3OH); 1H NMR (500 MHz, CD3OD): δ 0.00 (s, 9H, SiMe3),
0.97 (t, J = 8.4 Hz, 2H, SiCH2), 3.40-3.44 (m, 2H, Gal'-H3, Gal-H5), 3.54-3.63 (m,
3H, Gal-H2, Gal'-H2, OCH2-Ha), 3.64-3.71 (m, 5H, Gal-H6a, Gal-H6b, Gal'-H5,
Gal'-H6a, Gal'-H6b), 3.76 (dd, J2,3 = 9.7, J3,4 = 3.4 Hz, 1H, Gal-H3), 3.78 (d, J3,4 = 3.3
Hz, 1H, Gal'-H4), 4.00 (m, 1H, OCH2-Hb), 4.02 (d, J3,4 = 3.4 Hz, 1H, Gal-H4), 4.37
(d, J1,2 = 7.8 Hz, 1H, Gal-H1), 4.54, 4.57 (A, B of AB, J = 11.9 Hz, 2H, PhCH2), 4.58
(d, J1,2 = 7.8 Hz, 1H, Gal'-H1), 4.78, 4.84 (A, B of AB, J = 10.7 Hz, 2H, PhCH2),
7.21-7.33, 7.40 (m, 10H, 2×C6H5);
13C NMR (125 MHz, CD3OD): δ -1.49 (3C, SiMe3), 19.28 (SiCH2), 62.41 (Gal'-C6),
68.20 (OCH2), 70.16 (Gal'-C4), 70.53 (Gal-C4), 70.71 (Gal-C6), 72.65 (Gal'-C3),
74.24 (PhCH2), 74.60 (Gal'-C2), 75.75 (PhCH2), 76.55 (2C, Gal-C5, Gal'-C5), 80.33
(Gal-C2), 81.75 (Gal-C3), 104.33 (Gal-C1), 105.86 (Gal'-C1), 128.39, 128.55,
128.65, 129.02, 129.24, 129.30, 139.56, 140.16 (12C, 12×C6H5);
ESI-MS: Calcd for C31H46O11Si (M+Na)+: 645.3; Found: m/z 645.2.
2-(Trimethylsilyl)ethyl (β-D-galactopyranosyl)-(1→3)-β-D-galactopyranoside
(22), (GG-098, I-098).
A solution of 42 (45.0 mg, 72.3 µmol) in MeOH (2.5 mL) containing a catalytic
amount of AcOH was hydrogenolyzed (1 bar H2) in the presence of 10% Pd-C (15.0
mg) for 3 h at rt. The reaction mixture was filtered through a pad of Celite, which was
washed with MeOH (5 mL). The filtrate was concentrated and then purified by silica
gel chromatography (DCM/MeOH 3:1) to afford 22 (26.6 mg, 83%) as white foam.
[α]D -2.3° (c = 1, CH3OH); 1H NMR (500 MHz, CD3OD): δ 0.00 (s, 9H, SiMe3), 0.94
(m, 1H, SiCH2-Ha), 1.02 (m, 1H, SiCH2-Hb), 3.46 (dd, J2,3 = 9.7, J3,4 = 3.2 Hz, 1H,
Gal'-H3), 3.49-3.52 (m, 2H, Gal-H5, Gal'-H5), 3.55-3.74 (m, 8H, Gal-H2, Gal-H3,
Gal-H6a, Gal-H6b, Gal'-H2, Gal'-H6a, Gal'-H6b, OCH2-Ha), 3.75 (d, J3,4 = 3.2 Hz,
1H, Gal'-H4), 3.98 (ddd, J = 5.7, 9.6, 11.5Hz, 1H, OCH2-Hb), 4.08 (d, J3,4 = 3.0 Hz,
1H, Gal-H4), 4.26 (d, J1,2 = 7.7 Hz, 1H, Gal-H1), 4.45 (d, J1,2 = 7.6 Hz, 1H, Gal'-H1);
13C NMR (125 MHz, CD3OD): δ -1.47 (3C, SiMe3), 18.99 (SiCH2), 62.41 (2C, Gal-
C6, Gal'-C6), 67.91 (OCH2), 69.70, 70.13 (Gal-C4, Gal'-C4), 71.43, 72.88 (Gal-C2,
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Gal'-C2), 74.52, 76.09 (Gal-C5, Gal'-C5), 76.69 (Gal'-C3), 85.02 (Gal-C3), 103.79
(Gal-C1), 106.29 (Gal'-C1);
HRMS (FAB) Calcd for C17H34O11Si (M+Na)+: 465.1768; Found: m/z 465.1762.
2-(Trimethylsilyl)ethyl (5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
n o n u l o p y r a n o s y l o n i c  a c i d ) - ( 2→3)-β-D-galactopyranosyl-(1→3)-β-D-
galactopyranoside (20).
22 (10.0 mg, 22.6 µmol) and CMP-sialic acid (22.3 mg, 33.9 µmol) were dissolved in
a mixture of 50 mM sodium cacodylate-buffer pH 6.5 (2 mL), 60 mM aqueous MnCl2
(2 mL) and deionized water (1.3 mL) containing BSA (2.30 mg). The mixture was
incubated at 37°C with CIAP (2 µL) and recombinant ST3Gal III (500 µL, 9 U/L).
After 17 h, additional ST3Gal III (250 µL) was added and the incubation continued
for 3 d. The turbid solution was centrifuged and the supernatant passed over a RP-18
column, which was washed with water before the crude product was eluted with
MeOH. After evaporation of the solvent, the residue was chromatographied on silica
gel (DCM/MeOH/H2O 10:4:0.4, then 6:4:1) to yield starting material 22 (4.00 mg, 40
%) and trisaccharide 20 (9.70 mg, 59 %) as white solids after a final lyophilization
from water.
[α]D +4.1° (c = 0.63, H2O); 1H NMR (500 MHz, D2O): δ 0.02 (s, 9H, SiMe3), 0.97 (m,
1H, SiCH2-Ha), 1.07 (m, 1H, SiCH2-Hb), 1.79 (t, J3a,3b = J3a,4 = 12.1 Hz, 1H, Sia-H3a),
2.02 (s, 3H, CH3-NHAc), 2.75 (dd, J3a,3b = 12.4, J3a,4 = 4.5 Hz, 1H, Sia-H3b), 3.58 (dd,
J6,7 = 1.5, J7,8 = 9.2 Hz, 1H, Sia-H7), 3.59-3.66 (m, 4H, Gal-H2, Gal'-H2, Sia-H6, Sia-
H9a), 3.66-3.77 (m, 8H, Gal-H5, Gal-H6a, Gal-H6b, Gal'-H5, Gal'-H6a, Gal'-H6b,
Sia-H4, OCH2-Ha), 3.80 (dd, J2,3 = 9.9, J 3,4 = 3,4 Hz, 1H, Gal-H3), 3.84-3.88 (m, 3H,
Sia-H5, Sia-H8, Sia-H9b), 3.94 (d, J3,4 = 3.0 Hz, 1H, Gal'-H4), 4.04 (ddd, J = 5.2,
10.0, 12.7 Hz, 1H, OCH2-Hb), 4.10 (dd, J2,3 = 9.8, J3,4 = 3.1 Hz, 1H, Gal'-H3), 4.18 (d,
J3,4 = 3.3 Hz, 1H, Gal-H4), 4.45 (d, J1,2 = 8.0 Hz, 1H, Gal-H1), 4.68 (d, J1,2 = 7.8 Hz,
1H, Gal'-H1);
13C NMR (125 MHz, D2O): δ -2.0 (3C, SiMe3), 18.1 (SiCH2), 22.6 (CH3-NHAc), 40.2
(Sia-C3), 52.2 (Sia-C5), 61.4, 61.5 (Gal-C6, Gal'-C6), 63.1 (Sia-C9), 67.9 (Gal-C4),
68.6 (Sia-C7), 68.8 (Sia-C4), 68.9 (OCH2), 69.0 (Gal-C4), 70.1, 70.3 (Gal-C2, Gal'-
C2), 72.4 (Sia-C8), 73.4 (Sia-C6), 75.2, 75.4 (Gal-C5, Gal'-C5), 76.1 (Gal'-C3), 83.1
(Gal-C3), 100.4 (Sia-C2), 102.3 (Gal-C1), 104.6 (Gal'-C1);
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HRMS (FAB) Calcd for C28H51NO19Si (M+NH4)+: 751.3186; Found: m/z 751.3172.
2-(Trimethylsilyl)ethyl (6-O-benzoyl-β-D-galactopyranosyl)-(1→3)-2,6-O-
dibenzyl-β-D-galactopyranoside (60), (GG-078, I-097).
To a solution of 42 (26.0 mg, 41.6 µmol) in Et3N (0.5mL) and CH3CN (2.0mL), a
solution of benzoyl cyanide (4.90 mg, 37.4 µmol) in CH3CN (0.5 mL) was added
dropwise at –40°C under argon during 10 min. The reaction was stirred at –40°C for
2h, then quenched with a few drops of MeOH. The solution was concentrated under
reduced pressure and the residue was purified by flash silica gel chromatography
(DCM/MeOH 40:1) to afford 60 (22.0 mg, 73%) as white foam.
[α]D -0.30°, (c = 0.65, CH3OH); 1H NMR (500 MHz, CD3OD): δ 0.00 (s, 9H, SiMe3),
0.94-0.98 (m, 2H, SiCH2), 3.42-3.46 (m, 2H, Gal-H5, Gal-H6a), 3.51 (dd, J2,3 = 9.7,
J3,4 = 3.4 Hz, 1H, Gal'-H3), 3.55-3.64 (m, 5H, Gal-H2, Gal-H3, Gal-H6b, Gal'-H2,
OCH2-Ha), 3.83 (dd, J5,6a = 4.2, J5,6b = 8.5 Hz, 1H, Gal'-H5), 3.86 (d, J3,4 = 3.4 Hz, 1H,
Gal'-H4), 3.94-3.99 (m, 2H, Gal-H4, OCH2-Hb), 4.26 (d, J1,2 = 7.6 Hz, 1H, Gal-H1),
4.37 (dd, J5,6a = 4.2, J6a,6b = 11.4 Hz, 1H, Gal'-H6a), 4.43, 4.46 (A, B of AB, J = 12.0
Hz, 2H, PhCH2), 4.57 (d, J1,2 = 7.7 Hz, 1H, Gal'-H1), 4.63 (dd, J5,6b = 8.5, J6a,6b = 11.4
Hz, 1H, Gal'-H6b), 4.76 and 4.84 (A, B of AB, J = 10.6 Hz, 2H, PhCH2), 7.21-7.32,
7.40-7.46, 7.54-7.58, 7.99-8.01 (m, 15H, 3×C6H5);
13C NMR (125 MHz, CD3OD): δ -1.48 (3C, SiMe3), 19.25 (SiCH2), 65.04 (Gal'-C6),
68.17 (OCH2), 70.14, 70.63 (Gal-C4, Gal'-C4), 70.85 (Gal-C6), 72.43 (2C, Gal'-C2,
Gal'-C3), 73.95 (Gal'-C5), 74.13 (PhCH2), 74.63 (Gal-C5), 75.85 (PhCH2), 80.00
(Gal-C2), 82.65 (Gal-C3), 104.20 (Gal-C1), 105.94 (Gal'-C1), 128.43, 128.50,
128.56, 129.03, 129.23, 129.32, 129.60, 129.74, 130.52, 130.72, 131.14, 131.46,
132.22, 134.30, 139.56, 140.10  (18C, 3×C6H5), 167.57 (CO);
HRMS (FAB) Calcd for C38H50O12Si (M+NH4)+: 744.3415; Found: m/z 744.3402.
Methyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-D-glycero-
D-galacto-2-nonulopyranosid)onate (55), (GG-031, I-031).
A suspension of 7 (300 mg, 0.563 mmol) and activated molecular sieves 3Å (200 mg)
in DCM (3 mL) was stirred at rt for 3 h. Then TMSSMe (112 µL, 0.788 mmol) and
TMSOTf (76.0 µL, 0.400 mmol) were added. The reaction was stirred at 45°C under
argon for 5.5 h and at rt for further 16 h. The mixture was then diluted with DCM (5
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mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×5
mL), and the combined filtrates were washed with 5% NaHCO3 (2×10 mL) and H2O
(10 mL). The organic layer was dried over Na2SO4, filtrated and concentrated under
reduced pressure. The residue was purified by silica gel chromatography (PE/AcOEt
1:4) to afford 55 (270 mg, 92%) as a mixture of α and β anomers with a ratio of 1:1
according to the 1H NMR which was in accordance with Lit.166
M e t h y l  ( m e t h y l  5 - a m i n o - 3,5-dideoxy-2-thio-D-glycero-D-galacto-2-
nonulopyranosid)onate (65), (GG-106, I-106).
To a stirred solution of 55 (100 mg, 0.192 mmol) in MeOH (8 mL) was added MsOH
(124 µL, 1.92 mmol). The mixture was stirred for 24 h at 60°C and then neutralized
with Et3N. The solution was concentrated under reduced pressure, and the residue was
purified by silica gel chromatography (DCM/MeOH 5:1 to 1:1) to afford 65 (60.0 mg,
100%) as colorless oil, with a ratio of α:β=1:1 according to the 1H NMR which was in
accordance to Lit.167
Methyl (methyl 4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-5-trifluoroacetamido-D-
glycero-D-galacto-2-nonulopyranosid)onate (61), (GG-107, I-107).
To a solution of 65 (60.0 mg, 0.192 mmol) and Et3N (53.0 µL, 0.384 mmol) in MeOH
(4 mL) was added CF3COOMe (192 µL, 1.92 mmol). The mixture was stirred at rt for
2 h, then concentrated under reduced pressure. The resulting residue was stirred with
Ac2O (1.0 mL) and py (2.0 mL) at rt for 16 h, quenched with MeOH (2 mL),
concentrated and co-evaporated with toluene (3×5 mL). The residue was purified by
silica gel chromatography (PE/AcOEt 6:1) to afford 61 (69.0 mg, 55%) as white
foam, the NMR data of which were in accordance with Lit.161
Methyl 2,4,7,8,9-penta-O-acetyl-5-(N-acetylacetamido)-3,5-dideoxy-D-glycero-D-
galacto-2-nonulopyranosynate (66), (GG-027, I-027).
A solution of 6 (1.00 g, 3.10 mmol) and TsOH⋅H2O (47.8 mg, 0.250 mmol) in IPA
(25.0 mL, 0.229 mmol) was stirred at 65°C for 16 h. The reaction was then quenched
by adding Et3N (5 mL), concentrated and co-evaporated with toluene (3×10 mL). The
residue was purified by silica gel chromatography (PE/AcOEt 2:3) to afford 66 (1.38
110
g, 80%) as a mixture of α and β anomers with a ratio of 1:8 according to the 1H NMR
which was in accordance with with Lit.160
Methyl [methyl 4,7,8,9-tetra-O-acetyl-5-(N-acetylacetamido)-3,5-dideoxy-2-thio-
D-glycero-D-galacto-2-nonulopyranosid]onate (62), (GG-028, I-028).
A suspension of 66 (144 mg, 0.250 mmol) and activated molecular sieves 3Å (100
mg) in DCM (1.5 mL) was stirred at rt for 3 h, then TMSSMe (50.0 µL, 0.350 mmol)
and TMSOTf (34.0 µL, 0.190 mmol) were added. The reaction was stirred at 45°C
under argon for 6 h, and at rt for further 16 h. The mixture was diluted with DCM (5
mL), and filtered through a pad of Celite. The Celite was washed with DCM (3×5
mL), and the combined filtrates were washed with 5% NaHCO3 (2×10 mL) and H2O
(10 mL). The organic layer was dried over Na2SO4, filtered and concentrated under
reduced pressure. The residue was purified by silica gel chromatography (PE/AcOEt
1:1) to afford 62 (91.0 mg, 65%) as a mixture of α and β anomers with a ratio of 1:4,
the NMR data of which were in accordance with Lit.160
5-Acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-galacto-2-
nonulopyranosylonic acid (67), (GG-104, I-104).
Neu5Ac 5 (5.00 g, 16.1 mmol) was stirred with Ac2O (12.5 mL), py (25.0 mL) and
cat. DMAP at rt for 16 h under argon. The solution was concentrated under reduced
pressure and co-evaporated with toluene (3×15 mL) to afford 67 (9.00 g, 100%) as
white foam, which was used in the next step without further purification.
Benzyl 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-galacto-2-
nonulopyranosynate (68), (GG-105, I-105).
To a solution of 67 (9.00 g, 16.1 mmol) in DMF (85 mL) were added KF (2.30 g, 39.6
mmol) and BnBr (2.70 mL, 23.4 mmol). The mixture was stirred at rt for 20 h and
then evaporated under reduced pressure. The resulting syrup was diluted with DCM
(100 mL), filtered, washed with H2O (3×50 mL) and dried over Na2SO4. After
filtration and concentration, the residue was purified by silica gel chromatography
(PE/AcOEt/MeOH 6:3:0.5) to afford 68 (8.70 g, 89%) as white foam, which was used
in the next step without further purification.
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Methyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-2-thio-D-glycero-
D-galacto-2-nonulopyranosid)onate (63), (GG-111, I-111).
A suspension of 68 (75.0 mg, 123 µmol) and activated molecular sieves 3Å (200 mg)
in DCM (2 mL) was stirred at rt for 2 h. Then TMSSMe (24.0 µL, 172 µmol) and
TMSOTf (16.7 µL, 92.3 µmol) were added. The reaction was stirred at 50°C under
argon for 5 h and at rt for further 16 h. The mixture was diluted with DCM (5 mL)
and filtered through a pad of Celite. The Celite was washed with DCM (3×5 mL) and
the combined filtrate was washed with 5% NaHCO3 (2×10 mL) and H2O (10 mL).
The organic layer was dried over Na2SO4, filtered and concentrated under reduced
pressure. The residue was purified by silica gel chromatography (PE/AcOEt 1:1 to
1:1.25) to afford 63 (60.0 mg, 82%) as white foam.
Benzyl (5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-D-galacto-2-
nonulopyranosyl chloride)onate (69).
In a sealed vessel (Bombenrohr), AcCl (7.60 mL, 0.107 mol) was added at –20°C to a
solution of 68 (3.84 g, 6.32 mmol) in DCM (25 mL), followed by conc. HCl (0.958
mL, 9.74 mmol). After stirring at rt for 16 h, the mixture was concentrated and the
residue was diluted with DCM (50 mL) and washed with H2O (3×50 mL), 5%
KHCO3 (3×50 mL) and brine (30 mL). The organic layer was dried over Na2SO4,
filtered and concentrated under reduced pressure to afford 69 (3.50 g, 95%) as white
foam, the 1H NMR data of which were in accordance with Lit.169
O-Ethyl S-(benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosynate)dithiocarbonate (64).
A solution of 69 (500 mg, 0.853 mmol), potassium ethyl xanthogenate (164 mg, 1.02
mmol) and TBAHS (290 mg, 0.853 mmol) in AcOEt (5 mL) and 5% aq. NaHCO3 (5
mL) was stirred at rt for 3 h. The mixture was diluted with AcOEt (30 mL), washed
with H2O (2×30 mL) and brine (20 mL), dried over Na2SO4, filtered and concentrated
under reduced pressure. The residue was purified by silica gel chromatography
(PE/AcOEt/EtOH 6:4:1) to afford 64 (514 mg, 90%) as white foam.
1H NMR (500 MHz, CDCl3): δ 1.21-1.24 (m, 3H, CH2CH3), 1.89, 2.02, 2.12, 2.13 (4s,
15H, 5×CH3-OAc), 2.03 (m, 1H, Sia-H3a), 2.67 (dd, J3a,3b = 12.9, J3b,4 = 4.6 Hz, 1H,
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Sia-H3b), 4.04 (q, J4,5 = J5,6 = J5,NH = 10.4 Hz, 1H, Sia-H5), 4.21 (dd, J8,9a = 6.0, J9a,9b =
12.4 Hz, 1H, Sia-H9a), 4.33 (dd, J8,9b = 2.6, J9a,9b = 12.4 Hz, 1H, Sia-H9b), 4.36-4.46
(m, 2H, CH2-CH3), 4.56 (dd, J5,6 = 10.8, J6,7 = 2.0 Hz, 1H, Sia-H6), 4.85 (m, 1H, Sia-
H4), 5.20-5.24 (m, 3H, Sia-NH, CH2Ph), 5.27 (td, J7,8 = J8,9a = 6.0, J8,9b = 2.6 Hz, 1H,
Sia-H8), 5.32 (dd, J6,7 = 2.0, J7,8 = 6.2 Hz, 1H, Sia-H7), 7.33-7.39 (m, 5H, C6H5).
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(6-O-benzoyl-β-D-
galactopyranosyl)-(1→3)-2,6-O-dibenzyl-β-D-galactopyranoside (70), (GG-102, I-
176).
To a solution of 60 (170 mg, 0.234 mmol) and 55 (244 mg, 0.470 mmol) in CH3CN (6
mL) was added activated powdered molecular sieves 3Å (2.00 g). The mixture was
stirred at rt under argon for 6 h, then cooled to –30°C. To the stirred mixture were
added NIS (211 mg, 0.940 mmol) and TfOH (8.2 µL, 94.0 µmol), and the stirring was
continued for 16 h at –30°C. Then the mixture was diluted with DCM (10 mL), and
filtered through a pad of Celite. The Celite was washed with DCM (3×10 mL), and
the combined filtrate was successively washed with 20% aq. Na2S2O3 (30 mL), 5%
KHCO3 (2×20 mL) and H2O (20 mL), dried over Na2SO4, filtered and concentrated
under reduced pressure. The residue was purified by silica gel chromatography
(DCM/MeOH 60:1) to afford 70 (150 mg, 54%) as white foam.
[α]D +1.1°, (c = 0.80, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3),
1.00-1.03 (m, 2H, SiCH2), 1.89, 2.00, 2.04, 2.06, 2.10 (5s, 15H, CH3-NHAc, 4×CH3-
OAc), 2.10 (m, 1H, Sia-H3a), 2.66-2.69 (m, 2H, Sia-H3b, OH), 2.87 (bs, 1H, OH),
3.52-3.59 (m, 3H, Gal-H5, Gal-H6a, OCH2-Ha), 3.65-3.68 (m, 2H, Gal-H2, Gal-
H6b), 3.71 (dd,  J2,3 = 11.6, J3,4 = 3.3 Hz, 1H, Gal-H3), 3.76 (m, 1H, Gal'-H2), 3.79 (s,
3H, OCH3), 3.86 (m, 1H, Gal'-H5), 3.98 (dd, J8,9a = 5.6,  J9a,9b = 12.5 Hz, 1H, Sia-H9a),
4.00-4.05 (m, 4H, Gal-H4, Gal'-H4, Sia-H5, OCH2b), 4.10 (dd, J5,6 = 10.8, J6,7 = 1.9
Hz, 1H, Sia-H6), 4.11 (dd, J2,3 = 9.5, J3,4 = 3.5 Hz, 1H, Gal'-H3), 4.23 (dd, J8,9b = 2.6,
J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.34 (d, J1,2 = 7.6 Hz, 1H, Gal-H1), 4.46 and 4.51 (A, B
of AB, J = 12.0 Hz, 2H, PhCH2), 4.53 (m, 1H, Gal'-H6a), 4.61 (dd, J5,6b =  4.8, J6a,6b =
11.6 Hz, 1H, Gal'-H6b), 4.63 (d, J1,2 = 7.7 Hz, 1H, Gal'-H1), 4.83 (m, 2H, PhCH2),
4.97 (ddd, J3b,4 = 4.6, J3a,4 = 12.0, J4,5 = 10.3 Hz, 1H, Sia-H4), 5.23 (d, J5,NH = 9.7 Hz,
1H, Sia-NH), 5.31 (dd, J6,7 = 1.8, J7,8 = 8.6 Hz, 1H, Sia-H7), 5.36 (ddd, J7,8 = 8.4, J8,9a =
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5.5, J8,9b = 2.6 Hz, 1H, Sia-H8), 7.23-7.33, 7.38-7.42, 7.52-7.55, 8.01-8.04 (m, 15H,
3×C6H5);
13C NMR (125 MHz, CDCl3): δ  -1.45 (3C, SiMe3), 18.45 (SiCH2), 20.69, 20.73,
20.82, 21.16, 23.18 (CH3-NHAc, 4×CH3-OAc), 37.31 (Sia-C3), 49.58 (Sia-C5), 53.18
(OCH3), 62.29 (Sia-C9), 63.38 (Gal'-C6), 66.97 (Sia-C7), 67.18 (OCH2), 67.80 (Gal-
C3), 68.21 (Sia-C8), 68.57 (Sia-C4), 68.76, 69.38 (Gal-C4, Gal'-C4), 69.96 (Gal-C6),
72.16 (Sia-C6), 72.68 (Gal'-C5), 73.31 (Gal-C5), 73.51 (PhCH2), 74.94 (PhCH2),
76.11 (Gal-C3), 97.78 (Sia-C2), 102.85 (Gal-C1), 103.80 (Gal'-C1), 127.60, 128.22,
128.23, 128.37, 128.46, 129.65, 129.70, 138.24, 138.76 (18C, 3×C6H5), 168.34,
170.22 (7C, 7×CO);
ESI-MS: Calcd for C58H77NO24Si (M+Na)+: 1222.45; Found: m/z 1222.31.
2-(Trimethylsilyl)ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(6-O-benzoyl-β-D-
galactopyranosyl)-(1→3)-2,6-O-dibenzyl-β-D-galactopyranoside (72), (GG-126, I-
126).
To a solution of 60 (82.8 mg, 114 µmol) and 63 (136 mg, 228 µmol) in CH3CN (3
mL) was added activated powdered molecular sieves 3Å (1.00 g). The mixture was
stirred at rt under argon for 4 h, then cooled to –30°C. To the stirred mixture were
subsequently added NIS (102 mg, 456 µmol) and TfOH (4 µL, 45.6 µmol), and
stirring was continued for 16 h at –30°C. Then the mixture was diluted with DCM (10
mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×5
mL), the combined filtrate was successively washed with 20% aq. Na2S2O3 (20 mL),
5% KHCO3 (2×20 mL) and H2O (20 mL), dried over Na2SO4, filtered and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (DCM/MeOH 50:1) to afford 72 (74.6 mg, 51%) as white foam.
1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3), 1.00-1.03 (m, 2H, SiCH2), 1.90,
1.99, 2.04, 2.05, 2.12 (5s, 15H, CH3-NHAc, 4×CH3-OAc), 2.07 (m, 1H, Sia-H3a),
2.41 (bs, 1H, Gal'-4OH), 2.74 (dd, J3a,3b = 13.1, J3b,4 = 4.6 Hz, Sia-H3b), 3.40 (bs, 1H,
Gal-4OH), 3.50-3.53 (m, 2H, Gal-H5, Gal-H6a), 2.57 (m, 1H, OCH2-Ha), 3.64-3.75
(m, 5H, Gal-H2, Gal-H3, Gal-H6b, Gal'-H2, Gal'-H5), 3.98-4.03 (m, 4H, Gal-H4, Sia-
H5, Sia-H9a, OCH2-Hb), 4.05 (dd, J2,3 = 7.0, J3,4 = 3.4 Hz, 1H, Gal'-H3), 4.10 (dd, J5,6
= 10.8, J6,7 = 1.8 Hz, 1H, Sia-H6), 4.23 (dd, J8,9b = 2.6, J9a,9b = 12.5 Hz, 1H, Sia-H9b),
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4.33 (d, J1,2 = 7.6 Hz, 1H, Gal-H1), 4.37-4.42 (m, 2H, Gal'-H6a, Gal'-H6b), 4.44, 4.49
(A, B of AB, J = 12.0 Hz, 2H, PhCH2), 4.60 (d, J1,2 = 7.7 Hz, 1H, Gal'-H1), 4.81, 4.85
(A, B of AB, J = 11.0 Hz, 2H, PhCH2), 4.96 (ddd, J3b,4 = 4.6, J3a,4 = 11.9, J4,5 = 10.2
Hz, 1H, Sia-H4), 5.16-5.21 (m, 2H, PhCH2-HA, Sia-NH), 5.24 (B of AB, J = 11.8 Hz,
1H, PhCH2-HB), 5.31 (dd, J6,7 = 1.8, J7,8 = 8.6 Hz, 1H, Sia-H7), 5.36 (m, 1H, Sia-H8),
7.21-7.33, 7.37-7.52, 7.52-7.53, 8.01-8.03 (m, 20H, 4×C6H5);
13C NMR (125 MHz, CDCl3): δ  -1.45 (3C, SiMe3), 18.41 (SiCH2), 20.67, 20.73,
20.80, 21.21 (5C, CH3-NHAc, 4× CH3-OAc), 37.53 (Sia-C3), 49.49 (Sia-C5), 62.24
(Sia-C9), 63.63 (Gal'-C6), 66.92 (Sia-C7), 67.13 (OCH2), 67.73 (Gal'-C4), 68.26 (Sia-
C8), 68.35 (PhCH2), 68.72 (Sia-C4), 69.33 (Gal-C4), 70.06 (Gal-C6), 72.09 (Gal'-
C2), 72.74 (2C, Gal'-C5, Sia-C6), 73.35 (Gal-C5), 73.47 (PhCH2), 74.94 (PhCH2),
76.22 (Gal'-C3), 78.00 (Gal-C2), 83.11 (Gal-C3), 97.67 (Sia-C2), 102.77 (Gal-C1),
103.61 (Gal'-C1), 127.49, 127.55, 128.16, 128.21, 128.34, 128.34, 128.44, 128.84,
128.94, 129.24, 129.65, 129.73, 130.89, 133.23, 134.14, 138.27, 138.82 (24C,
4×C6H5), 166.17, 167.59, 169.95, 170.11, 170.30, 170.56, 170.74 (7×CO).
2-(Trimethylsilyl)ethyl (benzyl 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-
D-glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-6-O-benzoyl-β-D-
galactopyranoside (74), (GG-088, I-088).
To a stirred solution of 64 (50.0 mg, 74.4 µmol) and 3 (43.0 mg, 112 µmol) in
CH3CN/DCM (3:2, 2.5 mL) was added activated powdered molecular sieves 3 Å (200
mg). The reaction mixture was stirred at rt under argon for 5 h and then cooled to
–70°C. After the addition of NIS (31.8 mg, 0.141 mmol) and TfOH (1.24 µL, 14.1
µmol), stirring was continued for 16 h at –70°C. Then the mixture was diluted with
DCM (10 mL) and filtered through a pad of Celite. The Celite was washed with DCM
(3×10 mL), the combined filtrates were successively washed with 20% Na2S2O3 (20
mL), saturated KHCO3 (2×20 mL) and H2O (20 mL), and dried over Na2SO4. After
filtration and concentration under reduced pressure, the residue was purified by silica
gel chromatography (DCM/MeOH 60:1) to afford 74 (17.8 mg, 26%) as white foam.
1H NMR (500 MHz, CDCl3): δ -0.02 (s, 9H, SiMe3), 0.99-1.13(m, 2H, SiCH2), 1.89,
2.03, 2.04, 2.10, 2.14 (5s, 15H, CH3-NHAc, 4×CH3-OAc), 2.02 (m, 1H, Sia-H3a),
2.69 (bs, 1H, Gal-2-OH), 2.76 (dd, J3a,3b = 12.9, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.31 (m,
1H, Gal-H5), 3.63-3.69 (m, 3H, Gal-H2, Gal-H6a, OCH2-Ha), 3.97-4.08 (m, 4H, Gal-
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H6b, Sia-H5, Sia-H9a, OCH2-Hb), 4.10 (dd, J5,6 = 10.8, J6,7 = 1.9 Hz, 1H, Sia-H6),
4.25 (dd, J8,9b = 2.7, J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.39-4.42 (m, 3H, Gal-H1, Gal-H3,
Gal-H4), 4.93 (ddd, J3a,4 = 12.1, J3b,4 = 4.6, J4,5 = 10.2 Hz, 1H, Sia-H4), 5.14-5.17 (m,
2H, PhCH2-HA, Sia-NH), 5.20 (B of AB, J = 11.9 Hz, 1H, PhCH2-HB), 5.32 (dd, J6,7
= 1.9, J7,8 = 9.0 Hz, 1H, Sia-H7), 5.45 (ddd, J7,8 = 9.0, J8,9a = 5.1, J8,9b = 2.7 Hz, 1H, Sia-
H8), 7.35-7.43, 7.54-7.57, 8.02-8.04 (m, 10H, 2×C6H5).
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-di-O-acetyl-6-O-benzoyl-
β-D-galactopyranosyl)-(1→3)-4-O-acetyl-2,6-O-dibenzyl-β-D-galactopyranoside
(77), (GG-168, I-144).
To a stirred solution of 70 (100 mg, 83.1 µmol) in py (1.0 mL) at 0°C was added
Ac2O (0.5 mL). The mixture was stirred for 16 h at rt under argon, and then quenched
by MeOH (1 mL). The solution was concentrated under reduced pressure and co-
evaporated with toluene (3×10 mL). The residue was purified by silica gel
chromatography (toluene/AcOEt 1:1) to afford 77 (87.6 mg, 80%) as white foam.
[α]D -13.2°, (c=0.63, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3),
0.99-1.07 (m, 2H, SiCH2), 1.68 (t, J3a,3b = J3a,4 = 12.5 Hz, 1H, Sia-H3a), 1.83, 1.90,
1.98, 1.99, 2.00, 2.10, 2.11, 2.12 (8s, 24H, CH3-NHAc, 7×CH3-OAc), 2.58 (dd, J3a,3b =
12.7, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.47-3.58 (m, 3H, Gal-H6a, Gal-H6b, OCH2-Ha),
3.61 (dd, J5,6 = 10.9, J6,7 = 2.6 Hz, 1H, Sia-H6), 3.64 (dd, J1,2 = 7.9, J2,3 = 9.6 Hz, 1H,
Gal-H2), 3.72 (m, 1H, Gal-H5), 3.73 (s, 3H, OCH3), 3.88 (dd, J2,3 = 9.6, J3,4 = 3.6 Hz,
1H, Gal-H3), 3.94 (dd, J8,9a = 5.9, J9a,9b = 12.5 Hz, 1H, Sia-H9a), 4.02-4.04 (m, 3H,
Gal'-H5, Sia-H5, OCH2-Hb), 4.18 (dd, J5,6a = 7.8, J6a,6b = 11.0 Hz, 1H, Gal'-H6a), 4.30
(dd, J8,9b = 2.6, J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.41 (m, 1H, Gal'-H6b), 4.42 (d, J1,2 =
8.0 Hz, 1H, Gal-H1), 4.48 and 4.51 (A, B of AB, J = 11.8 Hz, 2H, PhCH2), 4.59 (dd,
J2,3 = 10.2, J3,4 = 3.2 Hz, 1H, Gal'-H3), 4.75 and 4.83 (A, B of AB, J = 11.0 Hz, 2H,
PhCH2), 4.84 (d, J1,2 = 7.7 Hz, 1H, Gal'-H1), 4.88 (m, 1H, Sia-H4), 5.05 (d, J3,4 = 3.2
Hz, 1H, Gal'-H4), 5.11 (dd, J1,2 = 7.9, J2,3 = 10.1 Hz, 1H, Gal'-H2), 5.21 (d, J5,NH = 10.2
Hz, 1H, Sia-NH), 5.34 (dd, J6,7 = 2.6, J7,8 = 8.9 Hz, 1H, Sia-H7), 5.46 (d, J3,4 = 3.6 Hz,
1H, Gal-H4), 5.50 (ddd, J7,8 = 8.8, J8,9a = 5.9, J8,9b = 2.7 Hz, 1H, Sia-H8), 7.24-7.28,
7.32-7.35, 7.40-7.43, 7.52-7.56, 8.03-8.05 (m, 15H, 3×C6H5);
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13C NMR (125 MHz, CDCl3): δ  -1.57 (3C, SiMe3), 18.39 (SiCH2), 20.62, 20.66,
20.69, 20.70, 20.87 (8C, CH3-NHAc, 7× CH3-OAc), 37.43 (Sia-C3), 49.01 (Sia-C5),
52.94 (OCH3), 67.06, 67.22 (Gal'-C4, Sia-C7), 67.71, 67.76 (Sia-C8, OCH2), 69.22,
69.25, 69.43 (Gal-C4, Gal-C6, Sia-C4), 70.13, 70.39 (Gal'-C2, Gal'-C5), 71.45, 72.02,
72.92 (Gal-C5, Gal'-C3, Sia-C6), 73.59 (PhCH2), 75.09 (PhCH2), 78.57 (Gal-C2),
80.16 (Gal-C3), 96.64 (Sia-C2), 100.71 (Gal'-C1), 103.01 (Gal-C1), 127.35, 127.59,
127.66, 127.70, 128.09, 128.14, 128.21, 128.30, 128.38, 128.75, 128.95, 129.61,
129.77, 130.84, 133.01, 137.77, 137.93, 138.85  (18C, 3×C6H5), 165.57, 167.89,
169.55, 169.62, 170.15, 170.21, 170.27, 170.45, 170.52, 170.79 (10×CO);
ESI-MS: Calcd for C64H83NNaO27Si (M+Na)+: 1348.48; Found: m/z 1348.27.
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-di-O-acetyl-6-O-benzoyl-
β-D-galactopyranosyl)-(1→3)-4-O-acetyl-β-D-galactopyranoside (7 6 ) and 2 -
(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-di-O-acetyl-6-O-benzoyl-
β-D-galactopyranosyl)-(1→3)-β-D-galactopyranoside (79), (GG-183-2 and GG-
183-4, I-183).
77 (81.0 mg, 61.1 µmol) in EtOH (4.0 mL) and AcOH (0.8 mL) was hydrogenolyzed
(1 bar H2) in the presence of 10% Pd-C (120 mg) for 4 h at 45-50°C. The reaction
mixture was filtered through a pad of Celite, which was washed with DCM. The
combined filtrates were concentrated and the residue was purified by silica gel
chromatography (DCM/MeOH 50:1) to afford 76 (53.5mg, 76%) and 79 (10.0 mg,
15%) as white foams.
76: [α]D -2.8°, (c = 0.68, CH3OH); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H,
SiMe3), 0.91-1.21 (m, 2H, SiCH2), 1.71 (t, J 3a,3b = J3a,4 = 12.4 Hz, 1H, Sia-H3a), 1.84,
1.99, 2.04, 2.07, 2.13, 2.21 (7s, 24H, CH3-NHAc, 7×CH3-OAc), 2.57 (dd, J3a,3b = 12.6,
J3b,4 = 4.6 Hz, 1H, Sia-H3b), 2.94 (bs, 1H, OH), 3.44 (m, 1H, Gal-H6a), 3.55-3.60 (m,
3H, Gal-H5, Gal-H6b, OCH2-Ha), 3.62 (dd, J5,6 = 10.6, J6,7 = 2.7 Hz, 1H, Sia-H6),
3.73 (s, 3H, OCH3), 3.78-3.79 (m, 2H, Gal-H2, Gal-H3), 3.93 (dd, J8,9a = 6.7, J9a,9b =
12.2 Hz, 1H, Sia-H9a), 3.97-4.00 (m, 2H, Gal'-H5, OCH2-Hb), 4.06 (q, J4,5 = J5,6 =
J5,NH = 10.4 Hz, 1H, Sia-H5), 4.16 (dd, J5,6a = 7.2, J6a,6b = 11.2 Hz, 1H, Gal'-H6a), 4.32
(d, J1,2 = 7.6 Hz, 1H, Gal-H1), 4.32-4.36 (m, 2H, Gal'-H6b, Sia-H9b), 4.58 (dd, J2,3 =
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10.2, J3,4 = 3.4 Hz, 1H, Gal'-H3), 4.85 (ddd, J3b,4 = 4.6, J3a,4 = J4,5 = 12.0 Hz, 1H, Sia-
H4), 4.91 (d, J1,2 = 7.9 Hz, 1H, Gal'-H1), 5.01-5.04 (m, 2H, Gal'-H2, Gal'-H4), 5.20
(d, J5,NH = 10.3 Hz, 1H, Sia-NH), 5.28 (d, J3,4 = 2.4 Hz, 1H, Gal-H4), 5.32 (dd, J6,7 =
2.7, J7,8 = 9.3 Hz, 1H, Sia-H7), 5.62 (ddd, J7,8 = 9.3, J8,9a = 6.7, J8,9b = 2.7 Hz, 1H,  Sia-
H8), 7.40-7.44, 7.53-7.56, 8.01-8.03 (m, 5H, C6H5);
13C NMR (125 MHz, CDCl3): δ  -1.51 (3C, SiMe3), 18.21 (SiCH2), 20.66, 20.72,
20.76, 20.80, 20.94 (8C, CH3-NHAc, 7×CH3-OAc), 37.37 (Sia-C3), 48.93 (Sia-C5),
52.97 (OCH3), 59.98 (Gal-C6), 61.51 (Gal'-C6), 62.91 (Sia-C9), 67.28, 67.33, 67.39
(Gal'-C4, Sia-C7, Sia-C8), 67.65 (OCH2), 69.24, 69.32 (Gal-C4, Sia-C4), 69.84 (Gal'-
C2), 70.59, 70.74, 70.96 (Gal-C2, Gal'-C3, Gal'-C5), 71.87 (Sia-C6), 73.24 (Gal-C5),
79.70 (Gal-C3), 96.66 (Sia-C2), 101.15 (Gal'-C1), 102.52 (Gal-C1), 128.15, 128.28,
129.64, 129.72, 133.11 (C6H5-CH), 165.68, 165.82, 167.88, 169.77, 170.12, 170.33,
170.62, 170.88, 170.96, 172.67 (11C, C6H5-C, 10×CO);
HRMS (FAB) Calcd for C50H71NO27Si (M+H)+: 1146.4061; Found: m/z 1146.4102;
79: 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3), 0.93-1.06 (m, 2H, SiCH2),
1.73 (t, J 3a,3b = J3a,4 = 12.5 Hz, 1H, Sia-H3a), 1.85 (s, 3H, CH3-NHAc), 2.01, 2.04,
2.08, 2.13, 2.15, 2.21 (6s, 18H, 6×CH3-OAc), 2.59 (dd, J3a,3b = 12.6, J3b,4 = 4.6 Hz, 1H,
Sia-H3b), 2.74 (bs, 1H, OH), 2.84 (bs, 1H, OH), 3.45 (t, J 5,6a = J5,6b = 5.7 Hz, 1H, Gal-
H5), 3.47-3.65 (m, 4H, Gal-H3, Gal-H6a, Sia-H6, OCH2-Ha), 3.75 (m, 1H, Gal-H2),
3.80 (s, 3H, OCH3), 3.86 (dd, J5,6b = 6.7, J6a,6b = 11.8 Hz, 1H, Gal-H6), 3.96 (dd, J8,9a =
6.2, J9a,9b = 12.4 Hz, 1H, Sia-H9a), 3.98 (d, J3,4 = 4.2 Hz, 1H, Gal-H4), 4.00-4.09 (m,
3H, Gal'-H5, Sia-H5, OCH2-Hb), 4.26 (d, J1,2 = 7.9 Hz, 1H, Gal-H1), 4.28 (m, 1H,
Gal'-H6a), 4.34 (dd, J8,9b = 2.8, J9a,9b = 12.3 Hz, Sia-H9b), 4.37 (dd, J5,6b = 7.6, J6a,6b =
11.4 Hz, 1H, Gal'-H6b), 4.62 (dd, J2,3 = 10.2, J3,4 = 3.4 Hz, 1H, Gal'-H3), 4.88 (m, 1H,
Sia-H4), 4.90 (d, J1,2 = 8.0 Hz, 1H, Gal'-H1), 5.02 (d, J3,4 = 3.3 Hz, 1H, Gal'-H4), 5.08
(dd, J1,2 = 8.1, J2,3 = 10.1 Hz, 1H, Gal'-H2), 5.17 (d, J5,NH = 10.2 Hz, 1H, Sia-NH), 5.34
(dd, J6,7 = 2.6, J7,8 = 9.4 Hz, 1H, Sia-H7), 5.61 (ddd, J7,8 = 9.2, J8,9a = 6.1, J8,9b = 2.9 Hz,
1H,  Sia-H8), 7.44-7.47, 7.57-7.60, 8.02-8.03 (m, 5H, C6H5);
13C NMR (125 MHz, CDCl3): δ  -1.45 (3C, SiMe3), 18.21 (SiCH2), 20.69, 20.76,
20.79, 20.81 (7C, CH3-NHAc, 6×CH3-OAc), 37.42 (Sia-C3), 49.00 (Sia-C5), 53.13
(OCH3), 62.12 (Gal'-C6), 62.43 (Gal-C6), 62.74 (Sia-C9), 67.18 (OCH2), 67.37, 67.59
(Sia-C7, Sia-C8), 68.13, 68.44 (Gal-C4, Gal'-C4), 69.23 (Sia-C4), 69.73 (Gal'-C2),
70.18 (Gal-C2), 70.83 (Gal'-C3), 71.05 (Gal'-C5), 71.90 (Sia-C6), 73.85 (Gal-C5),
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83.05 (Gal-C3), 96.70 (Sia-C2), 101.60 (Gal'-C1), 102.39 (Gal-C1), 128.45, 129.67,
133.41 (6C, C6H5), 165.84, 167.97, 169.79, 170.38, 170.40, 170.75, 170.92 (9C,
9×CO);
ESI-MS: Calcd for C48H69NNaO26Si (M+Na)+: 1126.38; Found: m/z 1126.56.
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-di-O-acetyl-6-O-benzoyl-
β-D-galactopyranosyl)-(1→3)-[(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
dideoxy-D-glycero-α- and β-D-galacto-2-nonulopyranosynate)]-(2→6)-4-O-acetyl-
β-D-galactopyranoside (80α and 80β), (GG-186-5 and GG-186-2, I-186).
To a solution of 76 (61.3 mg, 53.5 µmol) and 55 (70.0 mg, 13.4 µmol) in CH3CN (5
mL) was added activated powdered molecular sieves 3Å (2.00 g). The mixture was
stirred at rt under argon for 6 h and then cooled to –40°C. To the stirred mixture were
subsequently added NIS (60.0 mg, 0.267 mmol) and TfOH (2.4 µL, 26.7 µmol), and
stirring was continued for 16 h at –40°C. Then the mixture was diluted with DCM (10
mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×10
mL), the combined filtrates were successively washed with 20% aq. Na2S2O3 (20 mL),
5% aq. KHCO3 (2×10 mL) and H2O (10 mL), dried over Na2SO4, filtrated and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (DCM/MeOH 35:1) to afford 80α (33.0 mg, 38%) and 80β (10.0 mg,
12%) as white foams.
80α: [α]D –14.0°, (c = 1.2, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H,
SiMe3), 0.98-1.15 (m, 2H, SiCH2), 1.69 (t, J3a,3b = J3a,4 = 12.3 Hz, 1H, Sia-H3a), 1.83,
1.85 (2s, 6H, 2×CH3-NHAc), 1.90 (t, J3a,3b = J3a,4 = 12.6 Hz, 1H, Sia'-H3a), 1.98, 1.99,
2.00, 2.03, 2.06, 2.07, 2.08, 2.10, 2.12 (9s, 33H, 11×OAc), 2.55 (m, 2H, Sia-H3b,
Sia'-H3b), 3.18 (bs, 1H, OH), 3.28 (dd, J5,6a = 6.3, J6a,6b = 9.6 Hz, 1H, Gal-H6a), 3.46-
3.67 (m, 3H, Sia-H6, Sia'-H6, OCH2-Ha), 3.68-3.78 (m, 2H, Gal-H2, Gal-H5), 3.72
(s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.79-3.84 (m, 2H, Gal-H3, Gal-H6b), 3.91 (dd,
J8,9a = 7.2, J9a,9b = 12.2 Hz, 1H, Sia-H9a), 3.96 (t, J5,6a = J5,6b = 7.0 Hz, 1H, Gal'-H5),
4.00-4.04 (m, 3H, Sia-H5, Sia'-H5, OCH2-Hb), 4.07 (dd, J8,9a = 5.3, J9a,9b = 11.9 Hz,
1H, Sia'-H9a), 4.18 (m, 1H, Gal'-H6a), 4.27 (m, 1H, Sia'-H9b), 4.28 (d, J1,2 = 7.6 Hz,
1H, Gal-H1), 4.34-4.40 (m, 2H, Gal'-H6b, Sia-H9b), 4.55 (dd, J2,3 = 10.0, J3,4 = 3.4
Hz, 1H, Gal'-H3), 4.83 (m, 2H, Sia-H4, Sia'-H4), 4.97-5.01 (m, 2H, Gal'-H2, Gal'-
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H4), 5.05 (d, J1,2 = 8.0 Hz, 1H, Gal'-H1), 5.12 (d, J5,NH = 10.2 Hz, 1H, Sia-NH), 5.18
(d, J5,NH = 8.0 Hz, 1H, Sia'-NH), 5.27-5.34 (m, 3H, Sia-H7, Sia'-H7, Sia'-H8), 5.39 (d,
J3,4 = 3.5 Hz, 1H, Gal-H4), 5.61 (ddd, J7,8 = 9.5, J8,9a = 7.3, J8,9b = 2.8 Hz, 1H, Sia-H8),
7.41-7.42, 7.53-7.56, 8.00-8.02 (m, 5H, C6H5);
13C NMR (125 MHz, CDCl3): δ  -1.46 (3C, SiMe3), 18.22 (SiCH2), 20.69, 20.73,
20.79, 20.88, 20.94 (13C, 2×CH3-NHAc, 11×CH3-OAc), 37.70, 38.67 (Sia-C3, Sia'-
C3), 48.97, 49.38 (Sia-C5, Sia'-C5), 52.82, 52.97 (2×OCH3), 61.37 (Gal'-C6), 62.27
(Sia'-C9), 62.94, 63.07 (Gal-C6, Sia-C9), 67.26, 67.35 (3C, Gal'-C4, Sia-C8, Sia-C7),
67.52 (OCH2), 68.94, 69.26, 69.29, 70.57 (Sia-C4, Sia'-C4, Sia'-C7, Sia'-C8), 71.25,
71.34, 71.96, 72.05, 72.58 (7C, Gal-C2, Gal-C5, Gal'-C2, Gal'-C3, Gal'-C5, Sia-C6,
Sia'-C6), 77.80 (Gal-C3), 96.70, 98.69 (Sia-C2, Sia'-C2), 100.10 (Gal'-C1), 102.40
(Gal-C1), 128.29, 129.70, 133.11 (6C, C6H5), 165.67, 167.72, 169.63, 169.71, 169.99,
170.13, 170.21, 170.34, 170.59, 170.94, 171.16 (16C, 16×CO);
HRMS (FAB) Calcd for C70H98N2O39Si (M+NH4)+: 1636.5860; Found: m/z
1636.5869;
80β: [α]D -12.7°, (c = 0.7, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H,
SiMe3), 0.93-1.15 (m, 2H, SiCH2), 1.67-1.77 (m, 2H, Sia-H3a, Sia'-H3a), 1.83 (s, 6H,
2×CH3-NHAc), 1.92, 1.99, 2.01, 2.03, 2.04, 2.07, 2.08, 2.12, 2.13, 2.21, 2.22 (11s,
33H, 11×CH3-OAc), 2.40 (dd, J3a,3b = 12.8, J3b,4 = 5.0 Hz, 1H, Sia'-H3b), 2.57 (dd,
J3a,3b = 12.6, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.07 (bs, 1H, OH), 3.30 (t, J5,6a = J6a,6b  = 9.3
Hz, 1H, Gal-H6a), 3.40 (dd, J5,6b = 4.6, J6a,6b = 8.7 Hz, 1H, Gal-H6b), 3.57 (m, 1H,
OCH2-Ha), 3.62 (dd, J5,6 = 10.7, J6,7 = 2.7Hz, 1H, Sia-H6), 3.71 (dd, J5,6 = 10.6, J6,7 =
2.5 Hz, 1H, Sia'-H6), 3.73-3.83 (m, 3H, Gal-H2, Gal-H3, Gal-H5), 3.76 (s, 3H,
OCH3), 3.78 (s, 3H, OCH3), 3.92 (dd, J8,9a = 7.2, J9a,9b = 12.2 Hz, 1H, Sia-H9a), 3.95-
3.99 (m, 2H, Gal'-H5, OCH2-Hb), 4.02-4.06 (m, 2H, Sia-H5, Sia'-H9a), 4.09-4.21 (m,
2H, Gal'-H6a, Sia'-H5), 4.31 (d, J1,2 = 7.6 Hz, 1H, Gal-H1), 4.37 (dd, J8,9b = 2.8, J9a,9b =
12.2 Hz, 1H, Sia-H9b), 4.45 (dd, J5,6b = 5.6, J6a,6b = 10.9 Hz, 1H, Gal'-H6b), 4.56 (dd,
J2,3 = 10.2, J3,4 = 3.3 Hz, 1H, Gal'-H3), 4.73 (dd, J8,9b = 2.3, J9a,9b = 12.3 Hz, 1H, Sia'-
H9b), 4.84 (m, 1H, Sia-H4), 4.98-5.00 (m, Gal'-H1, Gal'-H2, Sia'-H8), 5.05 (d, J3,4 =
3.2 Hz, 1H, Gal'-H4), 5.10 (d, J5,NH = 10.3 Hz, 1H, Sia-NH), 5.30 (dd, J6,7 = 2.7, J7,8 =
9.1 Hz, 1H, Sia-H7), 5.33-5.35 (m, 2H, Sia'-H4, Sia'-H7), 5.59 (d, J3,4 = 3.1 Hz, 1H,
Gal-H4), 5.63 (ddd, J7,8 = 9.5, J8,9a = 7.2, J8,9b = 2.8 Hz, 1H, Sia-H8), 6.22 (d, J5,NH =
10.2 Hz, 1H, Sia'-NH), 7.38-7.41, 7.51-7.54, 7.97-7.98 (m, 5H, C6H5);
120
13C NMR (500MHz, CDCl3): δ -1.33 (3C, SiMe3), 18.41 (SiCH2), 20.84, 20.87, 20.92,
20.97, 21.11, 21.38, 21.50 (13C, 2×CH3-NHAc, 11×CH3-OAc), 37.21, 37.44 (Sia-C3,
Sia'-C3), 47.81 (Sia'-C5), 49.12 (Sia-C5), 53.01, 53.11 (2×OCH3), 60.19 (Gal-C6),
61.26 (Gal'-C6), 62.61 (Sia'-C9), 63.21 (Sia-C9), 67.46 (Gal'-C4), 67.52 (Sia-C7),
67.66 (OCH2), 68.24 (Sia'-C7), 68.35 (Sia-C8), 68.96, 68.99 (Gal-C4, Sia'-C4), 69.35
(Sia-C4), 70.06 (Sia'-C8), 70.56 (Gal'-C3), 71.24, 71.31 (Gal-C2, Gal'-C5), 72.13,
72.27, (3C, Gal-C5, Sia-C6, Sia'-C6), 72.52 (Gal'-C2), 79.12 (Gal-C3), 96.87, 98.13
(Sia-C2, Sia'-C2), 101.02 (Gal'-C1), 102.94 (Gal-C1), 128.88, 30.96, 133.17 (6C,
C6H5), 165.70, 167.65, 168.04, 170.00, 170.18, 170.26, 170.35, 170.39, 170.48,
170.62, 170.70, 170.73, 170.80, 171.03, 171.36, 172.28 (16C, 16×CO).
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosynate)-(2→3)-(β-D-galactopyranosyl)-(1→3 ) - [ ( s o d i u m  5 -
acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranosynate)]-(2→6)-β-
D-galactopyranoside (54α), (GG-162, I-162).
To a solution of 80α (30.0 mg, 18.5 µmol) in MeOH (2.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.3 mL). The mixture was stirred at rt under argon for 7
h, then H2O (1 mL) was added and stirring was continued for 16 hr at rt. The solution
was concentrated and the residue was purified by RP chromatography (5% gradient
MeOH in H2O), Dowex ion-exchange chromatography (Na+ type), and P2 size
exclusion chromatography to afford 54α as white solid (9.6mg, 48.5%) after a final
lyophilization from H2O.
[α]D +1.5°, (c = 0.64, H2O); 1H NMR (500 MHz, D2O): δ 0.00 (s, 9H, SiMe3), 0.95
(td, J = 12.9, J = 5.2 Hz, 1H, SiCH2-Ha), 1.04 (td, J = 12.9, J = 5.5 Hz, 1H, SiCH2-
Hb), 1.63 (t, J3a,3b = J3a,4 = 12.1 Hz, 1H, Sia'-H3a), 1.77 (t, J3a,3b = J3a, 4 = 12.1 Hz, 1H,
Sia-H3a), 2.00 (s, 6H, 2×CH3-NHAc), 2.68 (dd, J3a,3b = 12.4, J3b,4 = 4.6 Hz, 1H, Sia'-
H3b), 2.73 (dd, J3a,3b = 12.4, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.58-3.68 (m, 13H, Gal-H2,
Gal-H6a, Gal'-H2, Gal'-H6a, Gal'-H6b, Sia-H4, Sia-H6, Sia-H7, Sia-H9a, Sia'-H4,
Sia'-H6, Sia'-H7, Sia'-H9a), 3.70-3.88 (m, 10H, Gal-H3, Gal-H5, Gal'-H5, Sia-H5,
Sia-H8, Sia-H9b, Sia'-H5, Sia'-H8, Sia'-H9b, OCH2-Ha), 3.89-3.92 (m, 2H, Gal-H6b,
Gal'-H4), 4.00 (ddd, J = 10.1, J = 12.7, J = 5.2 Hz, 1H, OCH2-Hb), 4.08 (dd, J2,3 = 9.8,
J3,4 = 3.1 Hz, 1H, Gal'-H3), 4.18 (d, J3,4 = 3.4 Hz, 1H, Gal-H4), 4.42 (d, J1,2 = 8.0 Hz,
1H, Gal-H1), 4.63 (d, J1,2 = 7.8 Hz, 1H, Gal'-H1);
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13C NMR (500 MHz, D2O): δ -2.56 (3C, SiMe3), 17.51 (SiCH2), 21.95, 21.97 (2×CH3-
NHAc), 39.62, 40.26 (Sia-C3, Sia'-C3), 51.60, 51.80 (Sia-C5, Sia'-C5), 60.86 (Gal'-
C6), 62.47 (Sia'-C9), 62.53 (Sia-C9), 63.11 (Gal-C6), 67.36 (Gal'-C4), 68.02, 68.13,
68.27 (Sia-C4, Sia-C7, Sia'-C4), 68.33 (Gal-C4), 68.39 (OCH2), 69.40, 69.60 (3C,
Sia'-C7, Gal'-C5, Gal-C5), 71.59, 71.73 (Sia-C6, Sia'-C6), 72.56, 72.78 (Sia-C8, Sia'-
C8), 74.78 (2C, Gal-C2, Gal'-C2), 75.51 (Gal'-C3), 82.59 (Gal-C3), 99.71, 100.34
(Sia-C2, Sia'-C2), 101.67 (Gal-C1), 104.08 (Gal'-C1), 173.38, 173.80, 174.92, 174.99
(4×CO).
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-
2-nonulopyranosynate)-(2→3)-(β-D-galactopyranosyl)-(1→3 ) - [ ( s o d i u m  5 -
acetamido-3,5-dideoxy-D-glycero-β-D-galacto-2-nonulopyranosynate)]-(2→6)-β-
D-galactopyranoside (54β), (GG-228, I-228).
To a solution of 80β (10.0 mg, 6.20 µmol) in MeOH (1.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.2 mL,). The mixture was stirred at rt under argon for
7 h, then H2O (0.25 mL) was added and the mixture was stirred for 16 hr at rt. The
solution was concentrated and the residue was purified by RP chromatography (5%
gradient MeOH in H2O), Dowex ion-exchange chromatography (Na+ type), and P2
size exclusion chromatography to afford 54β as white solid (4.50 mg, 68%) after a
final lyophilization from H2O.
[α]D -2.9°, (c = 0.3, H2O); 1H NMR (500 MHz, D2O): δ 0.00 (s, 9H, SiMe3), 0.95 (td,
J = 13.0, J = 5.1 Hz, 1H, SiCH2-Ha), 1.05 (td, J = 13.0, J = 5.4 Hz, 1H, SiCH2-Hb),
1.61 (t, J3a,3b = J3a,4 = 12.2 Hz, 1H, Sia'-H3a), 1.78 (t, J3a,3b = J3a, 4 = 12.1 Hz, 1H, Sia-
H3a), 2.00, 2.02 (2s, 6H, 2×CH3-NHAc), 2.33 (dd, J3a,3b = 12.9, J3b,4 = 4.6 Hz, 1H, Sia'-
H3b), 2.74 (dd, J3a,3b = 12.3, J3b,4 = 4.4 Hz, 1H, Sia-H3b), 3.41 (dd, J5,6a = 6.2, J6a,6b =
9.2 Hz, 1H, Gal-H6a), 3.49 (d, J5,6 = 9.4 Hz, 1H, Sia'-H6), 3.56-3.70 (m, 9H, Gal-H2,
Gal-H6b, Gal'-H2, Gal'-H5, Sia-H8, Sia-H9a, Sia'-H4, Sia'-H8, Sia'-H9a), 3.71-3.76
(m, 3H, Gal'-H6a, Gal'-H6b, OCH2-Ha), 3.78-3.89 (m, 9H, Gal-H3, Gal-H5, Sia-H5,
Sia-H6, Sia-H7, Sia-H9b, Sia'-H5, Sia'-H7, Sia'-H9b), 3.93 (d, J3,4 = 2.7 Hz, 1H, Gal'-
H4), 3.97-4.04 (m, 2H, Sia-H4, OCH2-Hb), 4.09 (dd, J2,3 = 9.8, J3,4 = 2.9 Hz, 1H, Gal'-
H3), 4.22 (d, J3,4 = 2.8 Hz, 1H, Gal-H4), 4.46 (d, J1,2 =8.0 Hz, 1H, Gal-H1), 4.67 (d,
J1,2 = 7.9 Hz, 1H, Gal'-H1);
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13C NMR (500 MHz, D2O): δ -2.60 (3C, SiMe3), 17.51 (SiCH2), 21.97, 22.07 (2×CH3-
NHAc), 39.61, 39.70 (Sia-C3, Sia'-C3), 51.60, 51.84 (Sia-C5, Sia'-C5), 60.79 (Gal'-
C6), 61.03 (Gal-C6), 62.49, 63.41 (Sia-C9, Sia'-C9), 67.09 (Sia-C4), 67.40 (Gal'-C4),
68.02 (Sia'-C8), 68.32 (Sia-C8), 68.40 (OCH2), 68.43 (2C, Gal-C4, Sia'-C6), 69.49
(Sia'-C4), 69.72 (Sia-C6), 70.13 (Sia'-C7), 70.30 (Sia-C7), 71.76 (Gal-C5), 72.79,
72.83  (Gal-C2, Gal'-C2), 74.83 (Gal'-C5), 75.52 (Gal'-C3), 82.41 (Gal-C3), 99.72,
99.91 (Sia-C2, Sia'-C2), 101.76 (Gal-C1), 104.00 (Gal'-C1), 173.80, 174.64, 174.93,
175.08 (4×CO).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-β-
D-galactopyranoside (81), (GG-123, I-124).
A solution of 41 (100 mg, 96.2 µmol) in MeOH (2.0 mL), dioxane (0.5 mL) and
AcOH (0.5 mL) was hydrogenolyzed (4 bar H2) in the presence of 10% Pd-C (150mg)
for 9d. The reaction mixture was filtered through a pad of Celite, which was washed
with DCM (2×5 mL). The combined filtrates were concentrated and the residue was
purified by silica gel chromatography (PE/AcOEt 2:1) to afford 81 (55.4 mg, 67%) as
colorless oil.
1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3), 0.94-1.00 (m, 2H, SiCH2), 3.47 (t,
J5,6a=J5,6b =5.6 Hz, 1H, Gal-H5), 3.54 (m, 1H, OCH2-Ha), 3.65-3.68 (m, 2H, Gal-H3,
Gal-H6a), 3.73 (m, 1H, Gal-H2), 3.89 (dd, J5,6b=6.6, J6a,6b=11.7 Hz, 1H, Gal-H6b),
3.99 (m, 1H, OCH2-Hb), 4.08 (d, J3,4=2.9 Hz, 1H, Gal-H4), 4.22 (d, J1,2=7.6 Hz, 1H,
Gal-H1), 4.39 (m, 1H, Gal'-H5), 4.48 (dd, J5,6a=5.6, J6a,6b=11.5 Hz, 1H, Gal'-H6a),
4.68 (dd, J5,6b=7.2, J6a,6b=11.5 Hz, 1H, Gal'-H6b), 5.16(d, J1,2=7.9 Hz, 1H, Gal'-H1),
5.68 (dd, J2,3=10.5, J3,4=3.5 Hz, 1H, Gal'-H3), 5.81 (dd, J1,2=7.9, J2,3=10.4 Hz, 1H,
Gal'-H2), 6.01 (d, J3,4=3.2 Hz, 1H, Gal'-H4), 7.26-7.29, 7.37-7.40, 7.45-7.48, 7.51-
7.55, 7.59-7.62, 7.65-7.68, 7.80-7.81, 7.97-7.98, 8.03-8.05, 8.12-8.13 (m, 20H,
4×C6H5);
ESI-MS: Calcd for C45H50O15Si (M+Na)+: 881.3; Found: m/z 881.6.
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-2-
O-benzyl-β-D-galactopyranoside (82), (GG-121, I-121).
A solution of 41 (100 mg, 96.0 µmol) in dioxane (4.0 mL), containing cat. AcOH was
hydrogenolyzed (4 bar H2) in the presence of 10% Pd-C (100 mg) for 15h. The
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reaction mixture was filtered through a pad of Celite, which was washed with DCM
(2×5 mL). The combined filtrates were concentrated, and the residue was purified by
silica gel chromatography (PE/AcOEt 1:1) to afford 82 (4.50 mg, 5.0%) as colorless
oil.
1H NMR (500 MHz, CDCl3): δ -0.03 (s, 9H, SiMe3), 0.95-0.98 (m, 2H, SiCH2), 3.38
(m, 1H, Gal-H5), 3.50 (m, 1H, OCH2-Ha), 3.57 (m, 1H, Gal-H2), 3.65 (dd, J5,6a = 4.6,
J6a,6b = 11.6 Hz, 1H, Gal-H6a), 3.78 (dd, J2,3 = 9.3, J3,4 = 3.4 Hz, 1H, Gal-H3), 3.89 (dd,
J5,6b = 6.6, J6a,6b = 11.7 Hz, 1H, Gal-H6b), 3.95 (m, 1H, OCH2-Hb), 4.08 (d, J3,4 = 3.3
Hz, 1H, Gal-H4), 4.26-4.35 (m, 3H, PhCH2-HA, Gal-H1, Gal'-H5), 4.46 (dd, J5,6a =
5.5, J6a,6b = 11.5 Hz, 1H, Gal'-H6a), 4.64 (dd, J5,6b = 7.2, J6a,6b = 11.5 Hz, 1H, Gal'-
H6b), 4.67 (B of AB, J = 10.8 Hz, PhCH2-HB), 5.19 (d, J1,2 = 8.0 Hz, 1H, Gal'-H1),
5.59 (dd, J2,3 = 10.4, J3,4 = 3.4 Hz, 1H, Gal'-H3), 5.84 (dd, J1,2 = 8.0, J2,3 = 10.4 Hz, 1H,
Gal'-H2), 6.01 (d, J3,4 = 3.3 Hz, 1H, Gal'-H4), 7.09-7.10, 7.22-7.27, 7.41-7.46, 7.50-
7.54, 7.57-7.60, 7.63-7.66, 7.75-7.77, 7.84-7.85, 8.00-8.02, 8.10-8.12 (m, 25H,
5×C6H5).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→3)-4-O-
acetyl-2,6-di-O-benzyl-β-D-galactopyranoside (83), (GG-130, I-130).
To a stirred solution of 42 (82.8 mg, 133 µmol) in py (2.0 mL) at 0°C was added
Ac2O (1.0 mL) and cat. DMAP. The mixture was stirred for 16 h at rt under argon,
and then quenched by MeOH (1 mL). The solution was concentrated under reduced
pressure and co-evaporated with toluene (3×5 mL). The residue was purified by silica
gel chromatography (PE/AcOEt 3:1) to afford 83 (101 mg, 92%) as white foam.
1H NMR (500 MHz, CDCl3): δ 0.02 (s, 9H, SiMe3), 1.00-1.10 (m, 2H, SiCH2), 1.90,
1.98, 2.01, 2.10, 2.16 (5s, 15H, 5×CH3-OAc), 3.55 (d, J5,6 = 5.9 Hz, 2H, Gal-H6a, Gal-
H6b), 3.61 (m, 2H, Gal-H2, OCH2-Ha), 3.71 (t, J5,6 = 5.9 Hz, 1H, Gal-H5), 3.75 (t, J5,6
= 6.7 Hz, 1H, Gal'-H5), 3.83 (dd, J2,3 = 9.5, J3,4 = 3.2 Hz, 1H, Gal-H3), 4.02-4.12 (m,
3H, Gal'-H6a, Gal'-H6b, OCH2-Hb), 4.41 (d, J1,2 = 7.6 Hz, 1H, Gal-H1), 4.49, 4.53 (A,
B of AB, J = 11.6 Hz, 2H, PhCH2), 4.59 (A of AB, J = 10.3 Hz, 1H, PhCH2-HA),
4.86 (d, J1,2 = 7.9 Hz, 1H, Gal'-H1), 4.93-4.95 (m, 2H, PhCH2-HB, Gal'-H3), 5.16 (dd,
J1,2 = 8.1, J2,3 = 9.9 Hz, 1H, Gal'-H2), 5.33 (d, J3,4 = 3.4 Hz, 1H, Gal'-H4), 5.39 (d, J3,4 =
3.5 Hz, 1H, Gal-H4), 7.26-7.38 (m, 10H, 2×C6H5);
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13C NMR (125 MHz, CDCl3): δ  -1.51 (3C, SiMe3), 18.41 (SiCH2), 20.59, 20.61,
20.68, 20.76 (5C, 5×CH3-OAc), 61.07 (Gal'-C6), 66.94 (Gal'-C4), 67.88 (OCH2),
68.94 (Gal-C6), 69.14 (Gal'-C2), 69.58 (Gal-C4), 70.67 (Gal'-C5), 70.76 (Gal-C3),
72.77 (Gal-C5), 73.73 (PhCH2), 75.21 (PhCH2), 79.79 (Gal-C2), 100.71 (Gal'-C1),
103.11 (Gal-C1), 127.88, 128.06, 128.43, 128.54 (12C, 2×C6H5).
 2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(1→3)-4-O-
acetyl-β-D-galactopyranoside (84), (GG-131, I-131).
A solution of 83 (100 mg, 0.120 mmol) in MeOH (4.0 mL), dioxane (1.0 mL) and
AcOH (1.0 mL) was hydrogenolyzed (4 bar H2) in the presence of 10% Pd-C (150
mg) for 2d. The reaction mixture was filtered through a pad of Celite, which was
washed with DCM (2×5 mL). The combined filtrates were concentrated, and the
residue was purified by silica gel chromatography (PE/AcOEt 1:1) to afford 84 (73.9
mg, 94%) as white foam.
1H NMR (500 MHz, CDCl3): δ 0.02 (s, 9H, SiMe3), 0.94-1.08 (m, 2H, SiCH2), 1.99,
2.06, 2.15, 2.16 (4s, 15H, 5×CH3-OAc), 3.43 (dd, J5,6 = 7.8, 11.1 Hz, 1H, Gal-H5),
3.56-3.68 (m, 3H, Gal-H6a, Gal-H6b, OCH2-Ha), 3.71 (dd, J2,3 = 9.7, J3,4 = 3.4 Hz,
1H, Gal-H3), 3.77 (m, 1H, Gal-H2), 3.90 (t, J5,6 = 6.6 Hz, 1H, Gal'-H5), 4.00 (m, 1H,
OCH2-Hb), 4.08 (d, J5,6 = 6.6 Hz, 2H, Gal'-H6a, Gal'-H6b), 4.30 (d, J1,2 = 7.5 Hz, 1H,
Gal-H1), 4.72 (d, J1,2 = 7.9 Hz, 1H, Gal'-H1), 5.02 (dd, J2,3 = 10.5, J3,4 = 3.4 Hz, Gal'-
H3), 5.19 (dd, J1,2 = 7.9, J2,3 = 10.5 Hz, 1H, Gal'-H2), 5.26 (d, J3,4 = 3.4, 1H, Gal-H4),
5.37 (d, J3,4 = 3.5, 1H, Gal'-H4);
13C NMR (125 MHz, CDCl3): δ  -1.46 (3C, SiMe3), 18.25 (SiCH2), 20.58, 20.65,
20.80, 20.82 (5C, 5×CH3-OAc), 59.86 (Gal-C5), 61.09 (Gal'-C6), 66.78 (Gal'-C4),
67.80 (OCH2), 68.92 (Gal-C6), 70.48 (2C, Gal-C4, Gal'-C2), 70.78 (Gal'-C3), 73.32
(2C, Gal-C3, Gal'-C5), 79.91 (Gal-C2), 101.58 (Gal-C1), 102.48 (Gal'-C1), 169.90,
170.10, 170.19, 170.44 (5C, 5×CO).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-
[(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate)]-(2→6)-β-D-galactopyranoside (85), (GG-129, I-129).
To a solution of 81  (50.0 mg, 58.2 µmol) and 55  (60.7 mg, 0.12 mmol) in
CH3CN/DCM (3:1, 4 mL) was added activated powdered molecular sieves 3Å (1.00
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g). The suspension was stirred at rt under argon for 6 h, then cooled to –25°C. After
addition of NIS (52.4 mg, 0.233 mmol) and TfOH (2.0 µL, 23.3 µmol), stirring was
continued for 16 h at –25°C. Then the mixture was diluted with DCM (10 mL) and
filtered through a pad of Celite. The Celite was washed with DCM (3×10 mL), and
the combined filtrates were washed with 20% aq. Na2S2O3 (30 mL), 5% KHCO3
(2×20 mL) and H2O (20 mL), dried over Na2SO4, filtrated and concentrated under
reduced pressure. The residue was purified by silica gel chromatography
(DCM/MeOH 60:1) to afford 85 (35.0 mg, 45%) as white foam.
1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3), 0.95-1.01 (m, 2H, SiCH2), 1.89,
2.02, 2.03, 2.12, 2.15 (5s, 15H, CH3-NHAc, 4×CH3-OAc), 1.94 (m, 1H, Sia-H3a),
2.59 (dd, J3a,3b = 12.8, J3b, 4 = 4.6 Hz, 1H, Sia-H3b), 3.51-3.58 (m, 2H, Gal-H5, OCH2-
Ha), 3.65-3.68 (m, 2H, Gal-H2, Gal-H6a), 3.74 (dd, J2,3 = 9.4, J3,4 = 3.2 Hz, 1H, Gal-
H3), 3.81 (s, 3H, OCH3), 3.88 (dd, J5,6b = 5.5, J6a,6b = 9.6 Hz, 1H, Gal-H6b), 3.98 (m,
1H, OCH2-Hb), 4.06-4.13 (m, 4H, Gal-H4, Sia-H5, Sia-H6, Sia-H9a), 4.19 (d, J1,2 =
7.7 Hz, 1H, Gal-H1), 4.30-4.38 (m, 2H, Gal'-H5, Sia-H9b), 4.42 (dd, J5,6a = 7.0, J6a,6b =
11.1 Hz, 1H, Gal'-H6a), 4.70 (dd, J5,6b = 6.2, J6a,6b = 11.1 Hz, 1H, Gal'-H6b), 4.86 (ddd,
J3b,4 = 4.6, J3a,4 = 12.2, J4,5 = 9.8 Hz, 1H, Sia-H4), 5.24 (d, J5,NH = 9.6 Hz, 1H, Sia-NH),
5.30-5.34 (m, 2H, Gal'-H1, Sia-H7), 5.36-5.40 (m, 1H, Sia-H8), 5.66 (dd, J2,3 = 10.4,
J3,4 = 3.5 Hz, 1H, Gal'-H3), 5.80 (dd, J1,2 = 8.0, J2,3 = 10.4 Hz, 1H, Gal'-H2), 6.02 (d,
J3,4 = 3.4 Hz, 1H, Gal'-H4), 7.24-7.27, 7.36-7.39, 7.43-7.47, 7.50-7.55, 7.57-7.60,
7.63-7.66, 7.78-7.80, 7.95-7.97, 8.01-8.03, 8.10-8.12(m, 20H, 4×C6H5);
13C NMR (125 MHz, CDCl3): δ -1.44 (3C, SiMe3), 18.05 (SiCH2), 20.75, 20.81, 20.99
(4C, 4×C H3-OAc), 23.16 (CH3-NHAc), 37.56 (Sia-C3), 49.39 (Sia-C5), 52.91
(OCH3), 61.68 (Gal'-C6), 62.41 (Sia-C9), 62.61 (Gal-C6), 67.08 (OCH2), 67.47 (2C,
Gal-C4, Sia-C7), 67.64 (Gal'-C4), 67.95 (2C, Sia-C4, Sia-C8), 68.90 (Gal'-C2), 70.01
(Gal-C2), 71.13, 71.36 (Gal'-C5, Gal'-C3), 72.30 (Sia-C6), 72.80 (Gal-C5), 81.17
(Gal-C3), 98.96 (Sia-C2), 101.91, 102.10 (Gal-C1, Gal'-C1), 128.27, 128.42, 128.51,
128.64, 128.69, 128.97, 129.23, 129.29, 129.67, 129.76, 130.01, 130.99, 133.30,
133.36, 133.63 (24C, 4×C6H5), 165.50, 165.55, 165.61, 169.02, 169.88, 170.10,
170.27, 170.68, 170.94 (10C, 10×CO);
HRMS (FAB) Calcd for C66H77NO27Si (M+NH4)+: 1349.4796; Found: m/z 1349.4778.
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2-(Trimethylsilyl)ethyl β-D-galactopyranosyl-(1→3)-[(sodium 5-acetamido-3,5-
dideoxy-D-glycero-α-D-galacto-2-nonulopyranosynate)]-(2→6)-β-D-
galactopyranoside (45), (GG-136, I-136).
To a solution of 85 (32.5 mg, 24.4 µmol) in MeOH (1 mL) was added freshly
prepared 1M NaOMe/MeOH (1.0 mL). The mixture was stirred at rt under argon for
7h, then H2O (1 mL) was added and the mixture was stirred for 16 hr at rt. The
solution was concentrated and the residue was purified by RP chromatography (5%
gradient MeOH in H2O), Dowex ion-exchange chromatography (Na+ type), and P2
size exclusion chromatography to afford 45 as white solid (17.8 mg, 90%) after a final
lyophilization from H2O.
[α]D -3.5° (c = 0.54, H2O); 1H NMR (500 MHz, D2O): δ 0.00 (s, 9H, SiMe3), 0.95 (td,
J = 12.9, J = 5.2 Hz, 1H, SiCH2-Ha), 1.04 (td, J = 12.9, J = 5.5 Hz, 1H, SiCH2-Hb),
1.63 (t, J3a,3b = J3a,4 = 12.2 Hz, 1H, Sia-H3a), 2.00 (s, 3H, CH3-NHAc), 2.68 (dd, J3a,3b =
12.4, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.55 (m, 1H, Sia-H6), 3.56-3.60 (m, 3H, Gal-H2,
Gal'-H2, Sia-H9a), 3.61-3.64 (m, 2H, Gal-H6a, Gal'-H3), 3.66-3.68 (m, 3H, Gal'-H5,
Sia-H4, Sia-H7), 3.71 (m, 1H, Gal'-H6a), 3.72-3.79 (m, 4H, Gal-H3, Gal'-H6b, Sia-
H8, OCH2-Ha), 3.81-3.85 (m, 3H, Gal-H5, Gal-H6b, Sia-H5), 3.87-3.91 (m, 2H, Gal'-
H4, Sia-H9b), 4.00 (ddd, J = 5.1, J = 10.1, J = 12.7 Hz, 1H, OCH2-Hb), 4.20 (d, J3,4 =
3.3 Hz, 1H, Gal-H4), 4.42 (d, J1,2 = 8.0 Hz, 1H, Gal-H1), 4.55 (d, J1,2 = 7.6 Hz, 1H,
Gal'-H1);
13C NMR (125 MHz, D2O): δ 0.00 (3C, SiMe3), 19.28 (SiCH2), 42.14 (Sia-C3), 54.36
(Sia-C5), 63.59 (Gal'-C6), 65.19 (Gal-C6), 65.64 (Sia-C9), 70.67, 70.72 (Gal'-C5,
Sia-C6), 70.68 (OCH2), 71.10 (2C, Gal-C4, Gal'-C4), 72.20 (Gal-C2), 73.50 (Gal'-C2,
Sia-C7), 74.17 (Gal-C5), 75.14 (Sia-C4), 75.48 (Sia-C8), 77.57 (Gal'-C3), 85.18 (Gal-
C3), 102.41 (Sia-C2), 104.27 (Gal-C1), 106.97 (Gal'-C1), 175.43, 177.57 (2×CO);
ESI-MS: Calcd for C28H50NNaO19Si (M+Na)+: 778.3; Found: m/z 778.5.
2-(Trimethylsilyl)ethyl 2,6-O-di(p-methoxybenzyl)-3,4-O-isopropylidene-β-D-
galactopyranoside (90), (JPB-11).
To a solution of 39 (1.00 g, 3.12 mmol) in DMF (30 mL) at 0°C were added NaH
(60% in oil, 300 mg, 12.5 mmol) and a catalytic amount of TBAI. MPMCl (1.69 mL,
12.5 mmol) was added dropwise during 10 min under argon and the mixture was
stirred at 0°C for 3 h. The reaction was quenched by adding MeOH, then diluted with
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DCM (70 mL), and washed with 5% NaHCO3 (2×50 mL) and H2O (2×50 mL). The
organic layer was dried over Na2SO4, filtrated and concentrated under reduced
pressure. The residue was purified by silica gel chromatography (1% gradient AcOEt
in toluene, start from 5%) to afford 90 (1.07g, 61%) as white foam.
[α]D +18.3° (c = 0.49, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.02 (s, 9H, SiMe3),
1.03-1.07 (m, 2H, SiCH2), 1.31, 1.34 (2s, 6H, 2×CH3), 3.35 (dd, J1,2 = 8.1, J2,3 = 6.3,
1H, Gal-H2), 3.57 (m, 1H, OCH2-Ha), 3.74-3.76 (m, 2H, Gal-H6a, Gal-H6b), 3.78,
3.79 (2s, 6H, 2×OCH3-MPM), 3.93 (ddd, J4,5 = 1.6, J5,6a = 5.3, J5,6b = 6.9 Hz, 1H, Gal-
H5), 4.03 (m, 1H, OCH2-Hb), 4.09-4.13 (m, 2H, Gal-H3, Gal-H4), 4.29 (d, J1,2 = 8.1
Hz, 1H,  Gal-H1), 4.48, 4.55 (A, B of AB, J = 11.4 Hz, 2H, C6H4CH2), 4.72, 4.76 (A,
B of AB, J = 11.3 Hz, 2H, C6H4CH2), 6.84-6.87, 7.25-7.32 (m, 8H, 2×C6H4);
13C NMR (125 MHz, CDCl3): δ  -1.43 (3C, SiMe3), 18.45 (SiCH2), 26.39, 27.78
(2×CH3), 55.26 (2C, 2×OCH3-MPM), 67.16 (OCH2), 69.37 (Gal-C6), 72.19 (Gal-C5),
73.23, 73.27 (2×C6H4CH2), 73.87 (Gal-C4), 79.12 (Gal-C3), 79.34 (Gal-C2), 102.44
(Gal-C1), 109.81 (CMe2), 113.59, 113.78, 129.25, 129.83, 130.33, 130.56, 159.13,
159.21  (12C, 2×C6H4).
2-(Trimethylsilyl)ethyl 2,6-O-di(p-methoxybenzyl)-β-D-galactopyranoside (91),
(JPB-14).
90 (1.00 g, 1.78 mmol) was suspended in 80% aq. AcOH (30 mL) and stirred at 90°C
for 1.5 h. The reaction was concentrated under reduced pressure and the residue was
purified by flash silica gel chromatography (15% gradient AcOEt in toluene, start
from 30%) to afford 91 (460 mg, 50%) as white foam.
[α]D +8.3° (c = 0.53, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.04 (s, 9H, SiMe3),
1.04-1.07 (m, 2H, SiCH2), 3.46 (dd, J1,2 = 7.7, J2,3 = 9.4 Hz, 1H, Gal-H2), 3.55 (dd, J2,3
= 9.4, J3,4 = 3.2 Hz, 1H, Gal-H3), 3.57-3.62 (m, 2H, Gal-H5, OCH2-Ha), 3.71 (dd, J5,6a
= 5.7, J6a,6b = 10.1 Hz, 1H, Gal-H6a), 3.76 (dd, J5,6b = 5.6, J6a,6b = 10.1 Hz, 1H, Gal-
H6b), 3.79, 3.80 (2s, 6H, 2×OCH3-MPM), 3.97 (d, J3,4 = 3.0 Hz, 1H, Gal-H4), 4.04
(m, 1H, OCH2-Hb), 4.36 (d, J1,2 = 7.8 Hz, 1H, Gal-H1), 4.51 (s, 2H, C6H4CH2), 4.62,
4.89 (A, B of AB, J = 11.2 Hz, 2H, C6H4CH2), 6.86-6.89, 7.25-7.31 (m, 8H, 2×C6H4);
13C NMR (125 MHz, CDCl3): δ  -1.42 (3C, SiMe3), 18.53 (SiCH2), 55.26 (2C,
2×OCH3-MPM), 67.33 (OCH2), 69.05 (2C, Gal-C4, Gal-C6), 73.22 (Gal-C5), 73.33,
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74.11 (2×C6H4CH2), 78.62 (2C, Gal-C2, Gal-C3), 103.19 (Gal-C1), 113.84, 113.95,
129.33, 129.82, 129.95, 130.54, 159.29, 159.36 (12C, 2×C6H4).
2-(Trimethylsilyl)ethyl (2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-(1→3)-
2,6-O-di-(p-methoxybenzyl)-β-D-galactopyranoside (92), (GG-269, I-272).
A mixture of 91 (307 mg, 0.590 mmol), 30 (567 mg, 0.885 mmol) and activated
powdered molecular sieves 3Å (2.00 g) in DCM (10 mL) was stirred at rt for 6h under
argon. DMTST (685 mg, 2.65 mmol) was then added at 0°C. The reaction mixture
was stirred at 0°C for 16h, then diluted with DCM (10 mL) and filtered through a pad
of Celite. The Celite was washed with DCM (3×10 mL) and the combined filtrates
were washed with 5% NaHCO3 (2×20 mL) and H2O (20 mL). The organic layer was
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was
purified by flash silica gel chromatography (1% gradient AcOEt in toluene, start from
4%) to afford 92 (491 mg, 76%) as white foam.
[α]D +54.1° (c = 0.58, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.02 (s, 9H, SiMe3),
0.93-1.00 (m, 2H, SiCH2), 3.54-3.60 (m, 3H, Gal-H2, Gal-H5, OCH2-Ha), 3.68-3.74
(m, 2H, Gal-H6a, Gal-H6b), 3.77-3.87 (m, 7H, Gal-H3, 2×OCH3-MPM), 3.99-4.04
(m, 1H, OCH2-Hb), 4.12 (d, J3,4 = 3.1 Hz, 1H, Gal-H4), 4.27 (m, 1H, Gal-H5), 4.30,
4.66 (A, B of AB, J = 10.1 Hz, 2H, C6H4CH2), 4.32 (d, J1,2 = 7.8 Hz, 1H, Gal-H1),
4.46 (dd, J5,6a = 6.2, J6a,6b = 11.4 Hz, 1H, Gal'-H6a), 4.48, 4.52 (A, B of AB, J = 11.5
Hz, 2H, C6H4CH2), 4.63 (m, 1H, Gal'-H6b), 5.28 (d, J1,2 = 8.0 Hz, 1H, Gal'-H1), 5.65
(dd, J2,3 = 10.5, J3,4 = 3.5 Hz, 1H, Gal'-H3), 5.87 (dd, J1,2 = 8.0, J2,3 = 10.4 Hz, 1H, Gal'-
H2), 6.00 (d, J3,4 = 3.4 Hz, 1H, Gal'-H4), 6.90-6.92, 7.10-7.12, 7.26-7.32, 7.44-7.49,
7.54-7.60, 7.66-7.69, 7.80-7.81, 7.91-7.92, 8.03-8.05, 8.13-8.15 (m, 28H, 4×C6H5,
2×C6H4);
13C NMR (125 MHz, CDCl3): δ  -1.50 (3C, SiMe3), 18.47 (SiCH2), 55.25 (2C,
2×OCH3-MPM), 61.96 (Gal'-C6), 67.22 (OCH2), 68.13 (Gal'-C4), 68.86 (Gal-C4),
69.14 (Gal-C6), 69.93 (Gal'-C2), 71.42 (Gal'-C5), 71.49 (Gal'-C3), 73.13 (Gal-C5),
73.26, 74.40 (2C, 2×C6H4CH2), 78.59 (Gal-C2), 80.70 (Gal-C3), 101.53 (Gal'-C1),
102.95 (Gal-C1), 113.79, 113.81, 128.41, 128.49, 128.69, 128.93, 129.25, 129.30,
129.35, 129.68, 129.74, 129.78, 130.04, 130.23, 130.63, 133.35, 133.67, 159.03,
159.22 (36C, 4×C6H5, 2×C6H4), 165.508, 165.59, 165.91 (4C, 4×CO).
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2-(Trimethylsi lyl)ethyl (β -D - g a l a c t o p y r a n o s y l ) - ( 1→3)-2,6-O-di-(p-
methoxybenzyl)-β-D-galactopyranoside (93), (GG-273, I-273).
To a solution of 92 (491 mg, 0.447 mmol) in MeOH (20 mL) was added freshly
prepared 1M NaOMe/MeOH (2.0 mL). The mixture was stirred at rt for 2h under
argon, then neutralized with Amberlite IRC 50 ion-exchange resin and filtered
through a pad of Celite. The Celite was washed with MeOH (3×10 mL) and the
combined filtrates were evaporated under reduced pressure. The residue was purified
by flash silica gel chromatography (2% gradient MeOH in DCM) to afford 93 (260
mg, 85%) as white foam.
[α]D -7.7°, (c = 0.82, CH3OH); 1H NMR (500 MHz, CD3OD): δ 0.03 (s, 9H, SiMe3),
1.01 (t, J = 8.4 Hz, 2H, CH2Si), 3.43 (m, 1H, Gal-H5), 3.46 (dd, J2,3 = 9.8, J3,4 = 3.3
Hz, 1H, Gal'-H3), 3.57-3.72 (m, 8H, Gal-H2, Gal-H6a, Gal-H6b, Gal'-H2, Gal'-H5,
Gal'-H6a, Gal'-H6b, OCH2-Ha), 3.75 (m, 1H, Gal-H3), 3.76, 3.77 (2s, 6H, 2×OCH3),
3.81 (d, J3,4 = 3.0 Hz, 1H, Gal'-H4), 3.98-4.03 (m, 2H, Gal-H4, OCH2-Hb), 4.35 (d, J1,2
= 7.8 Hz, 1H, Gal-H1), 4.47, 4.51 (A, B of AB, J = 11.4 Hz, 2H, C6H4CH2), 4.59 (d,
J1,2 = 7.7 Hz, 1H, Gal'-H1), 4.73, 4.76 (A, B of AB, J = 10.1 Hz, 2H, C6H4CH2), 6.85-
6.89, 7.25-7.27, 7.35-7.37 (m, 8H, 2×C6H4);
13C NMR (125 MHz, CD3OD): δ -1.32 (3C, SiMe3), 19.45 (SiCH2), 55.65, 55.67
(2OCH3), 62.54 (Gal'-C6), 68.40 (OCH2), 70.28 (Gal'-C4), 70.52 (Gal-C6), 70.63
(Gal-C4), 72.80 (Gal'-C2), 74.08, (C6H4CH2), 74.66 (Gal-C5), 74.76 (Gal-C3), 75.67
(C6H4CH2), 76.66 (Gal-C5), 80.12 (Gal-C2), 81.82 (Gal-C3), 104.46 (Gal-C1), 105.94
(Gal'-C1), 114.53, 114.74, 130.48, 131.17, 131.58, 132.26, 160.75, 160.83 (12C,
2×C6H4);
Anal. Calcd for C33H50O13Si: C, 58.05; H, 7.38. Found: C, 58.07; H, 7.28.
2-(Trimethylsilyl)ethyl (6-O-benzoyl-β-D-galactopyranosyl)-(1→3)-2,6-O-di-(p-
methoxybenzyl)-β-D-galactopyranoside (89), (GG-275, I-276).
To a solution of 93 (260 mg, 0.381 mmol) in Et3N (4.0 mL) and CH3CN (16 mL) at
–40°C under argon, a solution of benzoyl cyanide (45.0 mg, 0.343 mmol) in CH3CN
(0.5 mL) was added dropwise during 15 min. The reaction was stirred at –40∼-45°C
for 1h and then quenched by a few drops of MeOH. The solution was concentrated
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under reduced pressure and the residue was purified by silica gel chromatography
(1% gradient MeOH in DCM) to afford 89 (180 mg, 60%) as white foam.
[α]D -3.1°, (c = 0.82, CH3OH); 1H NMR (500 MHz, CD3OD): δ 0.03 (s, 9H, SiMe3),
0.98-1.01 (m, 2H, SiCH2), 3.42-3.46 (m, 2H, Gal-H5, Gal-H6a), 3.53 (dd, J2,3 = 9.7,
J3,4 = 3.4Hz, 1H, Gal'-H3), 3.55-3.65 (m, 5H, Gal-H2, Gal-H3, Gal-H6b, Gal'-H2,
OCH2-Ha), 3.76, 3.77 (2s, 6H, 2×OCH3), 3.83 (dd, J5,6a = 4.5, J5,6b = 8.5 Hz, 1H, Gal'-
H5), 3.88 (d, J3,4 = 3.3 Hz, 1H, Gal'-H4), 3.96-3.99 (m, 2H, Gal-H4, OCH2-Hb), 4.25
(d, J1,2 = 7.4 Hz, 1H, Gal-H1), 4.37-4.41 (m, 3H, Gal'-H6a, C6H4CH2), 4.58 (d, J1,2 =
7.7 Hz, 1H, Gal'-H1), 4.63 (dd, J5,6b = 8.4, J6a,6b = 11.4 Hz, 1H, Gal'-H6b), 4.71, 4.77
(A, B of AB, J = 10.1 Hz, 2H, C6H4CH2), 6.85-6.87, 7.21-7.23, 7.35-7.36, 7.44-7.47,
7.56-7.59, 7.83-8.02 (m, 13H, C6H5, 2× C6H4);
13C NMR (125 MHz, CD3OD): δ -1.46 (3C, SiMe3), 19.28 (SiCH2), 55.51, 55.54
(2×OCH3), 66.01 (Gal'-C6), 68.14 (OCH2), 70.13 (Gal'-C4), 70.51 (Gal-C6), 70.59
(Gal-C4), 72.44 (Gal'-C2), 73.84 (C6H4CH2), 73.93 (Gal'-C5), 74.50 (Gal-C5), 74.57
(Gal'-C3), 75.50 (C6H4CH2), 79.67 (Gal-C2), 82.65 (Gal-C3), 104.21 (Gal-C1),
105.88 (Gal'-C1), 114.40, 114.59, 129.58, 130.23, 130.51, 130.83, 131.46, 133.08,
134.28 (18C, C6H5, 2×C6H4), 167.56 (CO);
Anal. Calcd for C40H54O14Si: C, 61.05; H, 6.92. Found: C, 60.57; H, 6.70.
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-9-azido-4,7,8-tri-O-acetyl-3,5,9-
trideoxy-D-glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(6-O-benzoyl-β-D-
galactopyranosyl)-(1→3)-2,6-O-di-(p-methoxybenzyl)-β-D-galactopyranoside
(94), (GG-281, I-282).
A mixture of 89 (77.0 mg, 97.8 µmol), methyl (methyl 5-acetamido-9-azido-4,7,8-tri-
O-acetyl-3,5,9-trideoxy-2-thio-D-glycero-D-galacto-2-nonulopyranosid)onate178 88
(98.0 mg, 196 µmol) and activated powdered molecular sieves 3Å (1.00 g) was stirred
in CH3CN (5 mL) at rt for 6 h under argon. DMTST (202 mg, 0.783 mmol) was then
added at 0°C. The reaction mixture was stirred at 0°C for 16 h, diluted with DCM (5
mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×5
mL), and the combined filtrates were washed with 5% NaHCO3 (2×10 mL) and H2O
(10 mL). The organic layer was dried over Na2SO4, filtered and concentrated under
reduced pressure. The residue was purified by silica gel chromatography (0.25%
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gradient MeOH in DCM) to afford 94 (90.5 mg, 47%) as white foam (β-isomer: 30.0
mg, 16%).
[α]D -3.3°, (c = 0.91, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.01 (s, 9H, SiMe3),
1.01-1.04 (m, 2H, SiCH2), 1.90 (s, 3H, CH3-NHAc), 2.04, 2.10, 2.13 (3s, 9H, 3×CH3-
OAc), 2.11 (m, 1H, Sia-H3a), 2.69 (dd, J3a,3b = 13.1, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.11
(dd, J8,9a = 5.4, J9a,9b = 13.6 Hz, 1H, Sia-H9a), 3.44 (dd, J8,9b = 2.6, J9a,9b = 13.6 Hz, 1H,
Sia-H9b), 3.49-3.59 (m, 3H, Gal-H5, Gal-H6a, OCH2-Ha), 3.61-3.71 (m, 4H, Gal-H2,
Gal-H3, Gal-H6b, Gal'-H4), 3.75-3.81 (m, 1H, Gal'-H2), 3.77, 3.78 (2s, 6H, 2×OCH3-
MPM), 3.80 (s, 3H, OCH3), 3.84 (m, 1H, Gal'-H5), 4.00 (d, J3,4 = 3.2 Hz, 1H, Gal-
H4), 4.01-4.13 (m, 4H, Gal'-H3, Sia-H5, Sia-H6, OCH2-Hb), 4.32(d, J1,2 = 7.5 Hz, 1H,
Gal-H1), 4.39, 4.43 (A, B of AB, J = 11.5 Hz, 2H, C6H4CH2), 4.50 (dd, J5,6a = 7.6,
J6a,6b = 11.6 Hz, 1H,  Gal'-H6a), 4.60 (d, J1,2 = 7.8Hz, 1H, Gal'-H1), 4.61 (m, 1H, Gal'-
H6b), 4.75, 4.78 (A, B of AB, 2J = 10.7 Hz, 2H, C6H4CH2), 4.94 (ddd, J3b,4 = 4.6, J3a,4 =
12.0, J4,5 = 10.0 Hz, 1H, Sia-H4), 5.24(d, J5,NH = 9.5 Hz, 1H, Sia-NH), 5.28-5.34 (m,
2H, Sia-H7, Sia-H8), 6.82-6.86, 7.21-7.23, 7.34-7.36, 7.39-7.42, 7.53-7.56, 8.01-8.03
(m, 13H, C6H5, 2× C6H4);
13C NMR (125 MHz, CDCl3): δ -1.50 (3C, SiMe3), 18.41 (SiCH2), 20.72, 20.76, 21.06
(3×CH3-OAc), 22.13 (CH3-NHAc), 37.42 (Sia-C3), 49.38 (Sia-C5), 50.98 (Sia-C9),
53.15 (CO2CH3), 55.15, 55.19 (2×O CH3-MPM), 63.21 (Gal'-C6), 67.10 (OCH2),
67.55, 67.57 (Gal'-C4, Sia-C7), 68.45 (Sia-C4), 68.64 (Gal-C4), 68.86 (Sia-C8), 69.30
(Gal'-C2), 69.50 (Gal-C6), 72.07 (Gal'-C5), 72.81 (Sia-C6), 73.12 (C6H4CH2), 73.18
(Gal-C5), 74.45 (C6H4CH2), 76.08 (Gal'-C3), 77.52 (Gal-C2), 84.00 (Gal-C3), 97.54
(Sia-C2), 102.83 (Gal-C1), 103.77 (Gal'-C1), 113.55, 113.73, 128.42, 129.20, 129.57,
129.62, 129.84, 130.27, 133.27, 159.11 (18C, C6H5, 2× C6H4), 166.18, 168.35, 170.02,
170.08, 170.30, 170.87 (6CO);
Anal. Calcd for C58H78N4O24Si: C, 56.03; H, 6.32; N, 4.51. Found: C, 55.81; H, 6.32;
N, 4.35.
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-9-azido-4,7,8-tri-O-acetyl-3,5-
dideoxy-D-glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-O-diacetyl-6-
O-benzoyl-β-D-galactopyranosyl)-(1→3)-4-O-acetyl-2,6-O-di-(p-methoxybenzyl)-
β-D-galactopyranoside (95), (GG-284, I-284).
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To a stirred solution of 94 (87.0 mg, 70.0 µmol) in py (0.4 mL) at 0°C was added
Ac2O (0.2 mL). The mixture was stirred at rt for 16 h under argon, and then quenched
by MeOH (1 mL). The solution was concentrated and co-evaporated with toluene
(3×5 mL), and the residue was purified by silica gel chromatography (10% gradient
AcOEt in toulene) to afford 95 (83.0 mg, 87%) as white foam.
[α]D -8.6°, (c = 0.66, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3),
0.99-1.04 (m, 2H, SiCH2), 1.67 (t, J3a,3b = J3a,4 = 12.5 Hz, 1H, Sia-H3a), 1.84 (s, 3H,
CH3-NHAc), 1.92, 2.00, 2.02, 2.09, 2.11, 2.15 (6s, 18H, 6×CH3-OAc), 2.58 (dd, J3a,3b
= 12.7, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.09 (dd, J8,9a = 5.8, J9a,9b = 13.6 Hz, 1H, Sia-H9a),
3.44-3.65 (m, 7H, Gal-H2, Gal-H5, Gal-H6a, Gal-H6b, Sia-H6, Sia-H9b, OCH2-Ha),
3.73 (s, 3H, CO2CH3), 3.78, 3.79 (2s, 6H, 2×OCH3-MPM), 3.86 (m, 1H, Gal-H3),
3.98-4.05 (m, 3H, Gal'-H5, Sia-H5, OCH2-Hb), 4.16 (dd, J5,6a = 7.9, J6a,6b = 11.0 Hz,
1H, Gal'-H6a), 4.36 (d, J1,2 = 7.8 Hz, 1H, Gal-H1), 4.38-4.44 (m, 3H, Gal'-H6b,
C6H4CH2), 4.54 (dd, J2,3 = 10.2, J3,4 = 3.3 Hz, 1H, Gal'-H3), 4.65, 4.76 (A, B of AB, J
= 10.6 Hz, 2H, C6H4CH2), 4.83 (d, J1,2 = 8.0 Hz, 1H, Gal'-H1), 4.85 (m, 1H, Sia-H4),
5.05 (d, J3,4 = 3.3 Hz, 1H, Gal'-H4), 5.07 (d, J5,NH = 10.4 Hz, 1H, Sia-NH), 5.11 (dd,
J1,2 = 8.0, J2,3 = 10.2 Hz, 1H, Gal'-H2), 5.33 (dd, J6,7 = 2.6, J7,8 = 8.7 Hz, 1H, Sia-H7),
5.40-5.43 (m, 2H, Gal-H4, Sia-H8), 6.84-6.87, 7.23-7.25, 7.32-7.33, 7.40-7.43, 7.53-
7.56, 8.02-8.04 (m, 13H, C6H5, 2×C6H4);
13C NMR (125 MHz, CDCl3): δ  -1.56 (3C, SiMe3), 18.44 (SiCH2), 20.65, 20.69,
20.81, 20.89, 21.18 (6C, 6×CH3-OAc), 23.08 (CH3-NHAc), 36.93 (Sia-C3), 48.99
(Sia-C5), 51.18 (Sia-C9), 53.03 (CO2CH3), 55.18 (2C, 2×OCH3-MPM), 61.15 (Gal'-
C6), 67.15 (Gal'-C4), 67.70 (2C, Sia-C7, OCH2), 68.63, 69.13 (Gal-C4, Sia-C8),
69.19 (Gal-C6), 69.46 (Sia-C4), 70.15 (Gal'-C2), 70.38 (Gal'-C5), 71.48 (Gal'-C3),
72.19 (Sia-C6), 72.93 (Gal-C5), 73.24, 74.69 (2×C6H4CH2), 78.31 (Gal-C2), 80.17
(Gal-C3), 96.67 (Sia-C2), 100.96 (Gal'-C1), 103.03 (Gal-C1), 113.49, 113.73, 128.23,
129.23, 129.34, 129.62, 129.74, 133.04, 130.05, 131.05, 158.99, 159.15 (18C, C6H5,
2×C6H4), 165.56, 167.86, 169.66, 170.15, 170.22, 170.39 (9C, 9×CO).
2-(Trimethylsilyl)ethyl (methyl 5-acetamido-4,7,8-tri-O-acetyl-9-benzoamido-
3,5,9-trideoxy-D-glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-(2,4-di-O-
acetyl-6-O-benzoyl-β-D-galactopyranosyl)-(1→3)-4-O-acetyl-2,6-O-di-(p-
methoxybenzyl)-β-D-galactopyranoside (96), (GG-286, I-286).
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95 (79.3 mg, 57.9 µmol) and benzoylchloride (27.0 µL, 0.232 mmol) were dissolved
in DCE (5 mL) and stirred at rt under argon. Ph3P (33.0 mg, 0.127 mmol) in DCE (1
mL) was added after 5 min. The reaction was stirred at rt for 16 h, then diluted with
DCM (10 mL) and washed with 5% NaHCO3 (2×10 mL) and H2O (10 mL). The
organic layer was dried over Na2SO4, filtered and concentrated under reduced
pressure. The residue was purified by silica gel chromatography (0.25% gradient
MeOH in DCM) to afford 96 (47.5 mg, 57%) as white foam.
[α]D: +2.3°, (c = 0.90, CHCl3); 1H NMR (500 MHz, CDCl3): δ 0.00 (s, 9H, SiMe3),
0.98-1.07 (m, 2H, SiCH2), 1.70 (t, J3a,3b = J3a,4 = 12.4 Hz, 1H, Sia-H3a), 1.84 (s, 3H,
CH3-NHAc), 1.95, 2.00, 2.08, 2.09, 2.10 (6s, 18H, 6×CH3-OAc), 2.58 (dd, J3a,3b =
12.7, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 2.82 (dt, J9a,9b = 15.0, J8,9a = J9a,NH = 3.9 Hz, 1H, Sia-
H9a), 3.42-3.49 (m, 2H, Gal-H6a, Gal-H6b), 3.53 (dd, J5,6 = 10.8, J6,7 = 2.6 Hz, 1H,
Sia-H6), 3.59-3.63 (m, 3H, Gal-H2, Gal-H5, OCH2-Ha), 3.71 (s, 3H, CO2CH3), 3.77,
3.78 (2s, 6H, 2×OCH3-MPM), 4.00-4.05 (m, 2H, Gal'-H5, OCH2-Hb), 4.11 (q, J4,5 =
J5,6 = J5,NH = 10.4 Hz, 1H, Sia-H5), 4.18 (dd, J5,6a = 7.6, J6a,6b = 11.0 Hz, 1H, Gal'-H6a),
4.31-4.38 (m, 2H, Gal'-H6b, Sia-H9b), 4.36 (d, J1,2 = 7.8 Hz, 1H, Gal-H1), 4.39, 4.42
(A, B of AB, J = 11.2 Hz, 2H, C6H4CH2), 4.66, 4.76 (A, B of AB, J = 10.3 Hz, 2H,
C6H4CH2), 4.67 (m, 1H, Gal'-H3), 4.85 (ddd, J3a,4 = 12.2, J3b,4 = 4.6, J4,5 = 10.5 Hz, 1H,
Sia-H4), 4.91 (d, J1,2 = 7.9 Hz, 1H, Gal'-H1), 5.07 (d, J3,4 = 2.7 Hz, 1H, Gal'-H4), 5.10
(dd, J1,2 = 7.9, J2,3 = 10.1 Hz, 1H, Gal'-H2), 5.13 (d, J5,NH = 10.4 Hz, 1H, Sia-NH), 5.20
(dd, J6,7 = 2.6, J7,8 = 9.2 Hz, 1H, Sia-H7), 5.34 (dt, J7,8 = 9.2, J8,9a = J8,9b = 3.2 Hz, 1H,
Sia-H8), 5.39 (d, J3,4 = 3.6 Hz, 1H, Gal-H4), 6.82-6.88, 7.23-7.26, 7.31-7.34, 7.39-
7.55, 7.77-7.79, 8.01-8.03 (m, 18H, 2×C6H5, 2×C6H4);
13C NMR (125 MHz, CDCl3): δ  -1.52 (3C, SiMe3), 18.49 (SiCH2), 20.71, 20.91,
20.93, 21.28 (6C, 6×CH3-OAc), 23.10 (CH3-NHAc), 37.50 (Sia-C3), 38.32 (Sia-C9),
48.18 (Sia-C5), 52.99 (CO2CH3), 55.21, 55.23 (2×OCH3-MPM), 61.34 (Gal'-C6),
67.32 (Gal'-C4), 67.71 (OCH2), 67.87 (Sia-C7), 68.51 (Sia-C8), 69.27 (Gal-C6),
69.32 (Sia-C4), 69.78 (Gal-C4), 70.31, 70.37 (Gal'-C2, Gal'-C5), 71.67 (Gal'-C3),
72.14 (Sia-C6), 73.01 (Gal-C5), 73.23, 74.73 (2×C6H4CH2), 78.31 (Gal-C2), 80.05
(Gal-C3), 96.71 (Sia-C2), 101.02 (Gal'-C1), 103.03 (Gal-C1), 113.61, 113.70, 113.75,
126.88, 128.24, 128.42, 128.51, 128.58, 129.34, 129.37, 129.48, 129.65, 129.82,
130.08, 130.13, 131.50, 131.88, 133.02, 134.19, 159.06, 159.16 (24C, 2×C6H5,
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2×C6H4), 165.59, 165.69, 167.13, 167.73, 169.60, 170.14, 170.30, 170.74, 170.94,
171.69 (10×CO);
Anal. Calcd for C71H90N2O28Si: C, 58.91; H, 6.27; N, 1.94. Found: C, 58.31; H, 6.24;
N, 1.67.
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-9-benzoamido-3,5,9-trideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-β-D-galactopyranosyl-(1→3)-
β-D-galactopyranoside (87), (GG-290, I-288, 290).   
To a stirred solution of 96 (23.0 mg, 15.9 µmol) in DCM (1.8 mL) were added DDQ
(10.8 mg, 47.7 µmol) and H2O (0.1 mL). The mixture was stirred at rt for 3 h, then the
precipitate was filtered and washed with DCM (2×5 mL). The combined filtrates were
washed with H2O (2×5 mL). The organic layer was dried over Na2SO4, filtered and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (0.5% gradient MeOH in DCM) to afford white foam (16.2mg,
84%), which was then dissolved in MeOH (1.8mL), and treated with freshly prepared
1M NaOMe/MeOH (0.2mL). The mixture was stirred at rt for 5 h under argon, then
H2O (0.5 mL) was added and the mixture was stirred at rt for 3 h. The solution was
neutralized by 0.5% HCl, concentrated, and the residue was purified by RP
chromatography (5% gradient MeOH in H2O), Dowex ion-exchange chromatography
(Na+ type), and P2 size exclusion chromatography to afford 87 as a white solid (10.1
mg, 88%, 74% for two steps) after a final lyophilization from H2O.  
[α]D: +2.2°, (c = 0.67, H2O); 1H NMR (500 MHz, D2O): δ 0.02 (s, 9H, SiMe3), 0.96
(td, J = J = 12.9, J = 5.2 Hz, SiCH2-Ha), 1.05 (td, J = J = 12.9, J = 5.5 Hz, SiCH2-
Hb), 1.80 (t, J3a,3b = J3a,4 = 12.1 Hz, Sia-H3a), 2.00 (s, 3H, CH3-NHAc), 2.76 (dd, J3a,3b
= 12.2, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.55-3.66 (m, 6H, Gal-H2, Gal-H5, Gal'-H2,
Gal'-H5, Sia-H7, Sia-H9a), 3.67-3.78 (m, 9H, Gal-H3, Gal-H6a, Gal-H6b, Gal'-H6a,
Gal'-H6b, Sia-H4, Sia-H6, Sia-H9b, OCH2-Ha), 3.87 (t, J4,5 = J5,6 = 10.2 Hz, 1H, Sia-
H5), 3.94 (d, J3,4 = 3.1 Hz, 1H, Gal'-H4), 3.99-4.07 (m, 2H, Sia-H8, OCH2-Hb), 4.11
(dd, J2,3 = 9.8, J3,4 = 3.1 Hz, 1H, Gal'-H3), 4.14 (d, J3,4 = 3.3 Hz, 1H, Gal-H4), 4.37 (d,
J1,2 = 8.0 Hz, 1H, Gal-H1), 4.64 (d, J1,2 = 7.8 Hz, 1H,  Gal'-H1), 7.53-7.56, 7.61-7.64,
7.78-7.80 (m, 5H, C6H5);
13C NMR (125 MHz, D2O): δ -2.17 (3C, SiMe3), 17.90 (SiCH2), 22.37 (CH3-NHAc),
40.13 (Sia-C3), 43.06 (Sia-C9), 52.04 (Sia-C5), 61.16, 61.27 (Gal-C6, Gal'-C6), 67.77
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(Gal'-C4), 68.62 (OCH2), 68.76 (Gal-C4), 69.80 (Sia-C4), 70.06, 70.13 (3C, Gal-C2,
Gal'-C2, Sia-C7), 70.72 (Sia-C8), 75.03 (2C, Gal-C5, Gal'-C5), 75.31 (Sia-C6), 76.05
(Gal'-C3), 83.05 (Gal-C3), 100.20 (Sia-C2), 102.05 (Gal-C1), 104.46 (Gal'-C1),
127.50, 129.16, 132.50, 134.06 (6C, C6H5), 171.64, 174.10 (2×CO).
Methyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid) onate (98), (GG-292, I-292).
To a solution of 55 (500 mg, 0.960 mmol) and benzyl alcohol (198 µL, 1.92 mmol) in
CH3CN (10 mL) was added activated powdered molecular sieves 3Å (2.00 g). The
suspension was stirred at rt under argon for 5 h, then cooled to –35°C. After addition
of NIS (432 mg, 1.92 mmol) and TfOH (16.9 µL, 0.192 mmol), stirring was
continued for 16 h at –35°C. Then the mixture was diluted with DCM (20 mL) and
filtered through a pad of Celite. The Celite was washed with DCM (3×20 mL), and
the combined filtrates were washed with 20% aq. Na2S2O3 (2×30 mL), 5% KHCO3
(2×30 mL) and H2O (30 mL), dried over Na2SO4, filtrated and concentrated under
reduced pressure. The residue was purified by silica gel chromatography
(PE/DCM/iPrOH 8:4:1) to afford 98 (198 mg, 35%) as white foam, the NMR data of
which were in accordance with Lit.178
Methyl (benzyl 5-acetamido-3,5-dideoxy-D -g l y c e ro -α-D-galacto-2-
nonulopyranosid) onate (99), (GG-293, I-293).
To a solution of 98 (112 mg, 0.193 mmol) in MeOH (3.0 mL) was added freshly
prepared 1M NaOMe/MeOH (0.3 mL). The mixture was stirred at rt for 2h under
argon, then neutralized with Amberlite IRC 50 ion-exchange resin and filtered
through a pad of Celite. The Celite was washed with MeOH (3×5 mL) and the
combined filtrates were evaporated under reduced pressure. The residue was purified
by silica gel chromatography (2% gradient MeOH in DCM) to afford 99 (61.5 mg,
78%) as white foam, the NMR data of which were in accordance with Lit.178
Methyl (benzyl 5-acetamido-8,9-O-benzylidene-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosid) onate (100), (GG-294, I-295).
To a stirred solution of 99 (36.0 mg, 87.1 µmol) and α,α-dimethoxytoluene (26.0 µL,
174 µmol) in CH3CN (2 mL) at 0°C, TsOH·H2O (1.30 mg, 6.70 µmol) was added.
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The mixture was stirred at rt for 1.5 h and then quenched by adding a few drops of
Et3N. After concentration under reduced pressure, the residue (∼50 mg) was used
directly in the next step. The 1H NMR data of 100 showed a 1:1 mixture of exo/endo
isomers, which were in accordance with Lit.161
Methyl (benzyl 5-acetamido-9-O-benzyl-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid) onate (101), (GG-296, I-296).
100 (87.1 µmol), BH3⋅NMe3 (25.4 mg, 0.348 mmol) and AlCl3 were dissolved in THF
(2.0 mL) under argon. After 5 min, H2O (2.60 µL, 0.131 mmol) was added and the
mixture was stirred at rt for 4 h. Then the reaction was quenched by adding H2O (1
mL) and 0.1 N HCl (1 mL). The solution was extracted with DCM (10 mL) and
washed by 5% NaHCO3 (2×5 mL) followed by H2O (5 mL). The organic layer was
dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was
purified by silica gel chromatography (1% gradient MeOH in DCM) to afford 101
(34.8 mg, 70% 99→101) as white foam.
[α]D +4.8°, (c = 0.51, CH3OH); 1H NMR (500 MHz, CD3OD): δ 1.80 (t, J3a,3b = J3a,4 =
12.5 Hz, 1H, Sia-H3a), 2.00 (s, 3H, CH3-NHAc), 2.74 (dd, J3a,3b = 12.8, J3b,4 = 4.6 Hz,
1H, Sia-H3b), 3.60 (dd, J6,7 = 1.5, J7,8 = 8.9 Hz, 1H, Sia-H7), 3.63-3.69 (m, 3H, Sia-
H4, Sia-H6, Sia-H9a), 3.76 (s, 3H, CO2CH3), 3.78-3.83 (m, 2H, Sia-H5, Sia-H9b),
4.02 (ddd, J7,8 = 8.6, J8,9 = 2.3, 5.8 Hz, 1H,  Sia-H8), 4.50, 4.80 (A,B of AB, J = 11.7
Hz, 2H, PhCH2), 4.57, 4.59 (A, B of AB, 2H, PhCH2), 7.24-7.37 (m, 10H, 2×C6H5);
13C NMR (125 MHz, CD3OD): δ 22.57 (CH3-NHAc), 41.68 (Sia-C3), 53.21 (OCH3),
53.76 (Sia-C5), 67.19 (PhCH2), 68.42 (Sia-C4), 70.09 (Sia-C7), 71.34 (Sia-C8), 72.59
(Sia-C9), 74.35 (PhCH2), 74.83 (Sia-C6), 100.05 (Sia-C2), 128.50, 128.62, 128.75,
128.82, 129.18, 129.24, 138.76 (12C, 2×C6H5), 170.93, 175.10 (2×CO);
Anal. Calcd for C26H33NO9+1/2 H2O: C, 60.93; H, 6.69; N, 2.73. Found: C, 61.14; H,
6.62; N, 2.65.
Benzyl (sodium 5-acetamido-9-O -benzyl-3,5-dideoxy-D-glycero-D-galacto-2-
nonulopyranosid)onate (97), (GG-297, I-297).
To a solution of 101 (35.0 mg, 69.5 µmol) in H2O/dioxane (1:1, 4.0 mL) under argon
was added LiOH (16.8 mg, 69.5 µmol). The mixture was stirred at rt for 1.5 h, then
neutralized by 0.5% HCl and concentrated. The residue was purified by silica gel
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chromatography (10% gradient MeOH in DCM), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 97 as a
white solid (31.0 mg, 87%) after a final lyophilization from H2O.    
[α]D -16.1°, (c = 0.65, H2O); 1H NMR (500 MHz, D2O): δ 1.68 (t, J3a,3b = J3a,4 = 12.2
Hz, 1H, Sia-H3a), 2.03 (s, 3H, CH3-NHAc), 2.77 (dd, J3a,3b = 12.4, J3b,4 = 4.6 Hz, 1H,
Sia-H3b), 3.60-3.64 (m, 2H, Sia-H7, Sia-H9a), 3.67-3.73 (m, 2H, Sia-H4, Sia-H6),
3.78-3.82 (m, 2H, Sia-H5, Sia-H9b), 3.86 (ddd, J7,8 = 8.6, J8,9 = 2.0, 6.3 Hz, 1H, Sia-
H8), 4.49, 4.69 (A, B of AB, J = 11.0 Hz, 2H, PhCH2), 4.58, 4.61 (A, B of AB, J =
12.0 Hz, 2H, PhCH2), 7.35-7.46 (m, 10H, 2×C6H5);
13C NMR (125 MHz, D2O): δ 22.04 (CH3-NHAc), 40.52 (Sia-C3), 51.89 (Sia-C5),
67.13 (PhCH2), 68.23, 68.35 (Sia-C4, Sia-C7), 70.37 (Sia-C8), 70.81 (Sia-C9), 72.61
(Sia-C6), 73.04 (PhCH2), 100.95 (Sia-C2), 128.19, 128.26, 128.32, 128.65, 128.68.
128.72, 137.11, 137.52 (12C, 2×C6H5), 173.48, 175.07 (2×CO).
Methyl (3'-phenoxybenzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α and β-D-galacto-2-nonulopyranosid) onate (109α) and (109β), (GG-205-
2 and GG-205-1, I-205).
To a solution of 55 (86.8 mg, 0.166 mmol) and 3-phenoxybenzyl alcohol 108 (43.4
µL, 0.250 mmol) in CH3CN (6 mL) was added activated powdered molecular sieves
3Å (2.00 g). The reaction mixture was stirred at rt under argon for 5 h, then cooled to
–30°C. After addition of NIS (75.0 mg, 0.332 mmol) and TfOH (3.0 µL, 33.2 µmol),
stirring was continued for 16 h at –30°C. Then the mixture was diluted with DCM (20
mL) and filtered through a pad of Celite. The Celite was washed with DCM (3×10
mL), and the combined filtrates were washed with 20% aq. Na2S2O3 (30 mL), 5%
KHCO3 (2×20 mL) and H2O (20 mL), dried over Na2SO4, filtrated and concentrated
under reduced pressure. The residue was purified by silica gel chromatography (1%
gradient of MeOH in DCM) to afford 109α (66.0 mg, 58%) and 109β (26.5 mg, 23%)
as white foams.
109α: [α]D +2.5°, (c = 1.26, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.82 (s, 3H,
CH3-NHAc), 1.95 (m, 1H, Sia-H3a), 1.96, 1.97, 2.06, 2.08 (4s, 12H, 4×CH3-OAc),
2.57 (dd, J3a,3b = 12.8, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.62 (s, 3H, OCH3), 4.01 (q, J4,5 =
J5,6 = J5,NH = 10.8 Hz, 1H, Sia-H5), 4.03 (m, 1H, Sia-H9a), 4.07 (dd, J5,6 = 10.7, J6,7 =
2.1 Hz, 1H, Sia-H6), 4.22 (dd, J8,9b = 2.7, J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.32, 4.73
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(A,B of AB, J = 12.2 Hz, 2H, PhCH2), 4.81 (ddd, J3a,4 = 12.3, J3b,4 = 4.6, J4,5 = 10.0 Hz,
1H, Sia-H4), 5.12 (d, J5,NH = 10.8 Hz, 1H, Sia-NH), 5.27 (dd, J6,7 = 2.1, J7,8 = 8.6 Hz,
1H, Sia-H7), 5.37 (ddd, J7,8 = 8.4, J8,9a = 5.5, J8,9b = 2.7 Hz, 1H, Sia-H8), 6.82-7.28 (m,
9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 20.75, 20.79, 20.83, 21.12 (4×CH3-OAc), 23.19
(CH3-NHAc), 38.69 (Sia-C3), 49.44 (Sia-C5), 52.57 (CO2CH3), 62.33 (Sia-C9), 66.46
(Ph-CH2), 67.21 (Sia-C7), 68.37 (Sia-C4), 69.01 (Sia-C8), 72.49 (Sia-C6), 98.53 (Sia-
C2), 118.11, 118.34, 118.79, 122.58, 123.18, 129.53, 129.71, 139.28, 157.14, 157.18
(12C, C6H4, C6H5), 168.33, 170.04, 170.14, 170.21, 170.63, 171.01 (6×CO);
109β: [α]D –8.1°, (c = 0.82, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.81 (s, 3H, CH3-
NHAc), 1.86 (m, 1H, Sia-H3a), 1.89, 1.94, 1.95, 2.08 (4s, 12H, 4×CH3-OAc), 2.47
(dd, J3a,3b = 13.0, J3b,4 = 5.0 Hz, 1H, Sia-H3b), 3.67 (s, 3H, OCH3), 3.90 (dd, J5,6 = 10.5,
J6,7 = 2.2 Hz, 1H, Sia-H6), 4.03 (dd, J8,9a = 7.6, J9a,9b = 12.4 Hz, 1H, Sia-H9a), 4.08 (q,
J4,5 = J5,6 = J5,NH = 10.4 Hz, 1H, Sia-H5), 4.41, 4.46 (A, B of AB, J = 12.1 Hz, 2H,
PhCH2), 4.74 (dd, J8,9b = 2.5, J9a,9b = 12.4 Hz, 1H, Sia-H9b), 5.17 (m, 1H, Sia-H8), 5.21
(m, 1H, Sia-H4), 5.26 (d, J5,NH = 10.2 Hz, 1H, Sia-NH), 5.32 (dd, J6,7 = 2.2, J7,8 = 4.3
Hz, 1H, Sia-H7), 6.85-7.30 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 20.77, 20.85 (4C, 4×CH3-OAc), 23.14 (CH3-NHAc),
38.20 (Sia-C3), 48.31 (Sia-C5), 51.73 (CO2CH3), 62.32 (Sia-C9), 65.33 (PhCH2),
68.22 (Sia-C7), 68.85 (Sia-C4), 71.73, 71.85 (Sia-C6, Sia-C8), 98.54 (Sia-C2),
117.61, 118.06, 119.08, 121.97, 122.39, 129.79, 129.85, 138.69, 156.95, 157.48 (12C,
C6H4, C6H5), 170.28, 170.63, 170.96 (6C, 6×CO).
Sodium (3'-phenoxybenzyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid) onate (104α), (GG-208, I-208).
To a solution of 109α (66.0 mg, 98.0 µmol) in MeOH (4.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.5mL). The mixture was stirred at rt for 5 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type) and P2 size exclusion chromatography to afford 104α as a
white solid (30.0 mg, 60%) after a final lyophilization from H2O.   
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[α]D –27.3°, (c = 0.75, H2O); 1H NMR (500 MHz, D2O) δ 1.58 (t, J3a,3b = J3a,4 = 12.1
Hz, 1H, Sia-H3a), 1.94 (s, 3H, CH3-NHAc), 2.66 (dd, J3a,3b = 12.3, J3b,4 = 4.4 Hz, 1H,
Sia-H3b), 3.50 (m, 1H, Sia-H7), 3.52 (dd, J8,9a = 5.9, J9a,9b = 12.1 Hz, 1H, Sia-H9a),
3.58 (m, 1H, Sia-H4), 3.62 (m, 1H, Sia-H6), 3.66 (m, 1H, Sia-H8), 3.70-3.80 (m, 2H,
Sia-H5, Sia-H9b), 4.39, 4.62 (A, B of AB, J = 11.2 Hz, 2H, C6H4CH2), 6.91-6.92,
6.97-6.98, 7.09-7.16, 7.26-7.34 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 22.37 (CH3-NHAc), 40.79 (Sia-C3), 52.22 (Sia-C5),
62.84 (Sia-C9), 66.88 (C6H4CH2), 68.48 (Sia-C7), 68.64 (Sia-C4), 71.99 (Sia-C8),
73.06 (Sia-C6), 101.26 (Sia-C2), 118.83, 119.07, 119.29, 124.11, 124.25, 130.46,
130.56, 139.75, 157.00, 157.23  (12C, C6H4, C6H5), 173.81, 175.44 (2×CO).
Sodium (3'-phenoxybenzyl 5-acetamido-3,5-dideoxy-D-glycero-β-D-galacto-2-
nonulopyranosid) onate (104β), (GG-207, I-207).
To a solution of 109β (25.0 mg, 37.1 µmol) in MeOH (4.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.5mL). The mixture was stirred at rt for 5 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 104β as
a white solid (12.0 mg, 63%) after a final lyophilization from H2O.   
[α]D +7.8°, (c = 0.62, H2O); 1H NMR (500 MHz, D2O): δ 1.39 (dd, J3a,3b = 13.0, J3a,4 =
11.6 Hz, 1H, Sia-H3a), 1.75 (s, 3H, CH3-NHAc), 2.10 (dd, J3a,3b = 13.1, J3b,4 = 4.9 Hz,
1H, Sia-H3b), 3.25 (d, J5,6 = 9.6 Hz, 1H, Sia-H6), 3.38 (dd, J8,9a = 5.5, J9a,9b = 12.0 Hz,
1H, Sia-H9a), 3.53 (dd, J8,9a = 2.7, J9a,9b = 12.0 Hz, 1H, Sia-H9b), 3.59-3.63 (m, 3H,
Sia-H5, Sia-H7, Sia-H8), 3.75 (m, 1H, Sia-H4), 3.98, 4.28 (A, B of AB, J = 10.4 Hz,
2H, C6H4CH2), 6.73-6.75, 6.79-6.81, 6.86, 6.91-6.97, 7.11-7.16 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, D2O): δ 22.27 (CH3-NHAc), 40.84 (Sia-C3), 52.69 (Sia-C5),
64.14 (Sia-C9), 65.11 (C6H4CH2), 67.68 (Sia-C4), 68.88 (Sia-C7), 70.61 (Sia-C6),
71.02 (Sia-C8), 100.78 (Sia-C2), 119.12, 119.54, 119.63, 124.56, 124.61, 130.83,
130.93, 140.10, 157.40, 157.60  (12C, C6H4, C6H5), 175.81 (2C, 2×CO).
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Methyl (4'-biphenylmethyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α and β-D-galacto-2-nonulopyranosid) onate (111α) and (111β), (GG-198-
2 and GG-198-1, I-198).
To a solution of 55 (94.4 mg, 0.181 mmol) and 4-biphenyl-methanol 110 (50.0 mg,
0.271 mmol) in CH3CN (6 mL) was added activated powdered molecular sieves 3Å
(2.00 g). The reaction mixture was stirred at rt under argon for 5 h, then cooled to
–30°C. After addition of NIS (81.4 mg, 0.362 mmol) and TMSOTf (6.5 µL, 36.2
µmol), stirring was continued for 16 h at –30°C. Then the mixture was diluted with
DCM (20 mL) and filtered through a pad of Celite. The Celite was washed with DCM
(3×10 mL), and the combined filtrates were washed with 20% aq. Na2S2O3 (30 mL),
5% KHCO3 (2×20 mL) and H2O (20 mL), dried over Na2SO4, filtered and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (toluene/AcOEt 2:1) to afford 111α (75.0 mg, 63%) and 111β (24.5
mg, 21%) as white foams.
111α: [α]D +5.5°, (c = 0.87, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.82, 1.96, 1.98,
2.08, 2.11 (5s, 15H, CH3-NHAc, 4×CH3-OAc), 1.99 (m, 1H, Sia-H3a), 2.61 (dd, J3a,3b
= 12.8, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.63 (s, 3H, OCH3), 4.01-4.07 (m, 2H, Sia-H5,
Sia-H9a), 4.09 (dd, J5,6 = 12.7, J6,7 = 2.1 Hz, 1H, Sia-H6), 4.28 (dd, J8,9b = 2.7, J9a,9b =
12.4 Hz, 1H, Sia-H9b), 4.40, 4.79 (A of AB, J = 12.0 Hz, 1H, C6H4CH2), 4.82 (ddd,
J3a,4 = 12.3, J3b,4 = 4.6, J4,5 = 9.9 Hz, 1H, Sia-H4), 5.20 (d, J5,NH = 9.7 Hz, 1H, Sia-NH),
5.29 (dd, J6,7 = 2.0, J7,8 = 8.5 Hz, 1H, Sia-H7), 5.37 (ddd, J7,8 = 8.4, J8,9a = 5.6, J8,9b = 2.7
Hz, 1H, Sia-H8), 7.26-7.29, 7.33-7.38, 7.49-7.52 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 20.76, 20.82, 20.84, 21.14, 23.17 (CH3-NHAc,
4×CH3-OAc), 38.11 (Sia-C3), 49.42 (Sia-C5), 52.65 (CO2CH3), 62.39 (Sia-C9), 66.59
(C6H4CH2), 67.27 (Sia-C7), 68.51 (Sia-C8), 68.07 (Sia-C4), 72.51 (Sia-C6), 98.53
(Sia-C2), 126.99, 127.03, 127.27, 128.32, 128.74, 129.00, 136.12, 140.66, 140.84
(12C, C6H4,  C6H5), 168.39, 170.12, 170.15, 170.25, 170.66, 171.02 (6×CO);
111β: [α]D –15.5°, (c = 0.8, CHCl3); 1H NMR (500 MHz, CDCl3): δ 1.88 (dd, J3a,3b =
13.0, J3a,4 = 11.6 Hz, 1H, Sia-H3a), 1.81, 1.91, 1.95, 1.98, 2.09 (5s, 15H, CH3-NHAc,
4×CH3-OAc), 2.51 (dd, J3a,3b = 13.0, J3b,4 = 5.0 Hz, 1H, Sia-H3b), 3.68 (s, 3H, OCH3),
3.96 (dd, J5,6 = 10.5, J6,7 = 2.2 Hz, 1H, Sia-H6), 4.06 (dd, J8,9a = 7.8, J9a,9b = 12.4 Hz,
1H, Sia-H9a), 4.08 (q, J4,5 = J5,6 = J5,NH = 10.3 Hz, 1H, Sia-H5), 4.48, 4.53 (A, B of
AB, J = 11.9 Hz, 2H, C6H4CH2), 4.80 (dd, J8,9b = 2.5, J9a,9b = 12.4 Hz, 1H, Sia-H9b),
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5.21-5.28 (m, 2H, Sia-H4, Sia-H8), 5.32 (d, J5,NH = 10.2 Hz, 1H, Sia-NH), 5.35 (dd,
J6,7 = 2.2, J7,8 = 4.1 Hz, 1H, Sia-H7), 7.27-7.54 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 20.79, 20.82, 20.87, 20.92, 23.13 (4×CH3-OAc, CH3-
NHAc), 37.42 (Sia-C3), 49.38 (Sia-C5), 52.73 (CO2CH3), 60.40 (Sia-C9), 65.55
(C6H4CH2), 68.39 (Sia-C7), 68.99 (Sia-C8), 71.88 (2C, Sia-C4, Sia-C6), 98.52 (Sia-
C2), 127.07, 127.25, 127.40, 127.98, 128.79, 135.57, 140.68, 140.92 (12C, C6H4,
C6H5), 167.38, 170.15, 170.30, 170.64, 170.75, 171.02 (6×CO).
Sodium (4'-biphenylmehtyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid) onate (106α), (GG-200, I-200).
To a solution of 111α (51.3 mg, 78.0 µmol) in MeOH (4.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.5mL). The mixture was stirred at rt for 5 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 106α as
a white solid (23.0 mg, 60%) after a final lyophilization from H2O.   
[α]D –22.4°, (c = 0.74, H2O); 1H NMR (500 MHz, D2O): δ 1.42 (t, J3a,3b = J3a,4 = 12.1
Hz, 1H, Sia-H3a), 1.74 (s, 3H, CH3-NHAc), 2.50 (dd, J3a,3b = 12.4, J3b,4 = 4.6 Hz, 1H,
Sia-H3b), 3.30 (dd, J6,7 = 1.8, J7,8 = 9.4 Hz, 1H, Sia-H7), 3.32 (dd, J8,9a = 5.8, J9a,9b =
12.1 Hz, 1H, Sia-H9a), 3.58 (m, 3H, Sia-H4, Sia-H6, Sia-H8), 3.52 (dd, J8,9a = 2.3,
J9a,9b = 12.0 Hz, 1H, Sia-H9b), 3.54 (t, J4,5 = J5,6 = 10.1 Hz, 1H, Sia-H5), 4.27, 4.47 (A,
B of AB, J = 11.3 Hz, 2H, C6H4CH2), 7.11-7.14, 7.17-7.25, 7.36-7.40 (m, 9H, C6H4,
C6H5);
13C NMR (125 MHz, CDCl3): δ 22.37 (CH3-NHAc), 40.91 (Sia-C3), 52.25 (Sia-C5),
62.79 (Sia-C9), 67.22 (C6H4CH2), 68.45 (Sia-C7), 68.67 (Sia-C4), 71.99 (Sia-C8),
73.09 (Sia-C6), 101.46 (Sia-C2), 127.30, 127.38, 128.13, 129.49, 129.66, 136.91,
140.55, 140.64 (12C, C6H4, C6H5), 174.00, 175.05 (2×CO).
Sodium (4'-biphenylmethyl 5-acetamido-3,5-dideoxy-D-glycero-β-D-galacto-2-
nonulopyranosid) onate (106β), (GG-202, I-202).
To a solution of 111β (24.5 mg, 37.3 µmol) in MeOH (4.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.5mL). The mixture was stirred at rt for 5 h under
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argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 106β as
a white solid (10.5 mg, 57%) after a final lyophilization from H2O.   
[α]D +21.2°, (c = 0.70, H2O); 1H NMR (500 MHz, D2O): δ 1.53 (t, J3a,3b = J3a,4 = 12.3
Hz, 1H, Sia-H3a), 1.87 (s, 3H, CH3-NHAc), 2.24 (dd, J3a,3b = 13.2, J3b,4 = 4.9 Hz, 1H,
Sia-H3b), 3.41 (d, J7,8 = 9.7 Hz, 1H, Sia-H7), 3.51 (dd, J8,9a = 5.6, J9a,9b = 12.0 Hz, 1H,
Sia-H9a), 3.69 (dd, J8,9a = 2.3, J9a,9b = 12.0 Hz, 1H, Sia-H9b), 3.73-3.80 (m, 2H, Sia-
H5, Sia-H8), 3.83 (d, J5,6 = 10.5 Hz, 1H, Sia-H6), 3.90 (m, 1H, Sia-H4), 4.15, 4.47
(A,B of AB, J = 10.2 Hz, 2H, C6H4CH2), 7.24-7.27, 7.33-7.39, 7.52-7.53 (m, 9H,
C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 22.48 (CH3-NHAc), 40.31 (Sia-C3), 52.43 (Sia-C5),
63.96 (Sia-C9), 64.97 (C6H4CH2), 67.39 (Sia-C4), 68.63 (Sia-C7), 70.36 (Sia-C8),
70.68 (Sia-C6), 100.50 (Sia-C2), 127.33, 127.46, 128.17, 129.52, 129.79, 136.88,
140.56, 140.71 (12C, C6H4, C6H5), 175.15, 175.62 (2×CO).
Methyl (4'-phenoxyphenyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranoside) onate (113α), (GG-214, I-214).
To a solution of 8 (100 mg, 0.196 mmol) in CHCl3 (5 mL) at rt was added 4-
phenoxyphenol 112 (183 mg, 0.981 mmol) dissolved in 0.2M aq. NaOH (5 mL),
followed by benzyltriethylammonium chloride (98.0 mg, 0.431 mmol). The reaction
mixture was stirred vigorously at 100°C for 2 h, then diluted with DCM (20 mL),
washed with 0.1M NaOH (2×10 mL), H2O (2×10 mL), and dried over Na2SO4. After
filtration and concentration under reduced pressure, the residue was purified by silica
gel chromatography (0.25% gradient of MeOH in DCM) to afford 113α (78.0 mg,
60%) as white foam.
[α]D -2.2° (c = 1.12, CHCl3); 1H NMR (500 Hz, CDCl3): δ 1.83 (s, 3H, CH3-NHAc),
1.95, 1.97, 2.05, 2.06 (4s, 12H, 4×CH3-OAc), 2.12 (t, J3a,3b = J3a,4 = 12.6 Hz, 1H, Sia-
H3a), 2.64 (dd, J3a,3b = 12.9, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.62 (s, 3H, OCH3), 4.02 (q,
J4,5 = J5,6 = J5,NH = 10.4 Hz, 1H, Sia-H5), 4.09 (dd, J8,9a = 4.7, J9a,9b = 12.2 Hz, 1H, Sia-
H9a), 4.24-4.27 (m, 2H, Sia-H6, Sia-H9b), 4.88 (ddd, J3b,4 = 4.6, J3a,4 = 12.2, J4,5 = 10.5
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Hz, 1H, Sia-H4), 5.25 (d, J5,NH = 10.1 Hz, 1H, Sia-NH), 5.27-5.31 (m, 2H, Sia-H7,
Sia-H8), 6.85-6.87, 6.89-6.92, 6.96-7.02, 7.23-7.26 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 20.72, 20.82, 20.94 (4C, 4×CH3-OAc), 23.17 (CH3-
NHAc), 37.74 (Sia-C3), 49.31 (Sia-C5), 52.88 (OCH3), 62.04 (Sia-C9), 67.40 (Sia-
C7), 68.86 (Sia-C4), 69.31 (Sia-C8), 73.29 (Sia-C6), 100.33 (Sia-C2), 118.28, 119.85,
122.01, 122.95 129.66, 149.35, 153.54, 157.80  (12C, C6H4, C6H5), 167.77, 169.95,
169.98, 170.25, 170.59, 170.92 (6×CO);
HRMS (FAB): Calcd for C32H37NO14 (M+Na)+: 682.2214; Found m/z 682.2212.
Sodium (4'-phenoxyphenyl 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosid) onate (105α), (GG-215, I-215).
To a solution of 113α (55.9 mg, 84.7 µmol) in MeOH (4.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.5mL). The mixture was stirred at rt for 5 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 105α as
a white solid (34.1 mg, 81%) after a final lyophilization from H2O.   
[α]D +29.4° (c = 0.85, H2O); 1H NMR (500 Hz, D2O): δ 1.73 (t, J3a,3b = J3a,4 = 11.9 Hz,
1H, Sia-H3a), 1.85 (s, 3H, CH3-NHAc), 2.73 (dd, J3a,3b = 12.2, J3b,4 = 3.6 Hz, 1H, Sia-
H3b), 3.41-3.45 (m, 2H, Sia-H7, Sia-H9a), 3.56 (m, 1H, Sia-H4), 3.61-3.74 (m, 4H,
Sia-H5, Sia-H6, Sia-H8, Sia-H9b), 6.78-6.80, 6.84-6.85, 6.97-6.99, 7.19-7.22 (m, 9H,
C6H4, C6H5);
13C NMR (125 MHz, D2O): δ 22.16 (CH3-NHAc), 40.80 (Sia-C3), 51.67 (Sia-C5),
62.17 (Sia-C9), 68.31 (2C, Sia-C4, Sia-C7), 72.07 (Sia-C8), 73.35 (Sia-C6), 103.00
(Sia-C2), 118.51, 119.79, 123.51, 123.71, 130.17, 149.67, 153.31, 157.24  (12C,
C6H4, C6H5), 172.64, 175.22 (2×CO).
Methyl 4-(4',4',5',5'-tetramethyl-1',2',3'-dioxaborolan-2'-yl)-phenylacetate (115),
(GG-2-006, II-006, 008).
To a solution of 4-bromophenylacetic acid 116 (700 mg, 3.25 mmol) in MeOH (20
mL) at rt was added CAN (2.68 g, 4.88 mmol). The mixture was stirred for 16 h, and
then evaporated under reduced pressure. The residue was diluted by DCM (50mL),
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washed with H2O (2×30 mL), and dried over Na2SO4. After filtration and
concentration, methyl 4-bromophenylacetate (660 mg, 90%) was obtained as colorless
oil. Without purification, methyl 4-bromophenylacetate (150 mg, 655 µmol) was
added to a MW tube together with bis(pinacolato)diboron (200 mg, 786 µmol), dry
KOAc (193 mg, 1.96 mmol), PdCl2(dppf) (16.0 mg, 19.7 µmol) and dppf (10.9 mg,
19.7 µmol), and dried under HV for 15 min.  Then dioxane (5 mL) was added under
argon, and the mixture was sonicated for 15 min and irradiated at 120°C for 1.5 h.
The reaction was then evaporated under reduced pressure, and the residue was diluted
with DCM (50 mL), washed with H2O (2×50 mL), dried over Na2SO4, filtered and
concentrated under reduced pressure. The residue was purified by silica gel
chromatography (1% gradient of AcOEt in toluene) to afford 115 (91.6 mg, 50%) as
white foam.
1H NMR (500 Hz, CDCl3): δ 1.33 (s, 12H, 4×CH3), 3.64 (s, 2H, CH2Ph), 3.68 (s, 3H,
OCH3), 7.29, 7.77 (AA', BB' of AA'BB', J=8.0 Hz, 4H, C6H4).
Methyl 4-[3-O-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-
α-D-galacto-2-nonulopyranosynate)-phenyl]-phenylacetate (117) and sodium 4-
[3-O - ( s o d i u m  5 - a c e t a m i d o - 3 , 5 - d i d e o x y - D -g l y c e r o -α-D-galacto-2-
nonulopyranosynate)-phenyl]-phenylacetate (107), (GG-2-013-3 and GG-2-013-
10, II-013).
114196 (149 mg, 0.230 mmol), BHT (35.5 mg, 0.160 mmol), dry K3PO4 (146.5 mg,
0.690 mmol), PdCl2(dppf) (5.60 mg, 6.90 µmol) and dppf (3.80 mg, 6.90 µmol) were
added to a MW tube, and dried under HV at 60°C for 15 min.  Then 115 (70.0 mg,
0.254 mmol) and dioxane (5 mL) were added under argon. The mixture was sonicated
for 20 min, and irradiated at 170°C for 2.25 h. The reaction was evaporated under
reduced pressure, and the residue was diluted with DCM (50 mL) and washed with
H2O (2×50 mL). The organic layer was dried over Na2SO4, filtered and concentrated
under reduced pressure. The residue was purified by silica gel chromatography
(PE/AcOEt 3:1 to 1:6) to afford 117 (12.5 mg, 8%) as white foam. The H2O layer was
concentrated under reduce pressure to give a brown solid, which was stirred with cold
MeOH (10 mL). After filtration and concentration under reduced pressure, the residue
was purified by silica gel chromatography (MeOH/H2O 10:1), RP chromatography
(5% gradient MeOH in H2O), Dowex ion-exchange chromatography (Na+ type), and
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P2 size exclusion chromatography to afford 107 as a white solid (4.00 mg, 3%) after a
final lyophilization from H2O.
117: [α]D +11.4° (c = 0.67, CHCl3); 1H NMR (500 Hz, CDCl3): δ 1.90 (s, 3H, CH3-
NHAc), 2.01, 2.02, 2.03, 2.11 (4s, 12H, 4×CH3-OAc), 2.20 (t, J3a,3b = J3a,4 = 12.6 Hz,
1H, Sia-H3a), 2.69 (dd, J3a,3b = 13.0, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.66 (s, 2H,
C6H4CH2), 3.70, 3.71 (2s, 6H, 2×OCH3), 4.06 (q, J4,5 = J5,6 = J5,NH = 10.4 Hz, 1H, Sia-
H5), 4.18 (dd, J8,9a = 5.5, J9a,9b = 12.5 Hz, 1H, Sia-H9a), 4.33-4.36 (m, 2H, Sia-H6, Sia-
H9b), 4.99 (ddd, J3b,4 = 4.7, J3a,4 = 12.1, J4,5 = 10.4 Hz, 1H, Sia-H4), 5.24 (d, J5,NH =
10.1 Hz, 1H, Sia-NH), 5.34 (dd, J6,7 = 1.9, J7,8 = 7.7 Hz, 1H, Sia-H7), 5.40 (m, 1H,
Sia-H8), 7.08-7.10, 7.29-7.30, 7.33-7.35, 7.54-7.55 (m, 8H, C6H4, C6H4);
13C NMR (125 MHz, CDCl3): δ 20.60, 20.77, 20.88, 20.99 (4×CH3-OAc), 23.24
(CH3-NHAc), 37.56 (Sia-C3), 40.83 (C6H4CH2), 49.46 (Sia-C5), 52.13 (OCH3), 62.01
(Sia-C9), 67.47 (Sia-C7), 68.89 (Sia-C4), 69.52 (Sia-C8), 73.39 (Sia-C6), 100.12
(Sia-C2), 119.23, 119.59, 122.98, 127.29, 129.72, 129.74, 133.35, 139.28, 142.03,
153.81  (12C, C6H4, C6H4), 160.08. 170.06, 170.08, 170.26, 170.62, 170.97 (6×
CO);
107: [α]D +12.5° (c = 0.26, H2O); 1H NMR (500 Hz, D2O): δ 1.96 (t, J3a,3b = J3a,4 = 12.2
Hz, 1H, Sia-H3a), 2.04 (s, 3H, CH3-NHAc), 2.86 (dd, J3a,3b = 12.5, J3b,4 = 4.7 Hz, 1H,
Sia-H3b), 3.41-3.45 (m, 2H, Sia-H7, Sia-H9a), 3.57 (s, 2H, C6H4CH2), 3.60-3.65 (m,
2H, Sia-H7, Sia-H9a), 3.75 (ddd, J3b,4 = 4.7, J3a,4 = 12.0, J4,5 = 9.2 Hz, 1H, Sia-H4),
3.80 (dd, J8,9b = 2.4, J9a,9b = 12.1 Hz, 1H, Sia-H9b), 3.87-3.94 (m, 3H, Sia-H5, Sia-H6,
Sia-H8), 7.12-7.14, 7.38, 7.40-7.50, 7.63 (m, 8H, C6H4, C6H4);
13C NMR (125 MHz, CDCl3): δ  22.31 (CH3-NHAc), 41.29 (Sia-C3), 44.41
(C6H4CH2), 52.05 (Sia-C5), 62.94 (Sia-C9), 68.38 (2C, Sia-C4, Sia-C7), 72.31 (Sia-
C8), 73.67 (Sia-C6), 103.12 (Sia-C2), 120.13, 120.52, 123.20, 127.29, 130.06,
130.16, 138.29, 141.86, 153.33, 154.59  (12C, C6H4, C6H4).
Methyl (4'-phenoxyphenyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α and β-D-galacto-2-nonulopyranosid)onate (113α) and (113β), (GG-214
and GG-209-1, I-268).
DEAD (47.5 µL, 0.3 mmol) was added to a stirred solution of 118 (100 mg, 0.204
mmol), Ph3P (80.0 mg, 0.306 mmol) and 4-phenoxyphenol 112 (75.8 mg, 0.408
mmol) in dry CH3CN (6 mL) at 0°C under argon. The reaction mixture was stirred at
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0°C for 3 h, diluted with DCM (15 mL) and filtered through a pad of Celite. The
Celite was washed with DCM (3×5 mL), and the combined filtrates were concentrated
under reduced pressure, dried at HV. A catalytic amount of RuCl3·H2O was added to a
vigorously stirred biphasic solution of the residue in NaIO4 (~100 mg), CCl4 (0.8 mL),
CH3CN (0.8 mL) and H2O (1.2 mL). After 5 min at rt the thick, yellowish-green
mixture was diluted with DCM (25 mL), and washed with H2O (2×10 mL). The
organic layer was dried over Na2SO4, filtered and concentrated under reduced
pressure. The residue was purified by flash chromatography on silica gel (0.25%
gradient MeOH in DCM) to afford 113 (101mg, 75%, α:β =76:24) as white foam.
The diastereomeric mixture of 113 could be separated by silica gel chromatography
(5% gradient EtOAc in toulene), yielding 113α (60.0 mg, 45%) and 113β (16.0 mg,
12%) as white foams. The data of 113α were in accordance with the data obtained
above.
113β: [α]D -31.3° (c = 0.74, CHCl3); 1H NMR (500 Hz, CDCl3): δ 1.72, 1.73, 1.83,
1.91, 2.01 (5s, 15H, 4×CH3-OAc, CH3-NHAc), 1.85 (m, 1H, Sia-H3a), 2.52 (dd, J3a,3b
= 12.9, J3b,4 = 4.9 Hz, 1H, Sia-H3b), 3.60 (s, 3H, OCH3), 3.96 (dd, J5,6 = 10.6, J6,7 = 2.3
Hz, 1H, Sia-H6), 4.00 (dd, J8,9a = 7.1, J9a,9b = 12.6 Hz, 1H, Sia-H9a), 4.08 (dd, J4,5 = J5,6
= J5,NH = 10.4 Hz, 1H, Sia-H5), 4.55 (dd, J8,9b = 2.2, J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.75
(ddd, J7,8 = 3.9, J8,9a = 7.1, J8,9b = 2.2 Hz, 1H, Sia-H8), 5.23(dd, J6,7 = 2.3, J7,8 = 3.9 Hz,
1H, Sia-H7), 5.29(d, J5,NH = 10.2 Hz, 1H, Sia-NH), 5.32 (td, J3a,4 = J4,5 = 11.1, J3b,4 =
4.9, 1H, Sia-H4), 6.74-6.76, 6.80-6.91, 6.91-6.94, 7.15-7.18 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, CDCl3): δ 19.69, 19.75, 19.81. 19.88 (4×CH3-OAc), 22.13
(CH3-NHAc), 37.34 (Sia-C3), 48.12 (Sia-C5), 52.14 (OCH3), 61.17 (Sia-C9), 67.17
(Sia-C7), 67.51 (Sia-C4), 71.21 (Sia-C8), 71.54 (Sia-C6), 98.18 (Sia-C2), 117.21,
117.29, 119.29. 122.01, 128.79, 148.44, 151.38, 156.56  (12C, C6H4, C6H5), 166.29,
169.11. 169.28, 169.47, 169.60, 170.03 (6×CO);
HRMS (FAB): Calcd for C32H37NO14 (M+Na)+: 682.2214; Found m/z 682.2225.
Sodium (4'-phenoxyphenyl 5-acetamido-3,5-dideoxy-D-glycero-β-D-galacto-2-
nonulopyranosid) onate (105β), (GG-210, I-210).
To a solution of 113β (14.8 mg, 22.4 µmol) in MeOH (4.5 mL) was added freshly
prepared 1M NaOMe/MeOH (0.5mL). The mixture was stirred at rt for 5 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
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solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 105β as
a white solid (10.6 mg, 95%) after a final lyophilization from H2O.   
[α]D –45.5° (c = 0.73, H2O); 1H NMR (500 Hz, D2O): δ 1.65 (dd, J3a,3b = 13.0, J3a,4 =
11.5 Hz, 1H, Sia-H3a), 1.89 (s, 3H, CH3-NHAc), 2.41 (dd, J3a,3b = 13.1, J3b,4 = 4.9 Hz,
1H, Sia-H3b), 3.31 (d, J7,8 = 9.3 Hz, 1H, Sia-H7), 3.44 (dd, J8,9a = 5.5, J9a,9b = 11.8 Hz,
1H, Sia-H9a), 3.55 (m, 1H, Sia-H8), 3.59 (dd, J8,9a = 2.6, J9a,9b = 11.8 Hz, 1H, Sia-
H9b), 3.63 (d, J5,6 = 10.5 Hz, 1H, Sia-H6), 3.85 (t, J4,5 = J5,6 = 10.3 Hz, 1H, Sia-H5),
4.12 (ddd, J3b,4 = 4.9, J3a,4 = 11.2, J4,5 = 10.3 Hz, 1H, Sia-H4), 6.85, 6.89, 6.92-6.94,
6.99-7.02, 7.23-7.26 (m, 9H, C6H4, C6H5);
13C NMR (125 MHz, D2O): δ 22.47 (CH3-NHAc), 41.00 (Sia-C3), 52.22 (Sia-C5),
63.48 (Sia-C9), 67.17 (Sia-C4), 68.71 (Sia-C7), 72.61 (Sia-C8), 71.47 (Sia-C6),
100.85 (Sia-C2), 118.30, 118.35, 120.66, 122.93, 123.68, 125.72, 126.19, 130.37,
150.97, 151.11, 157.91 (12C, C6H4, C6H5), 175.12, 175.18 (2×CO).
Methyl (3'-phenylacetylene 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranoside)onate (124), (GG-300, I-300).
To a solution of 8  (295 mg, 0.579 mmol) in CHCl3 (10 mL) was added 3-
hydroxyphenylacetylene 123 (0.300 mL, 2.89 mmol) dissolved in 0.2M aq. NaOH (10
mL) at rt, followed by benzyltriethylammonium chloride (290 mg, 1.27 mmol). The
reaction mixture was stirred vigorously at 100°C for 2 h, then diluted with DCM (30
mL), washed with 0.1M NaOH (2×20 mL), H2O (2×20 mL) and dried over Na2SO4.
After filtration and concentration under reduced pressure, the residue was purified by
silica gel chromatography (0.5% gradient of MeOH in DCM) to afford 124 (205 mg,
60%) as white foam.
[α]D +13.1° (c = 0.90, CHCl3); 1H NMR (500 Hz, CDCl3): δ 1.91 (s, 3H, CH3-NHAc),
2.04, 2.05, 2.13, 2.14 (4s, 12H, 4×CH3-OAc), 2.21 (m, 1H, Sia-H3a), 2.64 (dd, J3a,3b =
13.0, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.07 (s, 1H, C≡CH), 3.70 (s, 3H, OCH3), 4.08 (q,
J4,5 = J5,6 = J5,NH = 10.4 Hz, 1H, Sia-H5), 4.19 (dd, J8,9a = 4.9, J9a,9b = 12.4 Hz, 1H, Sia-
H9a), 4.32-4.37 (m, 2H, Sia-H6, Sia-H9b), 4.97 (ddd, J3b,4 = 4.7, J3a,4 = 11.9, J4,5 = 10.5
Hz, 1H, Sia-H4), 5.34-5.38 (m, 2H, Sia-H7, Sia-H8), 5.40 (d, J5,NH = 10.2 Hz, 1H, Sia-
NH), 7.11-7.28 (m, 4H, C6H4);
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13C NMR (125 MHz, CDCl3): δ 20.56, 20.60, 20.66, 20.79 (4×CH3-OAc), 23.01
(CH3-NHAc), 37.39 (Sia-C3), 49.16 (Sia-C5), 52.86 (OCH3), 61.92 (Sia-C9), 67.19
(Sia-C7), 68.58 (Sia-C4), 69.18 (Sia-C8), 73.22 (Sia-C6), 82.79 (C≡CH), 99.89 (Sia-
C2), 120.96, 124.06, 127.91, 129.24, (4C, C6H4-CH), 122.93, 153.10 (3C, C6H4-C,
C≡CH), 167.66, 169.86, 169.90, 170.08, 170.44, 170.74 (6×CO);
Anal. Calcd for C28H33NO13: C, 56.85; H, 5.62; N, 2.37. Found: C, 56.24; H, 5.52; N,
2.37.
Sodium (3'-phenylacetylene 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranoside) onate (131), (GG-2-027, II-027).
To a solution of 124 (45.0 mg, 76.1 µmol) in MeOH (2.0 mL) was added freshly
prepared 1M NaOMe/MeOH (0.2mL). The mixture was stirred at rt for 3 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 2 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 131 as a
white solid (27.5 mg, 84%) after a final lyophilization from H2O.   
[α]D +24.3° (c = 0.91, H2O); 1H NMR (500 Hz, D2O): δ 1.92 (t, J3a,3b = J3a,4 = 12.2 Hz,
1H, Sia-H3a), 2.03 (s, 3H, CH3-NHAc), 2.88 (dd, J3a,3b = 12.5, J3a,4 = 4.7 Hz, 1H, Sia-
H3b), 3.49 (s, 1H, C≡CH), 3.60 (dd, J6,7 = 1.5, J7,8 = 9.2 Hz, 1H, Sia-H7), 3.63 (dd,
J8,9a = 6.3, J9a,9b = 12.2 Hz, 1H, Sia-H9a), 3.74 (ddd, J3a,4 = 11.8, J3b,4 = 4.7, J4,5 = 9.6 Hz,
1H, Sia-H4), 3.84-3.93 (s, 4H, Sia-H5, Sia-H6, Sia-H8, Sia-H9b), 7.18-7.22, 7.31-
7.32 (m, 4H, C6H4);
13C NMR (125 MHz, D2O): δ 22.39 (CH3-NHAc), 41.11 (Sia-C3), 52.09 (Sia-C5),
62.95 (Sia-C9), 68.45, 68.51 (Sia-C4, Sia-C7), 72.32 (Sia-C8), 73.72 (Sia-C6), 78.74
(C≡CH), 103.08 (Sia-C2), 122.60 (C≡CH), 122.94, 125.45, 128.64, 129.92, 153.88
(6C, C6H4), 172.83, 175.46 (2×CO).
4-{4-[3-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-D-
galacto-2-nonulopyranosynate-2-O-yl)-phenyl]-1H-(1,2,3) triazole-1-yl}-benzoic
acid (128), (GG-2-001, I-001).
To a suspension of 124 (40.0 mg, 67.6 µmol) and 4-azidobenzoic acid 125 (11.0 mg,
67.6 µmol) in tBuOH (0.5 mL) and H2O (0.5 mL) was added sodium ascorbate (6.7
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µmol, 6.7 µL of a freshly prepared 1M solution in H2O), followed by CuSO4⋅5H2O
(0.170 mg, 0.676 µmol, in 5 µL of H2O). The heterogeneous mixture was stirred
vigorously at rt for 20 h, during which one additional portion of sodium ascorbate (6.7
µmol, 6.7 µL) and CuSO4⋅5H2O (0.170 mg, 0.676 µmol) were added according to
TLC. Then diluted with DCM (10 mL), washed with H2O (2×5 mL), and dried over
Na2SO4. After filtration and concentration under reduced pressure, the residue was
purified by silica gel chromatography (1% gradient of MeOH in DCM) to afford 128
(38.0 mg, 75%) as white foam.
[α]D +13.9° (c = 0.73, CH3OH); 1H NMR (500 Hz, CD3OD): δ 1.69 (s, 3H, CH3-
NHAc), 1.77, 1.83, 1.88, 1.93 (4s, 12H, 4×CH3-OAc), 1.96 (m, 1H, Sia-H3a), 2.64
(dd, J3a,3b = 12.9, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.51 (s, 3H, OCH3), 3.86 (t, J4,5 = J5,6 =
10.5 Hz, 1H, Sia-H5), 3.97 (dd, J8,9a = 5.1, J9a,9b = 12.5 Hz, 1H, Sia-H9a), 4.14 (dd, J8,9b
= 2.6, J9a,9b = 12.5 Hz, 1H, Sia-H9b), 4.28 (dd, J5,6 = 10.8, J6,7 = 1.2 Hz, 1H, Sia-H6),
5.19 (dd, J6,7 = 1.4, J7,8 = 8.8 Hz, 1H, Sia-H7), 5.24 (m,1H, Sia-H8), 6.94 (dd, J = 2.2,
J = 8.2 Hz, 1H, Ar1-H4), 7.19 (t, J = 8.0 Hz, 1H, Ar1-H5), 7.42 (s, 1H, Ar1-H2), 7.48
(d, J = 7.8 Hz, 1H, Ar1-H6), 7.85, 8.04 (AA', BB' of AA'BB', J = 8.6 Hz, 2H, 4×Ar3-
CH), 8.81 (s, 1H, Ar2-H5);
13C NMR (125 MHz, CD3OD): δ 20.65, 20.74, 20.80, 21.06 (4×CH3-OAc), 22.70
(CH3-NHAc), 39.32 (Sia-C3), 50.04 (Sia-C5), 53.53 (OCH3), 63.17 (Sia-C9), 68.64
(Sia-C7), 70.14 (Sia-C4), 70.37 (Sia-C8), 74.14 (Sia-C6), 101.56 (Sia-C2), 118.99
(Ar1-C2), 120.57 (Ar2-C5), 120.94 (2C, Ar3-C3, C5), 121.43 (Ar1-C4), 122.63 (Ar1-
C6), 131.13 (Ar1-C5), 132.47 (2C, Ar3-C2, C6), 141.15, 149.12, 155.71 (5C, ipso-C),
169.29, 171.60, 171.85, 171.92, 172.49, 173.59 (7C, 7×CO);
Anal. Calcd for C35H38N4O15+2H2O: C, 53.16; H, 5.35; N, 7.09. Found: C, 53.61; H,
5.20; N, 6.94.
Sodium 4-{4-[3-(sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate-2-O-yl)-phenyl]-1H-(1,2,3) triazole-1-yl}-benzoate (120),
(GG-2-002, II-002, 030).
a) From 128: to a solution of 128 (35.0 mg, 46.4 µmol) in MeOH (2.7 mL) was added
freshly prepared 1M NaOMe/MeOH (0.3 mL). The mixture was stirred at rt for 5 h
under argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h.
The solution was neutralized by 0.5% HCl and concentrated. The residue was purified
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by RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 120 as a
white solid (23.1 mg, 81%) after a final lyophilization from H2O;   
b) From 131: to a suspension of 131 (8 mg, 19.0 µmol) and ethyl 4-azidobenzoyic
acid (3.0 mg, 19.0 µmol) in tBuOH (0.2 mL) and H2O (0.2 mL) was added sodium
ascorbate (1.9 µmol, 1.9 µL of a freshly prepared 1M solution in H2O), followed by
CuSO4⋅5H2O (0.05 mg, 0.190 µmol, in 0.67 µL of H2O). The heterogeneous mixture
was stirred vigorously at rt for 16 h, and then concentrated by lyophilization. The
resulting solid was purified by RP chromatography (5% gradient MeOH in H2O) to
afford 120 as a white solid (10.2 mg, 87%) after a final lyophilization from H2O.
[α]D +13.9° (c = 1.16, H2O); 1H NMR (500 Hz, D2O): δ 1.96 (m, 1H, Sia-H3a), 2.04
(s, 3H, CH3-NHAc), 2.92 (dd, J3a,3b = 12.5, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.60-3.64 (m,
2H, Sia-H7, Sia-H9a), 3.74-3.81 (m, 2H, Sia-H4, Sia-H9b), 3.89-3.97 (m, 3H, Sia-H5,
Sia-H6, Sia-H8), 7.12-7.14, 7.37-7.40, 7.55-7.58, 7.59, 7.80-7.81, 8.00-8.02, 8.71 (m,
9H, 2×C6H4, C2HN3);
13C NMR (125 MHz, D2O): δ 23.38 (CH3-NHAc), 41.25 (Sia-C3), 52.10 (Sia-C5),
62.88 (Sia-C9), 68.50, 68.55 (Sia-C4, Sia-C7), 72.26 (Sia-C8), 73.72 (Sia-C6), 103.08
(Sia-C2), 118.95, 120.70, 121.95, 121.98, 130.46, 130.48, 130.72, 138.27, 147.84,
154.63 (14C, 2×C6H4, C2HN3), 172.91, 175.40 (3C, 3×CO).
Ethyl {4-[3-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-α-
D-galacto-2-nonulopyranosynate-2-O-yl)-phenyl]-1H-(1,2,3) triazole-1-yl}-acetate
(129), (GG-2-004, II-004).
To a suspension of 124 (20.0 mg, 33.8 µmol) and ethyl azidoacetate 126 (3.5 µL, 33.8
µmol) in tBuOH (0.15 mL) and H2O (0.15 mL) was added sodium ascorbate (3.4
µmol, 3.4 µL of a freshly prepared 1M solution in H2O), followed by CuSO4⋅5H2O
(0.085 mg, 0.338 µmol, in 1.1 µL of H2O). The heterogeneous mixture was stirred
vigorously at rt for 20 h, during which three additional portions of sodium ascorbate
(10.2 µmol, 10.2 µL) and CuSO4⋅5H2O (0.255 mg, 1.02 µmol) were added according
to TLC.  Then the mixture was diluted with DCM (10 mL), washed with H2O (2×5
mL), and dried over Na2SO4. After filtration and concentration under reduced
pressure, the residue was purified by silica gel chromatography (0.5% gradient of
MeOH in DCM) to afford 129 (10.0 mg, 41%) as white foam.
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[α]D +6.3° (c = 0.92, CHCl3); 1H NMR (500 Hz, CDCl3): δ 1.30 (X of ABX, J=7.1
Hz, 3H, CH2CH3), 1.90 (s, 3H, CH3-NHAc), 2.01, 2.03, 2.06, 2.11 (4s, 12H, 4×CH3-
OAc), 2.20 (t, J3a,3b = J3a,4 = 12.7 Hz, 1H, Sia-H3a), 2.71 (dd, J3a,3b = 13.0, J3b,4 = 4.7 Hz,
1H, Sia-H3b), 3.68 (s, 3H, OCH3), 4.04 (q, J4,5 = J5,6 = J5,NH = 10.3 Hz, 1H, Sia-H5),
4.14 (dd, J8,9a = 5.8, J9a,9b = 12.4 Hz, 1H, Sia-H9a), 4.27 (A, B of ABX, J = 14.3, J =
7.1 Hz, 2H, CH2CH3), 4.36-4.38 (m, 2H, Sia-H6, Sia-H9b), 5.10 (m, 1H, Sia-H4),
5.20, 5.24 (A, B of AB, J = 17.5 Hz, CH2CO), 5.32 (dd, J6,7 = 1.8, J7,8 = 8.0 Hz, 1H,
Sia-H7), 5.35 (d, J5,NH = 10.0 Hz, 1H, Sia-NH), 5.41 (ddd, J7,8 = 8.2,   J8,9a = 5.8, J8,9b =
2.9 Hz, 1H, Sia-H8), 7.07 (m, 1H, Ar1-H4), 7.33 (t, J = 8.0 Hz, 1H, Ar1-H5), 7.50 (m,
1H, Ar1-H2), 7.67 (d, J = 8.0 Hz, 1H, Ar1-H6), 8.06 (s, 1H, Ar2-H5);
13C NMR (125 MHz, CDCl3): δ 14.05 (CH2CH3), 20.65, 20.71, 20.83, 20.95 (4×CH3-
OAc), 23.18 (CH3-NHAc), 37.67 (Sia-C3), 49.41 (Sia-C5), 50.86 (CH2CO), 53.01
(OCH3), 62.21 (Sia-C9), 62.35 (CH2CH3), 67.51 (Sia-C7), 68.75 (Sia-C4), 69.22 (Sia-
C8), 73.25 (Sia-C6), 100.08 (Sia-C2), 118.33 (Ar1-C2), 120.30 (Ar1-C4), 121.62 (2C,
Ar1-C6, Ar2-C5), 129.84 (Ar1-C5), 131.64, 147.50, 153.74 (ipso-C), 166.31, 167.91,
170.08, 170.17, 170.22, 170.68, 170.91 (7×CO);
Anal. Calcd for C32H40N4O15: C, 53.33; H, 5.59; N, 7.77. Found: C, 53.54; H, 5.75; N,
7.45.
Sodium {4-[3-(sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate-2-O-yl)-phenyl]-1H-(1,2,3) triazole-1-yl}-acetate (121), (GG-
GG-2-007, II-007).
To a solution of 129 (12.0 mg, 16.7 µmol) in MeOH (1.8 mL) was added freshly
prepared 1M NaOMe/MeOH (0.2mL). The mixture was stirred at rt for 5 h under
argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for 16 h. The
solution was neutralized by 0.5% HCl and concentrated. The residue was purified by
RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 121 as a
white solid (9.00 mg, 98%) after a final lyophilization from H2O.   
[α]D +13.8° (c = 0.75, H2O); 1H NMR (500 Hz, D2O): δ 1.96 (m, 1H, Sia-H3a), 2.03
(s, 3H, CH3-NHAc), 2.92 (m, 1H, Sia-H3b), 3.60-3.62 (m, 2H, Sia-H7, Sia-H9a), 3.75
(m, 1H, Sia-H4), 3.82 (m, 1H, Sia-H9b), 3.89-3.93 (m, 3H, Sia-H5, Sia-H6, Sia-H8),
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5.08 (s, 2H, CH2CO), 7.16 (d, J = 8.0 Hz, 1H, Ar1-CH), 7.43 (t, J = 7.8 Hz, 1H, Ar1-
CH), 7.60-7.61 (m, 2H, Ar1-H2, H6), 8.28 (s, 1H, Ar2-H5);
13C NMR (125 MHz, D2O): δ 22.50 (CH3-NHAc), 41.38 (Sia-C3), 52.22 (Sia-C5),
63.07 (Sia-C9), 68.61, 68.67 (Sia-C4, Sia-C7), 72.41 (Sia-C8), 73.87 (Sia-C6),
119.19, 121.88, 122.18, 130.62, 147.46, 150.08, 154.78  (8C, C6H4, C2HN3), 175.53
(3C, 3×CO).
1-Benzyl-{4-[3-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-
α-D-galacto-2-nonulopyranosynate-2-O-yl)]-phenyl}-1H-[1,2,3] triazole (1 3 0 ) ,
(GG-2-005, II-005).
To a suspension of 124 (34.0 mg, 57.5 µmol) and benzyl azide 127 (7.2 µL, 57.5
µmol) in tBuOH (0.2 mL) and H2O (0.2 mL) was added sodium ascorbate (5.7 µmol,
5.7 µL of a freshly prepared 1M solution in H2O), followed by CuSO4⋅5H2O (0.140
mg, 0.57 µmol, in 1.9 µL of H2O). The heterogeneous mixture was stirred vigorously
at rt for 20 h, during which nine additional portions of sodium ascorbate (51.3 µmol,
51.3 µL) and CuSO4⋅5H2O (1.26 mg, 5.13 µmol) were added according to TLC.  Then
the mixture was diluted with DCM (10 mL), washed with H2O (2×5 mL) and dried
over Na2SO4. After filtration and concentration under reduced pressure, the residue
was purified by silica gel chromatography (0.5% gradient of MeOH in DCM) to
afford 130 (28.4 mg, 68%) as white foam.
[α]D +6.8° (c = 0.95, CHCl3); 1H NMR (500 Hz, CDCl3): δ 1.90 (s, 3H, CH3-NHAc),
2.01, 2.02, 2.03, 2.11 (4s, 12H, 4×CH3-OAc), 2.19 (m, 1H, Sia-H3a), 2.70 (dd, J3a,3b =
13.0, J3b,4 = 4.7 Hz, 1H, Sia-H3b), 3.67 (s, 3H, OCH3), 4.05 (q, J4,5 = J5,6 = J5,NH = 10.3
Hz, 1H, Sia-H5), 4.13 (dd, J8,9a = 5.6, J9a,9b = 12.4 Hz, 1H, Sia-H9a), 4.33 (dd, J8,9b =
2.8, J9a,9b = 12.4 Hz, 1H, Sia-H9b), 4.36 (dd, J5,6 = 10.8, J6,7 = 1.8 Hz, 1H, Sia-H6),
4.98 (ddd, 1H, J3a,4 = 12.0, J3b,4 = 4.7, J4,5 = 10.5 Hz, 1H, Sia-H4), 5.33 (dd, J6,7 = 1.8,
J7,8 = 7.9 Hz, 1H, Sia-H7), 5.34-5.41 (m, 2H, Sia-H8, Sia-NH), 5.56, 5.60 (A, B of
AB, J = 14.9 Hz, 2H, PhCH2), 7.05-7.07, 7.30-7.38, 7.39, 7.45-7.61 (m, 9H, C6H4,
C6H5), 7.83 (s, 1H, C2HN3);
13C NMR (125 MHz, CDCl3): δ 20.60. 20.71, 20.82, 20.94 (4×CH3-OAc), 23.17
(CH3-NHAc), 37.70 (Sia-C3), 49.38 (Sia-C5), 52.98 (OCH3), 54.16 (PhCH2), 62.09
(Sia-C9), 67.43 (Sia-C7), 68.77 (Sia-C4), 69.25 (Sia-C8), 73.25 (Sia-C6), 100.08
(Sia-C2), 118.08, 120.02, 120.09, 121.56, 128.09, 128.73, 129.08, 129.80, 131.84,
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134.74, 147.51, 153.81  (14C, C6H4, C2HN3, C6H5), 167.89, 170.05, 170.22, 170.63,
170.90 (6C, 6×CO);
Anal. Calcd for C35H40N4O13+1/2H2O: C, 57.29; H, 5.63; N, 7.64. Found: C, 57.20; H,
5.60; N, 7.22.
1-Benzyl-{4-[3-(sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate-2-O-yl)]-phenyl}-1H-[1,2,3] triazole (122), (GG-2-009, II-
009,028).
a) From 130: to a solution of 130 (25.6 mg, 35.3 µmol) in MeOH (2.25 mL) was
added freshly prepared 1M NaOMe/MeOH (0.25mL). The mixture was stirred at rt
for 5 h under argon, then H2O (0.5 mL) was added and the mixture was stirred at rt for
16 h. The solution was neutralized by 0.5% HCl and concentrated. The residue was
purified by RP chromatography (5% gradient MeOH in H2O), Dowex ion-exchange
chromatography (Na+ type), and P2 size exclusion chromatography to afford 122 as a
white solid (17.3 mg, 87%) after a final lyophilization from H2O,
b) From 131: to a suspension of 131 (10 mg, 23.2 µmol) and benzyl azide (2.9 µL,
23.2 µmol) in tBuOH (0.2 mL) and H2O (0.2 mL) was added sodium ascorbate (2.3
µmol, 2.3 µL of a freshly prepared 1M solution in H2O), followed by CuSO4⋅5H2O
(0.06 mg, 0.232 µmol, in 0.8 µL of H2O). The heterogeneous mixture was stirred
vigorously at rt for 16 h, and then concentrated by lyophilization. The resulting solid
was purified by RP chromatography (5% gradient MeOH in H2O) to afford 122 as a
white solid (11.7 mg, 89%) after a final lyophilization from H2O.
[α]D +15.6° (c = 0.58, H2O); 1H NMR (500 Hz, D2O): δ 1.95 (t, J3a,3b = J3a,4 = 12.2 Hz,
1H, Sia-H3a), 2.03 (s, 3H, CH3-NHAc), 2.91 (dd, J3a,3b = 12.5, J3a,4 = 4.7 Hz, 1H, Sia-
H3b), 3.53 (dd, J8,9a = 5.8, J9a,9b = 12.0 Hz, 1H, Sia-H9a), 3.61 (dd, J6,7 = 1.6, J7,8 = 9.2
Hz, 1H, Sia-H7), 3.67 (dd, J8,9b = 2.4,  J9a,9b = 12.0 Hz, 1H, Sia-H9b), 3.75 (ddd, J3a,4 =
11.9, J3b,4 = 4.7, J4,5 = 9.5 Hz, 1H, Sia-H4), 3.82 (ddd, J7,8 = 8.7,  J8,9a = 5.8, J8,9b = 2.4
Hz, 1H, Sia-H8), 3.87 (dd, J5,6 = 10.4, J6,7 = 1.7 Hz, 1H, Sia-H6), 3.91 (q, J4,5 = J5,6 =
J5,NH = 10.4 Hz, 1H, Sia-H5), 5.56 (s, 2H, PhCH2), 7.11-7.13, 7.32-7.42, 7.48-7.51 (m,
9H, C6H4, C6H5), 8.21 (s, 1H, Ar2-H5);
13C NMR (125 MHz, D2O): δ 22.18, (CH3-NHAc), 41.03 (Sia-C3), 51.91 (Sia-C5),
54.10 (PhCH2), 62.57 (Sia-C9), 68.24, 68.29 (Sia-C4, Sia-C7), 72.01 (Sia-C8), 73.53
(Sia-C6), 102.86 (Sia-C2), 118.91, 121.70, 121.73, 122.45, 128.16, 128.89, 129.27,
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130.27, 130.59, 134.96, 147.33, 154.50 (14C, C6H4, C6H5, C2HN3), 172.68, 175.24
(2×CO).
Ethyl {4- [3-(sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate-2-O-yl)-phenyl]-1H-[1,2,3] triazole-1-yl}-acetate (132), (GG-
2-029, II-029).
To a suspension of 131 (10 mg, 23.2 µmol) and ethyl azidoacetate 126 (2.4 µL, 23.2
µmol) in tBuOH (0.2 mL) and H2O (0.2 mL) was added sodium ascorbate (2.3 µmol,
2.3 µL of a freshly prepared 1M solution in H2O), followed by CuSO4⋅5H2O (0.06
mg, 0.232 µmol, in 0.8 µL of H2O). The heterogeneous mixture was stirred
vigorously at rt for 16 h, and then concentrated by lyophilization. The resulting solid
was purified by RP chromatography (5% gradient MeOH in H2O) to afford 132 as a
white solid (12.0 mg, 93%) after a final lyophilization from H2O.
[α]D +18.4° (c = 0.68, H2O); 1H NMR (500 Hz, D2O): δ  1.28 (t, 3H, J = 7.1 Hz,
CH2CH3), 1.97 (t, J3a,3b = J3a,4 = 12.2 Hz, 1H, Sia-H3a), 2.04 (s, 3H, CH3-NHAc), 2.92
(dd, J3a,3b = 12.5, J3b,4 = 4.6 Hz, 1H, Sia-H3b), 3.60-3.64 (m, 2H, Sia-H7, Sia-H9a),
3.76 (m, 1H, Sia-H4), 3.79 (dd, J8,9b = 2.1, J9a,9b = 12.0 Hz, 1H, Sia-H9b), 3.88-3.95
(m, 3H, Sia-H5, Sia-H6, Sia-H8), 4.27, 4.30 (A, B of ABX, J = 7.1 Hz, CH2CH3),
5.40 (s, 2H, NCH2), 7.16-7.18, 7.42-7.45, 7.59-7.61, 8.34 (m, 5H, C6H4, C2HN3);
13C NMR (125 MHz, D2O): δ 13.56 (CH2CH3), 22.39 (CH3-NHAc), 41.31 (Sia-C3),
52.50 (N-CH2), 52.12 (Sia-C5), 63.01 (Sia-C9), 63.74 (CH2CH3), 68.48, 68.56 (Sia-
C4, Sia-C7), 72.37 (Sia-C8), 73.78 (Sia-C6), 103.12 (Sia-C2), 119.03, 122.01,
124.00, 130.56, 130.72, 147.56, 154.70  (8C, C6H4, C2HN3), 169.10 (3C, 3×CO).
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